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summAry
Neurofibromatosis type 1 (NF1) is a single-gene disorder associated with complex 
cognitive dysfunction including learning disabilities, attention deficit hyperactive disorder, 
executive function, visuospatial and motor coordination deficits. Neuroimaging techniques 
can contribute to identify the neurobiological basis underlying these impairments. Here, 
I used spectroscopy, functional and structural brain imaging to identify the neural and 
neurotransmitter systems involved in the aetiology of  the cognitive deficits in NF1. 
Particularly, I focused on basic physiological features that have the potential to unravel 
downstream alterations that can cause higher order cognitive deficits. This approach was 
chosen to scrutinise the contributions of  visual sensory processing, neurotransmitter 
regulation and neuroanatomical characteristics to the NF1 phenotype.
Visual sensory processing was investigated by probing the neural activation of  the two 
main pathways conduction information from the retina to the cortex, the magnocellular and 
parvocellular streams. This study examined for the first time the function of  the early visual 
cortex in patients with NF1 and identified a pattern of  deficient activation to both stimulus 
types. This analysis was performed in children, adolescents and adults with NF1 to investigate 
whether deficits in visual sensory processing ameliorated with age. It is shown that this is 
not the case and that the pattern observed in children persists into adulthood. Furthermore, 
we investigated the activation pattern of  high-level visual and non-visual regions modulated 
by the different stimuli to examine possible functional consequences of  low-level visual 
impairments. This led to the observation that during M-biased stimulation, patients with 
NF1 failed to deactivate or even activated anterior and posterior midline regions of  the 
default mode network, while controls deactivated these regions. By definition, the default 
mode network is composed by a set of  brain regions that are active during task-irrelevant 
thoughts and deactivate during performance of  cognitively demanding or engaging tasks. 
The observation that the early visual magnocellular processing is impaired in NF1 and 
is specifically associated with a deficient deactivation of  the default mode network may 
provide a neural explanation for high-order cognitive deficits present in NF1, particularly 
attentional.
NF1 belongs to a cluster of  neurodevelopmental disorders for which alterations in 
the main inhibitory neurotransmitter, γ-aminobutyric acid (GABA), were proposed as the 
underlying cause of  the cognitive deficits. This theory is the result of  cellular and molecular 
studies on a mouse model of  the disorder (Nf1+/-), which indicated an imbalance in 
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excitatory/inhibitory push-pull systems as a consequence of  increased GABA-mediated 
inhibitory neurotransmission. To test whether a similar mechanism translates to the 
human disorder, magnetic resonance spectroscopy was applied to measure GABA 
levels in the visual cortex of  children and adolescents with NF1 and matched controls. 
Measurements were performed in the visual cortex to provide further insight into the 
neural mechanisms causing the deficient visual sensory processing previously observed. 
We found that patients with NF1 have significantly lower GABA levels than controls 
and that NF1 mutation type significantly predicted cortical GABA. Our results provide 
the first evidence of  GABAergic dysfunction in patients with NF1. This constitutes a 
relevant finding to understand the physiological profile of  the disorder with implications 
for the identification of  targets for therapeutic strategies.
I finalize the set of  studies presented in this thesis by providing novel data on NF1 
neuroanatomy. In order to understand how mutations in the NF1 gene impact brain 
structure it is essential to characterize in detail the brain structural abnormalities in 
patients with this condition. Here we investigated the volumes of  subcortical structures 
and for the first time the composite dimensions of  the cortex, through the analysis of  
cortical volume, cortical thickness, cortical surface area and gyrification. It is shown that 
macrocephaly observed in patients is due to an increase in white matter volume and 
grey matter subcortical volume. Subcortical analysis revealed disproportionately larger 
thalami, right caudate and middle corpus callosum in patients with NF1. Moreover, it is 
shown that patients with NF1 have significant lower gyrification indices than typically 
developing children, primarily in frontal and temporal lobes, but also affecting the insula, 
cingulate cortex, parietal and occipital regions. These neuroanatomic abnormalities 
were localized to specific brain regions indicating that particular areas might constitute 
selective targets for NF1 gene mutation. Furthermore, the lower gyrification indices were 
accompanied by a disproportionate increase in brain size without the corresponding 
increase in folding in patients with NF1. Taken together these findings suggest that 
specific neurodevelopmental processes, such as gyrification, are more vulnerable to NF1 
dysfunction than others. 
As a single gene disorder, there is a great potential for establishing genetic, 
neurochemical and brain-behaviour relationships in NF1. The work presented in this 
thesis contributes to the understanding of  these complex connections and identified 
novel neurobiological markers of  NF1. 
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sumário
A Neurofibromatose de tipo 1 (NF1) é uma doença provocada por alterações no gene 
da NF1 e está associada a disfunções cognitivas complexas que incluem dificuldades 
de aprendizagem, défice de atenção e hiperatividade, alterações da função executiva, 
visuoespacial e da coordenação motora. O uso de técnicas de neuroimagem pode contribuir 
para a identificação das bases neurobiológicas que contribuem para estas alterações. Na 
presente tese foram utilizadas técnicas de espectroscopia, imagem funcional e estrutural por 
ressonância magnética, para identificar os sistemas neurais e de neurotransmissão envolvidos 
na etiologia dos défices cognitivos na NF1. O foco destes estudos incidiu sobre a investigação 
de padrões fisiológicos cujas alterações possuem potencial para causar défices cognitivos. 
Esta abordagem permitiu escrutinar as contribuições relativas do processamento sensorial 
visual, da regulação dos níveis de neurotransmissores e as características neuroanatómicas 
que definem o fenótipo da NF1.
O processamento visual foi investigado recorrendo ao estudo da ativação neuronal das 
duas principais vias que conduzem informação visual da retina até ao córtex, ou seja, as vias 
magnocelular e parvocelular. Este estudo examinou pela primeira vez a função do córtex 
visual em doentes com NF1, permitindo a identificação de um padrão de ativação deficitária 
em resposta a ambos os estímulos (magnocelular e parvocelular). A análise destes padrões 
de ativação foi efetuada em crianças, adolescentes e adultos com NF1, com o objetivo de 
determinar se os défices no processamento visual são atenuados com a idade. Mostramos que 
tal não ocorre e que o padrão observado nas crianças persiste na idade adulta. Investigámos 
ainda o padrão de ativação em regiões de processamento visual de alto nível e outras 
regiões cerebrais moduladas pelos dois tipos de estímulo, com o propósito de identificar as 
consequências funcionais de alterações visuais de baixo nível. Esta análise permitiu observar 
que, em resposta ao estímulo visual magnocelular os doentes com NF1 não evidenciavam 
deativação ou ainda ativaram regiões da linha média anterior e posterior da “rede neuronal 
de funcionamento por defeito” (em inglês, default mode network (DMN)). Por definição, a 
DMN é composta por um conjunto de áreas cerebrais que estão ativas durante pensamentos 
irrelevantes para uma determinada tarefa e que deativam durante a performance de tarefas 
cognitivas exigentes ou que necessitam atenção. A observação de que a via magnocelular 
tem um funcionamento deficitário na NF1 e está especificamente associada a um défice 
do funcionamento da DMN, pode contribuir para a explicação das dificuldades cognitivas 
presentes na doença, principalmente as de cariz atencional.
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A NF1 pertence a um grupo de doenças do neurodesenvolvimento para as quais foi 
proposto que alterações no principal neurotransmissor inibitório, o ácido γ-aminobutírico 
(GABA), conduzem a défices cognitivos. Esta teoria é o resultado de estudos celulares 
e moleculares efetuados num modelo animal da doença, o ratinho Nf1+/-. Estes estudos 
evidenciaram um aumento da neurotransmissão GABAérgica que acarreta uma alteração 
no balanço dos sistemas inibitórios e excitatórios. Por forma a testar se um mecanismo 
similar se traduz para a doença humana, a espectroscopia por ressonância magnética foi 
aplicada para medir os níveis de GABA no córtex visual de crianças e adolescentes com 
NF1 e respetivos participantes controlo. Esta medição foi efetuada no córtex visual para 
aprofundar os mecanismos neuronais que causam os défices do processamento visual 
verificados no estudo anterior. Identificámos por um lado, uma redução significativa dos 
níveis de GABA nos doentes com NF1 em relação aos controlos e por outro, que o tipo 
de mutação no gene da NF1 permite prever esta diminuição dos níveis de GABA. Estes 
resultados estabelecem a primeira evidência de alteração GABAérgica nos doentes com 
NF1, constituindo um achado relevante para compreender o perfil fisiológico da doença, 
com implicações para a identificação de alvos terapêuticos.
Finalizo o conjunto de estudos apresentado nesta tese expondo novos dados sobre 
a neuroanatomia da NF1. Para compreender a forma como mutações no gene da NF1 
interferem com a estrutura cerebral é essencial caracterizar em detalhe as alterações da estrutura 
do cérebro nos doentes com NF1. Desta forma, investigámos os volumes subcorticais e 
explorámos ainda, pela primeira vez, as diversas dimensões do córtex, através de análises 
de volume, espessura, superfície e girificação corticais. Mostramos que a macrocefalia 
observada em doentes é devida a um aumento do volume da matéria branca e da matéria 
cinzenta subcortical. A análise subcortical detalhada revelou aumentos desproporcionados 
dos tálamos, do núcleo caudado direito e do corpo caloso médio nos doentes com NF1. 
Identificámos ainda que os doentes com NF1 possuem índices de girificação reduzidos em 
comparação com os observados em crianças com desenvolvimento típico, particularmente 
dos lobos frontais e temporais, mas que afetam também a ínsula, o córtex cingulado, e 
regiões parietais e occipitais. Estas alterações neuroanatómicas foram localizadas em regiões 
cerebrais específicas, indicando que determinadas áreas podem constituir alvos seletivos 
das mutações no gene da NF1. Os índices de girificação reduzidos nos doentes com NF1 
apresentaram-se acompanhados de um aumento do tamanho do cérebro, na ausência do 
correspondente incremento de convoluções corticais. Em suma, estes achados sugerem que 
processos específicos do desenvolvimento neural, tal como a girificação, são mais vulneráveis 
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do que outros a disfunções do gene da NF1.
Tratando-se de uma doença que afeta um único gene, a NF1 possui um elevado potencial 
para o estabelecimento de relações genéticas, neuroquímicas e ainda entre o funcionamento 
cerebral e o comportamento. O trabalho apresentado nesta tese contribui para a compreensão 
destas complexas conexões e identifica novos marcadores neurobiológicos da NF1.
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The “Wart Man”, Johann Gottfried Rheinhard, as reported by Tilesius von Tilenau, 1793. 
Reproduced from Ruggieri and Polizzi, 2003. With permission from the publisher.
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Neurofibromatosis constitutes a group of  genetic disorders characterized by the devel-
opment of  tumours of  the nervous system, particularly of  the nerve sheath (Friedman 
and Riccardi, 1999; McClatchey, 2007). Three major forms of  neurofibromatosis are 
recognized as separate entities on the basis of  their genetic origin and pathogenesis: 
neurofibromatosis type 1, neurofibromatosis type 2 and schawnnomatosis (MacCollin 
et al., 2005; Ferner, 2007). 
The focus of  this thesis is on the neurobiological basis underlying the cognitive defi-
cits observed in patients with neurofibromatosis type 1 (NF1). Although cognitive defi-
cits constitute the most common neurological complication in NF1 (North et al., 1997; 
Hyman et al., 2005) and pose a significant impact on patients’ quality of  life (North, 
2000), few studies focused on the neurobiological basis of  such impairments. In the 
present thesis a tripartite methodological approach was followed to acquire functional 
information on neural activity, and structural and neurochemical profiles of  patients 
with NF1, with the goal of  elucidating the pathophysiological mechanisms leading to al-
tered brain function. To gain access into the living human brain, studies were performed 
using magnetic resonance imaging and spectroscopy. Such techniques revolutionized 
our ability to study brain anatomy and physiology and have proven to be critical for 
future understanding of  the neurobiological basis underlying cognitive deficits in NF1 
and other neurodevelopmental disorders. 
This introductory chapter will first present background information on the clinical 
and genetic features of  the disorder and summarize the current understanding on the 
function of  the NF1 gene. In the second part the focus will be on brain structure and 
function in NF1 and their relevance to the main research goal of  this Thesis. Particularly, 
I discuss contributions to the neurobiology of  cognitive deficits from both animal mod-
els of  the disorder and studies in human patients. I will finish by providing an outline of  
the content and specific aims of  the following chapters.
HistoriCAl perspeCtive on nF1
Although descriptions in the literature that could fit the NF1 diagnosis go back to the 
13th century (Morse, 1999), it was not until 1768 that the first convincing description of  
NF1 was reported by Mark Akenside (Akenside, 1768):
“ … a man about three score years of  age came to St. Thomas’ Hospital. […] [He] 
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had been accustomed during the greater part of  his life to a constant succession of  
wens [tumours] that shot out in several places on his head, trunk, arms and legs: which 
indisposition he inherited from his father.”
However, only at 1882, NF1 was recognized as a disorder and characterized by von 
Recklinghausen (von Recklinghausen, 1882) on a report entitled “On multiple cutane-
ous fibromas and their relationship with multiple neuromas” (Wilkins and Brody, 1971; 
Crump, 1981):
“... it appears that these multiple neuromas and cutaneous fibromas existed simulta-
neously. It also appears that this was not a fortuitous combination, but rather that the 
tumours were related structurally [...] the evidence [...] is: 1) the nature of  the neoplastic 
tissue in both types of  tumour was almost identical, 2) nerve tumours penetrated the un-
dersurface of  the tumours of  the skin and sometimes could be peeled out of  them, and 
3) the cutaneous fibromas presented an arrangement different from the usual multiple 
fibromatous neoplasms.” (von Recklinghausen, 1882; Wilkins and Brody, 1971).
Recklinghausen gave substantial contributions to the knowledge of  the pathological 
condition by identifying its cutaneous and neurologic manifestations and by demon-
strating its nervous origin. He was the first to connect the simultaneous appearance of  
fibromas and neuromas and he coined the term neurofibroma. On this basis, NF1 is also 
known as von Recklinghausen’s disease.
CliniCAl FeAtures
NF1 is one of the most common genetic disorders affecting the human nervous system, oc-
curring with an estimate incidence of  1 per 3500 individuals, independent of  ethnicity, race and 
gender (Huson et al., 1988; Friedman and Riccardi, 1999). 
The National Institute of  Health Consensus Development Conference formulated the cur-
rent diagnostic criteria, described in Panel 1, and also proposed the name neurofibromatosis type 
1 (National Institutes of  Health Consensus Development Conference Statement: neurofibro-
matosis., 1988). 
NF1 is a multisystem disorder, with a wide variety of  manifestations affecting the skin, eyes, 
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skeleton, the endocrine system, and blood vessels, as well as the central and peripheral nervous 
system.
Individuals with NF1 typically present the first manifestations of  characteristic pig-
mentary abnormalities in childhood, including café-au-lait macules, skinfold freckling 
and Lisch nodules. Café-au-lait spots are local changes in the skin pigmentation that 
develop in virtually all patients and are usually noticeable at birth and invariably by age 
3 years (Huson et al., 1988). Axillary and inguinal freckling is detected most frequently 
between 3 and 5 years of  age (Korf, 2002). Additional sites for freckling include the area 
above the eyelids, around the neck and under the breasts (Huson et al., 1988). Lisch nod-
ules are melanocytic iris harmatomas that do not affect vision (Huson et al., 1987). Char-
acterization of  histopathological and ultrastructural features of  a Lisch nodule revealed 
that it was composed of  three main cytotypes: pigmented cells, fibroblast-like cells and 
mast cells, showing a pattern similar to a neurofibroma (Richetta et al., 2004). 
The neurofibroma is the most common tumor seen in individuals with NF1. It aris-
es from the fibrous tissue surrounding peripheral nerve sheaths and is composed of  
Schwann cells, fibroblasts, perineural cells and mast cells (Gutmann et al., 1997). Neu-
rofibromas manifest as benign, focal cutaneous or subcutaneous lesions, or plexiform 
tumours. Focal cutaneous or dermal neurofibromas typically appear in late childhood or 
Panel 1 – Diagnostic criteria for NF1 (as defined by the National Institutes of  
Health Consensus Development Conference Statement: neurofibromatosis., 1988) 
Two or more of  the below criteria are required for diagnosis:
Six or more café-au-lait macules ( > 5 mm in diameter in children or                    • 
> 15 mm in adolescents and adults)
Two or more cutaneous or subcutaneous neurofibromas or one plexiform • 
neurofibroma
Axillary or groin freckling• 
Two or more Lisch nodules (iris harmatomas)• 
Optic pathway glioma• 
A distinctive osseous lesion such as sphenoid wing dysplasia or thinning of     • 
the long bone cortex with or without pseudoarthrosis
A first-degree relative with NF1• 
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early adolescence and do not transform into malignant tumours. Plexiform neurofibro-
mas arise from multiple nerve fascicles and tend to grow along the length of  the nerve 
and often involve multiple nerve fascicles, branches and plexi (Korf, 1999). Individuals 
with NF1 have a lifetime risk of  8-13% of  developing malignant peripheral nerve sheath 
tumours (MPNST), typically arising from pre-existing plexiform neurofibromas (Evans 
et al., 2002). MPNSTs are poorly responsive to conventional therapies, prone to metas-
tasize and have a poor overall prognosis.
In children, the most common neoplasms apart from neurofibromas are gliomas, 
which occur in all parts of  the brain but are more likely to appear in the optic pathways, 
brainstem and cerebellum (Korf, 2000; Sylvester et al., 2006; Ullrich et al., 2007). Within 
the gliomas, optic pathway gliomas are the most common and are found in ~15% of  
children with NF1, typically arising in the first decade of  life (Listernick et al., 2007).
Several other features are often associated with NF1, including macrocephaly, short 
stature, at 10th–25th percentiles, scoliosis, headache, hyperintension, and T2-weighted sig-
nal intensity lesions on magnetic resonance imaging of  the brain (Huson et al., 1989; 
Gutmann et al., 1997). Furthermore, 30-60% of  the individuals with NF1 have learning 
disabilities (North et al., 1997; Hyman et al., 2005), with a significant impact on qual-
ity of  life (North, 2000). The cognitive profile of  patients with NF1 is discussed in the 
second part of  the Introduction.
GenetiCs oF nF1
Linkage studies were able to identify the disease-causing gene in NF1 to chromosome 17 
(Barker et al., 1987; Seizinger et al., 1987). Later, gene mapping identified the NF1 gene 
at chromosome 17q11.2 and its protein product, neurofibromin (Cawthon et al., 1990b; 
Viskochil et al., 1990; Wallace et al., 1990).
The NF1 gene is large, spanning over 350 kb of  genomic DNA (Figure 1) (Marchuk 
et al., 1991) and can be classified as a tumour suppressor gene, since mutations in both 
alleles are detected in neurofibromas (Colman et al., 1995) and malignant tumours as-
sociated with NF1 (Legius et al., 1993; Shannon et al., 1994; Cichowski and Jacks, 2001). 
The gene contains 60 exons organized into four clusters, which are separated by four 
large introns (Li et al., 1995). Intron 27b contains three small unrelated genes, EV12A, 
EV12B and OMGP, each of  which containing two exons (Cawthon et al., 1990a). These 
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genes are transcribed in the reverse orientation to the NF1 gene and their role in regulat-
ing the NF1 gene expression is presently unknown.
The NF1 gene is ubiquitously expressed, in line with the diverse clinical manifesta-
tions of  the disorder (Gutmann et al., 1991; Daston et al., 1992). However, the high-
est level of  gene expression is seen in neural tissues, including neurons and glial cells 
(Daston et al., 1992). Additionally, NF1 expression occurs across multiple brain systems 
including subcortical and cortical structures. In the cortex, expression spans all cortical 
layers, whereas in the striatum, is sparse, occurring in a pattern suggestive of  interneu-
ronal expression (Gutmann et al., 1995a). 
The large size of  the NF1 gene may help explain the high incidence of  mutations at 
Figure 1. Diagram of  the NF1 gene. The arrow at the superior left corner represents the transcrip-
tion start site. Exons are represented as rectangular boxes and the scale bar in the left corner indicates 
their size. The exons of  the NF1 Ras-GAP-related domain are striped and those of  the Sec14 domain 
have a squared pattern. Alternatively spliced exons (9a, 23a and 48a) are filled in. Introns are not drawn 
to scale and the four large introns are marked with facing-down arrows. Adapted from Thomas and 
De Vries, 2009. 
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the NF1 locus. Indeed it has one of  the highest mutation rates in humans (Fahsold et 
al., 2000) and approximately 50% of  the patients with NF1 present new mutations with-
out a family history of  NF1 (Thomson et al., 2002). The disease is supposed to result 
from loss-of-function mutations because >80% of  germline mutations described cause 
truncation of  the gene product (Ars et al., 2000; Messiaen et al., 2000; Ars et al., 2003). 
Several types of  mutations have been observed, including missense and nonsense muta-
tions, small and large deletions, insertions, intronic changes affecting splicing, alterations 
of  the 3’ untranslated region of  the gene and gross chromosomal rearrangements (Jett 
and Friedman, 2010). Individuals affected by NF1 are heterozygous for the mutation, as 
homozygous mutations appear to be lethal (Friedman and Riccardi, 1999).  
tHe protein neuroFibromin And its FunCtions
The protein product of  the NF1 gene is neurofibromin (RefSeq: NP_000258.1, Uni-
ProtKB P21359-2), a large protein with 2818 amino acids and a calculated molecular 
mass of  250-280 kDa (DeClue et al., 1991; Gutmann et al., 1991). Neurofibromin is 
a cytoplasmatic protein expressed in all tissues and cell lines examined. Is detected in 
human, rat, and mouse neurons, astrocytes, oligodendrocytes, Schawnn cells, adrenal 
medullary cells, white blood cells and gonadal tissue (DeClue et al., 1991; Gutmann 
et al., 1991; Daston et al., 1992). During early embryonic development is ubiquitously 
expressed (Daston and Ratner, 1992; Baizer et al., 1993; Huynh et al., 1994; Gutmann 
et al., 1995a) and in adults the expression is highest in the nervous system and adrenal 
glands (Daston and Ratner, 1992; Daston et al., 1992; Golubic et al., 1992; Gutmann et 
al., 1995a).
Despite its large size, the function of  neurofibromin is not clearly understood and a 
variety of  mutations across the entire gene are associated with NF1 (Castle et al., 2003). 
To date, it is known to have two functional domains, Sec14 and RasGAP related domain 
(Trovo-Marqui and Tajara, 2006). Sec14-interactive domain (see Figure 1) is homolo-
gous to the yeast Sec14p, which is known to regulate intracellular proteins and lipid traf-
ficking in yeast (Mousley et al., 2006). However, the biological role of  Sec14 domain in 
NF1 is currently unknown, although structural studies seem to support its role in lipid 
binding (Welti et al., 2011). The RasGAP domain (see Figure 1), allows neurofibromin to 
act as a Ras-GAP (GTPase activating protein) protein to negatively regulate Ras signal-
IntroduCtIon | 27
ling (Martin et al., 1990; Weiss et al., 1999), while it can also influence the adenylyl cyclase 
pathway, as observed in the fruit fly (Drosophila melanogaster) and mice (Tong et al., 2002; 
Dasgupta et al., 2003).  
The Ras protein belongs to a large super-family of  low-molecular weight G-proteins, 
known as GTPases, which mediate signalling from membrane receptor to intracellular 
cascades of  kinases. Ras GTPases promote the hydrolysis of  active Ras-GTP to inactive 
Ras-GDP (Bernards and Settleman, 2004). 
In NF1, haploinsufficiency resulting in reduced levels of  functional neurofibromin 
leads to enhanced activation of  Ras, which in turn hyperactivates the  cascades of  down-
stream signalling pathways, including those that involve mitogen-activated protein kinase 
(MAPK)/ERK (MEK), phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB) 
and mammalian target of  rapamycin (mTOR) kinase (see Figure 2). MEK activates 
members of  the extracellular signal-regulated kinase (ERK), which then phosphorylates 
a variety of  targets. A number of  these signals are then transmitted to the nucleus, regu-
lating the expression of  genes controlling cell proliferation, cell death, differentiation 
and migration (see Trovo-Marqui and Tajara, 2006 for a comprehensive review). mTOR 
functions involve the regulation of  cell growth, proliferation and motility as well as 
signal integration from different pathways important for controlling cellular processes 
(Raught et al., 2001; Hay and Sonenberg, 2004; Dasgupta et al., 2005; Johannessen et 
al., 2005).
Neurofibromin also holds a microtubule association function (Gregory et al., 1993), 
which is relevant for the integrity of  neuronal axonal and dendritic projections and con-
sequently to signal transduction and neuronal connections.
Collectively, these findings argue that alterations in neurofibromin function may af-
fect different intracellular signalling pathways in specific cell types. 
To complicate matters further, neurofibromin has five isoforms (II, 3, 4, 9a and 
10a-2), arising from the four alternatively splicing exons (9a, 10a-2, 23a and 48a) (Figure 
1) (Gutmann et al., 1995b; Gutmann et al., 1999), with varied functional roles and ex-
hibiting differential expression in distinct tissues. Neurofibromin type II is an isoform 
to which a functional role has been established. It results from the insertion of  exon 
23a and has a reduced GAP ability (Andersen et al., 1993; Gutman et al., 1993) and loss 
of  association with microtubules (Gutmann et al., 1995b). This isoform was proven to 
be relevant for cognition, as mice lacking exon 23a presented learning deficits with no 
elevated tumour predisposition (Costa et al., 2001). This indicates a critical role of  the 
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GAP domain in modulating learning and memory. Although type I and II isoforms ap-
pear to be ubiquitously expressed in the brain, type I is the major form expressed by 
neurons, whereas type II is mainly expressed in glial cells (Gutmann et al., 1995a).
Figure 2. Interactions of  neurofibromin (NF1) with different cell signaling pathways. NF1 is a 
GTPase activating protein (GAP) that negatively regulates Ras-MAPK signaling cascade. The GAP function 
of  NF1 can be counteracted by guanine-necleotide exchange factors (GEFs). NF1 also acts as an activator 
of  adenylate cyclase (AC) and the phosphatidylinositol 3-kinase (PI3K)-AKT-mTOR cascade. Some 
of  these signals are then transmitted to the nucleus, regulating the expression of  genes controlling 
cell proliferation, cell death, differentiation and migration. NF1 also holds a microtubule association 
function. Arrows and barred lines indicate activation and suppression, respectively. MEK, mitogen-
activated protein kinase or extracellular signal-regulated kinase; NMDAR, N-methyl-D-aspartate recep-
tor; GPCR, G protein-coupled receptor; RTK, receptor tyrosine kinase; PKA, protein kinase A; PKC, 
protein kinase C; SHP2, Src homology 2-containing tyrosine phosphatase; AKT, serine/threonine pro-
tein kinase, mTOR, mammalian target of  rapamycin. Adapted from Shilyansky et al., 2010a.
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tHe vAriAtion oF pHenotypes in nF1 or tHe HArd tAsk oF FindinG 
Genotype-pHenotype CorrelAtions
In NF1, there is complete genetic penetrance but variable expressivity. This means that all the 
individuals with NF1 carrying a disease-causing allele, express the disease phenotype, how-
ever, the degree to which the genotype is phenotypically expressed varies among individuals. 
In this regard, the highly variable clinical expressivity observed in NF1 is manifested by 
marked inter- and intra-familial variation in both the number of  major features and the 
occurrence of  complications (Ward and Gutmann, 2005). Accordingly, it has been diffi-
cult to establish correlations between specific mutation and clinical presentations (Castle 
et al., 2003). In general, no solid correlation was observed between the type of  muta-
tion and a distinctive phenotypic expression of  the disease. Exceptions to this are the 
patients with a NF1 microdeletion, who have earlier onset of  neurofibromas, profound 
developmental delays and distinctive facial features (Tonsgard et al., 1997; Upadhyaya et 
al., 1998), and also a substantially higher lifetime risk for the development of  MPNSTs 
(De Raedt et al., 2003).
Contributing to the low number of  known genotype-phenotype correlations is the 
fact that, on one hand, mutational analysis has proven to be difficult due to the large size 
of  the gene, the occurrence of  mutations in nearly every exon, the presence of  pseudo-
genes in other chromosomes, and the great variety of  possible mutations. On the other 
hand, variable phenotypes can be caused by several factors including modifier genes 
(Easton et al., 1993; Sabbagh et al., 2009), environmental factors, and complex genetic 
and environmental interactions. 
Despite the difficulties to identify genotype-phenotype correlations, patients that 
participated in the studies presented in this thesis were genotyped for the NF1 gene. 
Genotyping allows a better characterization of  the NF1 population studied and the 
identification of  the disease causing mutations. In fact, we were able to show that the 
NF1 mutation type significantly predicted cortical γ-aminobutyric acid (GABA) levels 
in the visual cortex of  our cohort of  patients, and thereby succeeded in identifying a 
genotype-phenotype correlation. 
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CoGnitive proFile oF pAtients witH nF1
The most common neurological complication of  NF1 in childhood is cognitive impair-
ment, which does not seem to resolve in adulthood (North et al., 1997; Hyman et al., 
2005) and has significant impact in quality of  life (North, 2000). In spite of  the plethora 
of  studies investigating cognition in NF1, there is not a general consensus regarding 
the exact cognitive profile (Levine et al., 2006). This might reflect in part methodologi-
cal differences regarding the variety of  comparison groups used (unaffected siblings or 
unrelated controls), controlling or not for intelligent quotient (IQ) or including children 
with brain tumours. 
Typically, studies report IQs in the low-average range as compared with siblings, con-
trols and norms (as reviewed by Levine et al., 2006). However, mental retardation (IQ < 
70) occurs only in 4 - 8% of  the NF1 population (North, 2000). The reported frequency 
of  learning disabilities is high and ranges between 30-65% (Ozonoff, 1999).  
Learning disabilities constitute an umbrella term applied to define a significant dis-
crepancy between ability (intellect) and achievement in a specific domain (Kronenberger 
and Dunn, 2003). The Diagnostic and Statistical Manual of  Mental Disorders, Fourth 
Edition (DSM-IV) divides learning disabilities into five main categories: reading disor-
ders, mathematical performance disorders, disorders of  written expression, nonverbal 
learning disorders, and learning disorders not otherwise specified. In general, neuropsy-
chological evaluation has identified deficits in the NF1 population involving visuospatial, 
executive function, motor, language and memory domains. Therefore, a single learning 
disability category is insufficient to describe the NF1 phenotype.
Visuospatial deficits are considered one of  the hallmark characteristics of  the NF1 
cognitive profile, and the most common impairment is observed in the judgment of  line 
(JLO) test (Eldridge et al., 1989; Dilts et al., 1996; Hyman et al., 2005; Levine et al., 2006; 
Clements-Stephens et al., 2008; Ribeiro et al., 2012). Indeed, visuospatial performance 
represents a strong predictor of  NF1 diagnosis and the pattern of  performance on a set 
of  visuospatial measures was able to identify 90% of  over 100 children and adolescents 
with NF1, providing a strong predictor of  diagnosis (Schrimsher et al., 2003). Never-
theless, from the four visuospatial/motor tests used by the authors (JLO, BlockDesign 
subtest of  the Wechsler Intelligence Scale for Children-third edition (WISC-III), the 
Recognition–Discrimination Test, and the Beery Visual–Motor Integration Test), the 
JLO alone had essentially the same discriminative outcome as the multivariate combi-
nation of  all the other tests in terms of  correctly classifying NF1 cases. In agreement 
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with this observation, Levine et al (2006) pointed out that other tasks used to assess 
visuospatial function do not present the same degree of  impairment, and tasks requir-
ing recognition of  complex objects are matched between NF1 and control groups. In 
addition, there is evidence suggesting that the visuospatial deficits observed in the JLO 
test might be linked to executive functions. In particular, NF1 affects planning, working 
memory, cognitive flexibility and inhibitory control (Descheemaeker et al., 2005; Row-
botham et al., 2009; Huijbregts et al., 2010). Furthermore, there is a high comorbidity 
(~50%) between NF1 and attention deficit hyperactive disorder (ADHD) (Koth et al., 
2000; Rosser and Packer, 2003), which is commonly associated with deficits in execu-
tive function. Besides visuospatial and executive function, motor coordination is also 
frequently impaired in NF1 (Feldmann et al., 2003; Levine et al., 2006; Huijbregts et al., 
2010).
Patients with NF1 also show aspects of  verbal learning deficits, particularly in ex-
pressive and receptive language, vocabulary, visual naming and phonological awareness 
(Ozonoff, 1999; Levine et al., 2006). 
 
brAin struCturAl And FunCtionAl neuroimAGinG Contributions to 
understAnd tHe nF1 CoGnitive proFile
Neuroanatomy 
The most evident brain structural alteration observed in NF1 is macrocephaly, which 
occurs in approximately 50% of  children with this condition (North et al., 1994; Van 
Es et al., 1996). Macrocephaly is defined as a head circumference greater than the 95th 
percentile. The commonest cause for macrocephaly is megalencephaly, i.e. larger brain 
volume (Steen et al., 2001). There is no known association between macrocephaly and 
neuropsychological function in NF1 and there is still a debate on the structures contrib-
uting to this enlargement and their impact on cognitive function (Payne et al., 2010). 
The neuroimaging studies performed so far can be divided between volumetric mea-
surements of  overall grey matter and white matter tissues (Said et al., 1996; Steen et al., 
2001) and studies that included brain parcellation to identify regions with abnormal 
volume (Moore et al., 2000; Cutting et al., 2002b; Greenwood et al., 2005). The ma-
jority of  these studies points to macrocephaly being caused by increased white mat-
ter (Said et al., 1996; Steen et al., 2001) or a combination of  white and grey matter 
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(Cutting et al., 2002a; Greenwood et al., 2005). 
The most consistent structural finding across studies is an enlargement of  the corpus 
callosum in patients with NF1 (Kayl et al., 2000; Moore et al., 2000; Dubovsky et al., 
2001; Steen et al., 2001; Cutting et al., 2002b; Wignall et al., 2010). The corpus callosum 
is the major commissural structure in the human brain and it connects the left and right 
cerebral hemispheres. Its principal function is to facilitate interhemispheric communica-
tion and transfer motor, sensory, and cognitive information between the hemispheres. 
Other brain structure anomalies observed included increased brainstem growth rate, 
suggestive of  abnormal cell proliferation (DiMario et al., 1999) and smaller surface area 
and grey matter volume of  the left planum temporal of  NF1 boys compared with controls 
(Billingsley et al., 2002). 
It is clear that the study of  neuroanatomy in NF1 has a lot to gain from recent 
methodological advances, which can provide information on the composite dimensions 
of  the cortex (volume, thickness and surface area) and additional morphometric param-
eters. Moreover, the application of  powerful statistical methods to brain imaging data 
can aid in the identification of  structures that contain information to distinguish patients 
from controls without an a priori hypothesis. Recently, our group employed a multivari-
ate statistical pattern analysis to classify whole-brain anatomical images. We were able to 
reveal the existence of  brain structural differences in grey matter and white matter tissue 
that could accurately discriminate individuals with NF1 from controls (Duarte et al., 
2012). The statistical map provided by the classifier showed spatially distributed clusters 
enclosing a number of  regions, thus providing strong indications for localized abnor-
malities in patients with NF1. Those regions included the hippocampus, basal ganglia, 
thalamus, and occipital cortex.
Attempts to find relationships between structural alterations and cognitive function 
did not result, so far, on any firm conclusions. However, there is some evidence that 
grey matter properties influence cognitive function (Said et al., 1996; Moore et al., 2000; 
Steen et al., 2001).
Besides morphometric and volumetric studies, there are several reports of  altered 
white matter microstructure as investigated using diffusion tensor imaging (DTI) (Sheikh 
et al., 2003; Zamboni et al., 2007; van Engelen et al., 2008; Ferraz-Filho et al., 2012). 
This technique can reveal microscopic details about tissue architecture by probing water 
molecule diffusion patterns (Schaefer et al., 2000; Hagmann et al., 2006). Two main pa-
rameters can be determined from diffusion-weighted MRI data: the apparent diffusion 
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coefficient (ADC), which indicates the degree of  diffusion of  water molecules, and frac-
tional anisotropy (FA), that describes the degree of  anisotropy of  a diffusion process. 
Low FA values indicate that diffusion is isotropic, i.e. it is unrestricted in all directions, 
this typically occurs in the cerebrospinal fluid (CSF). High values of  FA indicate that dif-
fusion occurs mainly according to one axis and is restricted along other directions, which 
is seen for white matter fibers.
Despite of  the fact that there is no published DTI study on the context of  cognitive 
function, alterations in white matter microstructure of  the thalamus were consistently 
found (Zamboni et al., 2007; van Engelen et al., 2008; Ferraz-Filho et al., 2012). The 
thalamus is a highly interactive structure, with widespread connections to multiple corti-
cal regions, that provides selection and transformation of  different sensory inputs to the 
cortex. The various nuclei of  the thalamus are involved in the integration of  sensory and 
motor information, memory and executive functions (Schmahmann and Pandya, 2008), 
competences in which NF1 patients show disabilities (Hyman et al., 2005; Levine et al., 
2006; Roy et al.). Moreover, patients with NF1 presented significantly reduced FA values 
and/or elevated ADC of  several other anatomical brain locations, including brain stem, 
cerebellar white matter, basal ganglia, corpus callosum, and frontal and parietal white 
matter regions (Zamboni et al., 2007; van Engelen et al., 2008). Given the importance 
of  white matter integrity to efficient information transit, alterations in white matter mi-
crostructure and structural connectivity could have significant contributions to impaired 
cognition (Nagy et al., 2004).
Unidentified bright objects 
Neuroimaging studies applying magnetic resonance imaging (MRI) identified focal areas 
of  hyperintensity on T2-weighted images. Those have a frequency of  55-90% in child-
hood (Payne et al., 2010) and commonly occur in the basal ganglia, cerebellum, thalamus, 
brain stem and subcortical white matter (Van Es et al., 1996; Lopes Ferraz Filho et al., 
2008). These lesions are isointense on T1-weighted images and are not visible on com-
puted tomographic scans, they exert no mass effect, there is no surrounding oedema 
and they do not enhance with contrast. These hyperintensities are often referred as 
unidentified bright objects (UBOs) to reflect their mysterious nature. A neuropathologic 
autopsy study of  MRI-confirmed UBOs in NF1 demonstrated an atypical astrocytic 
infiltrate with areas of  microscopic fluid-filled vacuoles (DiPaolo et al., 1995). Although 
it was initially thought that UBOs resolved with age, a prospective study involving a large 
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number of  patients showed that the natural history of  these lesions is more complex 
than initially envisioned (Gill et al., 2006). Their disappearance seems to depend on their 
location; with UBOs in the basal ganglia, thalamus, brainstem and cerebellum regressing 
with age, while those in cerebellar cortex and deep white matter not.
The high frequency of  UBOs in NF1 leads to the hypothesis that these lesions might 
be associated with the cognitive profile. This relationship has been studied with several 
approaches focusing on the presence, location, number of  locations, and/or volume 
of  UBOs (see North, 2000; Levine et al., 2006 for a review). However, the results are 
not consensual. In terms of  IQ, evidence suggests that patients with NF1 and UBOs 
have lower IQs than patients without UBOs (Hofman et al., 1994; North et al., 1994; 
Feldmann et al., 2003; Hyman et al., 2003; Chabernaud et al., 2009), however this was 
not reproducible across all studies (Duffner et al., 1989; Dunn and Roos, 1989; Ferner et 
al., 1993; Legius et al., 1995). More detailed studies focusing on the impact of  UBOs on 
specific locations have observed that their presence in thalamic (Moore et al., 1996; Hy-
man et al., 2007) or thalamo-striatal (Goh et al., 2004; Chabernaud et al., 2009) structures 
negatively influence cognitive performances. Future studies should discern the role of  
UBOs on cognitive impairment and establish whether they constitute a causal relation. 
For now, there is no sufficient clear evidence that UBOs can predict cognitive deficits 
in NF1. 
Functional neuroimaging studies
A more complete understanding of  the neural correlates underlying the cognitive defi-
cits requires methods that can assess functional activity. However, there are very few 
functional (f) MRI studies in patients with NF1. 
The first fMRI study in NF1 focused on phonological processing (Billingsley et al., 
2003b), a core component of  reading. Participants performed two phonologic process-
ing tasks, an auditory and an orthographic task, and they were required to determine 
whether two pronounceable nonsense words rhymed. In the auditory task, patients with 
NF1 revealed greater activation than controls in the inferior frontal cortex, middle tem-
poral and parietal regions. However, patients also showed reduced activation of  dorso-
lateral prefrontal cortical areas, relative to posterior (temporal, parietal, and occipital), in 
comparison with controls. This pattern, was found to be similar to the one observed in 
dyslexic patients by Shaywitz and colleagues (Shaywitz et al., 1998). However, while the 
pattern of  neural deficits in dyslexia is also characterized by decrease activity of  the left 
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hemisphere, the opposite pattern was seen in NF1, with greater undearctivation of  the 
right hemisphere. Concerning the written task, patients with NF1 displayed relatively 
less frontal compared with posterior activity, a pattern opposite to the one observed 
with the auditory task. The authors interpreted this variation in the patterns of  regional 
activity between tasks as a reflection of  compensatory neural recruitment, due to either 
inefficient or dysfunctional neural networks, particularly of  the frontal lobe.
Two studies have investigated the neural correlates of  visuospatial processing in NF1 
(Billingsley et al., 2004; Clements-Stephens et al., 2008). Billingsley et al presented al-
phanumeric stimuli in either their conventional form, inverted or rotated (Billingsley et 
al., 2004). Participants were asked to respond if  the stimulus presented was a letter or a 
number. Patients relied to a greater degree than controls on posterior cortex (including 
occipital, parietal, and middle temporal cortices), relative to lateral and inferior frontal 
regions. This pattern was related to patients’ behavioural performance on the task. The 
authors hypothesized that the increase in posterior activity may reflect a compensatory 
mechanism for deficient frontal activation, which could be related to morphological 
abnormalities in the inferior frontal areas observed in a previous study (Billingsley et 
al., 2003a). Clement-Stephens et al conducted a study using an adaptation of  the judg-
ment of  line orientation task (Clements-Stephens et al., 2008). The authors reported that 
subjects with NF1 relied more on left than right hemisphere structures for task comple-
tion, while controls did the opposite. This left hemisphere dominance for visuospatial 
processing suggests that visuospatial problems occur due to inefficient right hemisphere 
network. Moreover, this pattern was accompanied by an unexpected underactivation of  
the primary visual cortex in NF1, while parietal regions did not present between-group 
differences. 
A more recent study assessed working memory in humans and mice (Shilyansky et 
al., 2010b). Two visuospatial working memory tasks were applied to human subjects: 1) 
a spatial working memory maintenance and manipulation task (task 1), and 2) a para-
metric spatial working memory capacity task (task 2). In both tasks subjects were shown 
an array of  dots. In task 1, subjects had to either hold the array as it was or flip it across 
the horizontal axis. After a fixed delay, subjects were shown a probe array and were 
asked to determine if  the probe was in the same position as the previously shown array 
(maintenance condition) or corresponded to the flipped array (manipulation condition). 
In task 2, the difficulty of  the task increased parametrically, as subjects were shown 
an array of  one, three, five or seven dots. After a delay, subjects were shown a single 
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probe circle and were asked to determine if  the probe was in the same position as one 
of  the target circles. Authors performed a region-of-interest analysis, involving frontal 
(dorsolateral prefrontal cortex, frontal eye fields), parietal and striatal regions (caudate 
and putamen) (Shilyansky et al., 2010b). Individuals with NF1 performed significantly 
worse than controls in both tasks. In task 1, significantly reduced activation in patients 
compared with controls was observed in frontal, parietal and striatal brain regions, while 
in task 2 differences were observed only for frontal and parietal regions. Furthermore, 
the neural activation in the right dorsolateral prefrontal cortex was significantly corre-
lated with patients’ performance in both tasks. Interestingly, during task 2, patients with 
NF1 showed impaired deactivation of  the medial prefrontal cortex when compared to 
controls. This region belongs to the brain default mode network, which is composed 
by a set of  regions that are active during task irrelevant thoughts (McKiernan et al., 
2003), and deactivate during performance of  cognitively demanding tasks (Shulman et 
al., 1997; Raichle et al., 2001; McKiernan et al., 2003). This study points once more to 
frontal impairments in patients with NF1.
Unfortunately, none of  these studies performed whole-brain between-groups com-
parisons, being limited to the investigation of  activity in a priori defined regions. This 
approach has the disadvantage of  limiting the overall identification of  the functional 
networks involved in task completion. Importantly, fMRI can also be used to monitor 
response to therapy at the level of  brain functional connectivity, as performed as a part 
of  an ongoing clinical trial on NF1 (Chabernaud et al., 2012).
 
Other evidences of  regional brain alterations 
Positron emission tomography (PET) constitutes an additional valuable tool to study 
metabolism and can identify patterns of  abnormal brain activity. Studies employing ra-
diotracers of  glucose observed altered metabolism of  the thalamus in patients with 
NF1 (Kaplan et al., 1997; Buchert et al., 2008), indicating that this structure could be of  
potential relevance for the NF1 cognitive phenotype. Moreover, decreased levels of  the 
neuronal marker N-acetylaspartate were observed using magnetic resonance spectros-
copy (Wang et al., 2000), indicating either neuronal loss or neuronal dysfunction.
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studies on AnimAl models oF nF1
Genetic manipulations in animal models have provided important insights to study and 
improve our understanding of  human genetic diseases. A variety of  models capturing 
different features of  the disease can be used to understand the complexity of  the hu-
man disorder. In that sense, several NF1 models were developed using mice, the fruit fly 
(Drosophila melanogaster) and zebrafish. 
Regardless of  the species being studied, neurofibromin is involved in cognitive pro-
cesses and neural development. Even so, it is important to keep in mind that the bio-
logical consequences of  the alterations seen in animal models might not be conserved 
across species.
Mice models
The main mice model applied to study NF1 bears a heterozygous null mutation in the 
Nf1 gene (Nf1+/-) (Jacks et al., 1994), whereas homozygous Nf1-/- mice die in utero, as a 
result of  a cardiac anomaly (Brannan et al., 1994). 
Although Nf1+/- mice do not develop neurofibromas, the hallmark feature of  NF1, 
they are cancer prone and the behavioural phenotype shows a pattern that is reminiscent 
of  the human cognitive manifestations. Impairments in memory, attention and visu-
ospatial domains have been successfully recapitulated by the mice models (Shilyansky 
et al., 2010a). Furthermore, studies employing the Nf1+/- mice, as well as, conditional 
mutants contributed extensively to identify the cellular and molecular mechanisms that 
underlie the cognitive and behavioural changes associated with NF1. Conditional mu-
tants were created using the Cre-loxP system, which enables gene deletions to specific 
time frames, cell types, or areas (Gu et al., 1994). 
Overall, Nf1+/- mice and a number of  other Nf1 mutants, showed impairments in 
spatial memory and learning in the hidden version of  the Morris water maze, which were 
reversed by increasing the training trials (Silva et al., 1997; Costa et al., 2001; Costa et al., 
2002; Li et al., 2005; Cui et al., 2008). The Morris water maze is a test sensitive to hip-
pocampal function (Morris et al., 1982) and long-term potentiation (LTP) mechanisms 
(Moser et al., 1998). Furthermore, the Nf1+/- mice also have working memory (Shilyan-
sky et al., 2010b) and attention deficits (Li et al., 2005). 
The first key finding contributing to understand learning deficits in mice came from 
the study of  Costa et al (2001), where authors related increased Ras signalling with im-
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paired learning. Further developments arose from studying LTP to determine whether 
changes in synaptic plasticity account for the hippocampal related functional deficits ob-
served in mice (Costa et al., 2002). The LTP deficits were revealed by theta-burst stimu-
lation but not high-frequency stimulation indicating that the LTP deficits were more 
sensitive to alterations in GABA-mediated inhibition. Taking into account this evidence 
and to further identify cell-type physiological effects, Cui et al (2008) developed a series 
of  Cre-LoxP mice to limit neurofibromin heterozigoty to specific brain cell types. They 
observed that Nf1 expression in interneurons seems to be critical for behaviour, whereas 
its role in pyramidal neurons or glia do not alter performance in the Morris water maze 
and is therefore nonessential for hippocampal learning. Furthermore, it was determined 
that increased inhibition was related to increase in miniature inhibitory postsynaptic 
potentials (mIPSPs) frequency as a result of  Nf1 heterozigosity in inhibitory neurons, 
linking neurofibromin to GABAergic neurotransmission. In turn, increased frequency 
of  mIPSPs was attributable to higher levels of  GABA release as a consequence of  in-
creased phosphorilation of  synapsin 1, a protein with a critical role in the regulation of  
neurotransmitter storage and release (Hilfiker et al., 1999). Glutamatergic neurotrans-
mission does not seem to be affected, suggesting a shift in the balance between inhibi-
tory and excitatory processes within hippocampal networks. Recently, it was shown that 
spontaneous IPSPs are also increased in the prefrontal cortex and striatum of  the Nf1+/- 
mice (Shilyansky et al., 2010b). Overall, these results suggest that neurofibromin may be 
part of  a general feedback mechanism that adjusts the rate of  GABA release to match 
the level of  synaptic activity. Inadequate GABA release during high levels of  synaptic 
activity might lead to erroneous synaptic strengthening and learning deficits. 
The learning, memory and attention deficits in the Nf1+/- mice could be rescued 
by two methods: 1) Reducing of  Ras/MAPK activity, as shown by the use of  Nf1/
Ras double mutants (Nf1+/-/Kras+/-) or farnesyl transferase inhibitors, as lovastatin, that 
pharmacologically decrease levels of  Ras signalling (Costa et al., 2002; Li et al., 2005). 2) 
Reducing GABAergic neurotransmission. GABAA receptor antagonist, picrotoxin, was 
able to rescue behavioural deficits associated with impaired hippocampal function (Cui 
et al., 2008) and working memory (Shilyansky et al., 2010b). 
Another cognitive domain that has been studied in the animal model is attention. A 
recent contribution to this subject came from the study of  Brown et al (2010). Authors 
used an Nf1+/- mutant with a complete loss of  the Nf1 gene in GFAP expressing glial 
cells (Nf1 OPG mouse) to gain insight into the attention abnormalities seen in children 
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with NF1. The mice presented non-selective and selective attention deficits (as measured 
by the frequency of  rearing in response to a novel environment) without an accompa-
nying hyperactivity phenotype. This behavioural pattern is the consequence of  reduced 
dopamine levels in the striatum, which is normalized following either methylphenidate 
or L-dopa administration (Brown et al., 2011).
Given the complex reciprocal modulation of  neural transmission, particularly be-
tween dopamine, GABA and glutamate, it is probable that an interplay between these 
neurotransmitters contribute to the cognitive deficits observed in NF1.
Besides the cellular and molecular alterations discussed, studies in the Nf1 mice also 
provide relevant information to understand the impact of  altered structure in brain 
function. Particularly, it was shown that mice lacking neurofibromin in the majority of  
cortical neurons and astrocytes fail to form cortical barrels in the somatosensory cortex, 
demonstrating a role for neurofibromin in cortical development (Lush et al., 2008).
Drosophila and zebrafish models
The fruit fly, Drosophila melanogaster has been extensively used as a genetic model to study 
the neural mechanisms underlying learning and memory deficits. In part because of  its 
rapid generation time, comparatively low cost, and vast battery of  genetic and transgenic 
capabilities available (Gatto and Broadie, 2011). Drosophila Nf1-null mutants are viable, 
fertile, and normally patterned, but display a 15%–20% size reduction (The et al., 1997) 
and lack a circadian rest–activity rhythm (Williams et al., 2001). 
In the Drosophila, Nf1 is involved in both Ras-dependent and cAMP-dependent path-
ways interacting with the rutabaga (rut) gene encoding adenylyl cyclase (AC). Neuro-
fibromin activation of  the Rut/AC pathway is an essential component of  Drosophila 
learning and memory functions (Guo et al., 2000). Introduction of  human NF1 into the 
Drosophila disease model revealed distinct functional domains of  NF1. The GAP-relat-
ed domain was necessary for long-term memory, while the C-terminal for immediate 
memory (Ho et al., 2007). Recently, it was shown that Nf1 is required in the operational 
phase of  memory acquisition, but not for stabilization and maintenance (Buchanan and 
Davis, 2010).
The circadian defect is partially restored by mutations that attenuate Ras signalling 
(Williams et al., 2001). However, the other analyzed phenotypes are Ras-insensitive. In-
stead, they are suppressed by decreasing the activity of  the cAMP/PKA signalling path-
way (Guo et al., 1997; The et al., 1997; Guo et al., 2000).
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A zebrafish model of  NF1 was recently developed with the purpose to elucidate 
novel developmental functions of  neurofibromin (Padmanabhan et al., 2009). Zebrafish 
has two genes, nf1a and nf1b highly similar to NF1 at the amino acid level (90.4% and 
90.7%, respectively). Knockdown of  the nf1 genes results in cardiovascular and neural 
abnormalities in embryos and increased tumorigenesis (Shin et al., 2012). Furthermore 
nf1-null larvae seem to have motor and learning deficits (Shin et al., 2012).
pHArmAColoGiCAl tHerApies
Pharmachological therapies to treat the cognitive deficits in patients with NF1 have 
been inspired by findings in mice models. Researchers have shown that neurofibromin 
regulates Ras/MAPK signalling presynaptically and deficits in neurofibromin result in 
augmented GABA release (Costa et al., 2002; Cui et al., 2008) causing learning deficits. 
If  this mechanism translates to the human disorder it would be theoretically possible to 
reverse learning deficits by either decreasing Ras signalling or GABA activity.
 Picrotoxin is a drug that blocks the binding of  GABA to its receptors and at sub-
convulsant doses reversed LTP and learning deficits on the Nf1+/- mice (Cui et al., 2008). 
However, this is an analeptic drug with potential to cause seizures and there is little 
quantitative information on the effects of  picrotoxin in humans. Furthermore, approxi-
mately 6% of  the individuals with NF1 have epilepsy (Korf  et al., 1993), making this 
group of  patients unsuitable to receive this treatment. Moreover, the prominent role of  
GABA in the central nervous system (Owens and Kriegstein, 2002) might lead to non-
specific consequences while there are also uncertainty relatively to the long-term effects 
of  chronic drug use. Concerns raised by the use of  GABA antagonists and the sparse 
information of  their effects in humans make pharmacological manipulations of  the 
Ras-MAP-kinase pathway an alternative choice for clinical trials.  Particularly, the FDA-
approved drug lovastatin, conventionally used for lowering cholesterol levels. Lovastatin 
decreases the activation of  Ras and can reverse LTP and learning impairments of  the 
Nf1+/- mice (Li et al., 2005). 
Pharmacological therapies can additionally be applied to treat attention deficits in 
children. Studies in a Nf1 mice showed that attention abnormalities are a consequence 
of  reduced dopamine levels in the striatum, which is normalized by methylphenidate or 
L-dopa administration (Brown et al., 2011). Moreover, attention deficits in the Nf1+/- 
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mice were also rescued by lovastatin (Li et al., 2005). These data suggests that agents 
that normalize abnormalities in either Ras signalling or dopamine homeostasis, might be 
potentially used to treat attention deficits in NF1.
The first targeted therapeutic intervention trial in children with NF1 employed an 
analogue of  lovastatin, simvastatin (Krab et al., 2008). The results of  this clinical trial in-
dicated that simvastatin did not improve cognitive function in children with NF1 (Krab 
et al., 2008). In consequence, another clinical trial was set up using lovastatin. Early re-
ports showed improvements exceeding those of  test-retest or practice effects limited to 
some participants in areas of  verbal and nonverbal memory at phase I studies (Acosta et 
al., 2011). Two additional multicenter double-blind placebo control clinical trials, target-
ing cognitive deficits in NF1, are currently ongoing (NCT00352599, NCT00853580). 
Results concerning these clinical trials have not yet been disclosed.  
Aims And outline oF tHe tHesis
As a single gene disorder, NF1 bears an enormous potential for establishing genetic, 
neurochemical and brain-behaviour relationships, constituting a relevant model to elu-
cidate the neural mechanisms underlying cognitive impairment in neurodevelopmental 
disorders. 
In Chapter 1, the genetics and pathophysiology of  the disorder were presented. Ge-
netic alterations in the NF1 gene disrupt the normal trajectory of  neural development 
in complex ways resulting in a heterogeneous pattern of  cognitive and behavioural phe-
notypes. The cognitive pattern of  dysfunction has been extensively examined at the be-
havioural level, now it remains to be determined the biological mechanisms contributing 
to the observed phenotype in patients. 
The aim of  this thesis is to provide new insights into brain structure, function and 
neurochemical alterations in NF1 that might contribute to identify the aetiology of  the 
cognitive deficits observed in the disorder. This identification of  physiological altera-
tions is critical to understand the pathogenesis and find adequate treatments. 
In order to explore physiological alterations in the human brain appropriate meth-
odologies are required. Magnetic resonance is a suitable technique as it provides in vivo 
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and non-invasively multidimensional neurological information. Chapter 2 provides an 
overview of  the fundamentals of  magnetic resonance for the study of  brain structure, 
functional activation and neurochemistry that were applied in this thesis. 
Chapter 3 describes the participant’s recruitment and selection criteria and the pro-
tocols followed for participants’ characterization, and overviews the research timeline 
followed in the course of  this work. 
The following chapters are presented as individual self-standing contributions. 
Therefore, each chapter has its own methodology and results sections. 
Chapter 4 describes a study using functional magnetic resonance imaging (fMRI) to 
test whether information processing in early visual cortical areas is impaired. This study 
provides the first fMRI study on basic visual processing deficits in children, adolescents 
and adult patients with NF1. Previous fMRI studies have focused on higher order cog-
nitive mechanisms (i.e. phonological processing, visuospatial processing and working 
memory). However, it is crucial to assess whether sensory deficits are present in patients 
with NF1, namely early visual processing deficits, as they can contribute to the poor 
performance of  individuals with NF1 in visuospatial tasks. Moreover they can play a 
role in impaired function of  higher order cognitive mechanisms (Doniger et al., 2002; 
Dias et al., 2011). 
Inspired by studies in NF1 mice models indicating that the balance between excita-
tion and inhibition is altered due to increased GABAergic neurotransmission, we sought 
to translate this hypothesis to the human disorder. Therefore, in Chapter 5, magnetic 
resonance spectroscopy (MRS) was applied to measure GABA levels in children and 
adolescents with NF1.
In order to understand how mutations in the NF1 gene impact brain structure it is 
also essential to characterize in detail the brain structural abnormalities in patients with 
NF1. Chapter 6 adds to the present knowledge on structural brain alterations in chil-
dren with NF1 by investigating the volume of  subcortical structures and the composite 
dimensions of  the cortex, through the analysis of  cortical volume, cortical thickness, 
cortical surface area and gyrification.
Finally, the overall results are discussed in Chapter 7 with the objective of  providing 
a comprehensive and integrative view of  the different studies developed in this thesis 
and its conclusions.
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Neuroimaging modalities constituted a revolution in the ability to investigate brain anat-
omy and physiology. Magnetic resonance imaging (MRI) is broadly applied to map the 
human brain because of  its noninvasive nature and its versatility, thereby conferring po-
tential to improve diagnosis, monitor therapeutic approaches and provide insights into 
the mechanisms of  brain disease.
This chapter provides an overview of  the magnetic resonance (MR) methods em-
ployed throughout this thesis to assess brain morphology, metabolism, physiology and 
function of  the NF1 brain. 
mr pHysiCAl prinCiples – semi-ClAssiCAl ApproACH
MRI is based on the magnetic excitation of  a tissue and the recording of  returned elec-
tromagnetic signals. More precisely, it is based upon the interaction between an applied 
magnetic field and a nucleus that possesses spin. 
Nuclear spin or spin angular momentum is one of  the intrinsic properties of  a nucle-
us and its value depends on atomic composition. The spin, I, is quantized meaning that 
it can only admit certain discrete values. These values depend on the atomic number and 
atomic weight of  the nucleus. Three groups of  values are possible for I: zero, half-inte-
gral-values, and integral values. Nuclei with an overall spin different from zero (e.g. 1H, 
13C, 31P, 15N, 19F) are susceptible to the MR technique, whereas those with an overall spin 
of  zero (e.g. 12C, 16O, 32S) are not because they do not interact with the external magnetic 
field. In MRI, the nucleus that is mostly accessible to experimental research is 1H (I = 
½), as it is widely abundant in human tissue and possesses favourable magnetic proper-
ties. The two biggest sources of  protons in human tissue are water followed by fat.
The nucleus can be considered to be rotating about an axis at a constant velocity. 
Normally, the orientation of  the nuclear spins is random. However, when placed in a 
strong static magnetic field (B0) precession occurs (rotation around the direction of  B0). 
The precession of  the nucleus occurs at the Larmor or resonance frequency ω0, given 
by the Larmor equation:
                                                              ω = γB0                                      [Equation 1]
The Larmor frequency, schematically represented in Figure 1, is dependent on the 
gyromagnetic ratio (γ), a constant unique of  each nucleus, and the external magnetic 
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field (B0). This precession process generates an electric field with frequency ω0. For hy-
drogen protons, γ= 42.56 MHz per Tesla. Therefore, at the magnetic field strength of  a 
3 Tesla scanner, the precession frequency of  hydrogen protons is 128 MHz.
The orientations that a nucleus’ magnetic moment can take against an external mag-
netic field are not of  equal energy. Spin states which are oriented parallel to the external 
field are lower in energy than in the absence of  an external field. In contrast, spin states 
whose orientations oppose the external field are higher in energy than in the absence of  
an external field (Figure 2). The nuclei will be distributed throughout the various spin 
states available. The number of  nuclei in each spin state is described by the Boltzmann 
distribution so that at thermal equilibrium the lower energy level will have a relatively 
small excess of  population of  spins. Where energy separation occurs there is a pos-
sibility to induce a transition between the various spin states. By irradiating the nucleus 
with electromagnetic radiation of  the correct energy (as determined by its resonance 
Figure 1. A nuclear spin precessing in an external magnetical field 
B0 at the Larmor frequency (ω). The Larmor frequency is dependent on 
the gyromagnetic ratio (γ) and the external magnetic field (B0).
Figure 2.  The orientations that a nucleus’ magnetic moment can take against an external 
magnetic field are not of  equal energy. In the absence of  a magnetic field (left side of  figure), spins 
will have equal energy so that there is no preferential alignment between the spin up and spin down 
orientations. In the presence of  a magnetic field (right side), the spin up orientation (parallel to B0) is of  
lower energy and its configuration contains more protons than the higher energy, spin down configura-
tion. The difference in energy between the two levels is proportional to B0.
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frequency), a nucleus with a low energy orientation can be induced to “transition” to an 
orientation with a higher energy. The absorption of  energy during this transition forms 
the basis of  the MR method.
The difference in spin population results in a net microscopic magnetization M0, 
aligned parallel to the magnetic field B0. This net (or longitudinal) magnetization can be 
manipulated, which is done in MR experiments.
In a typical MR experiment, the net macroscopic magnetization M0 is tilted from its 
original orientation along B0 (or z-axis) to the transversal orientation by a radio frequen-
cy (RF) pulse at the Larmor frequency, as indicated by an effective field B1 (Figure 3). 
During the application of  the RF pulse, M0 will rotate towards the xy-plane (Mxy). 
The power and length of  the RF pulse can be adjusted, and by this way modulate the 
extension of  rotation. Directly after the application of  the RF excitation pulse, the spins 
are still precessing along B0, but their precession is no longer random; they precess in 
phase, and a maximum signal is detected. When the pulse ends, the nuclei relax and 
return to their original equilibrium positions, and the MR signal decays. This decaying 
signal contains the sum of  the frequencies from all the target nuclei in the sample. It 
is picked up by the coil as an oscillating voltage generated by the magnetic moments 
Figure 3. Schematic representation of  a typical MR experiment in the rotation frame of  refer-
ence. In a rotating frame, the coordinate system rotates about one axis while the other two axes vary 
with time. In this rotation frame of  reference, B1 and M0, are stationary, while the x and y axes rotate 
at the Larmor frequency. When viewed in this fashion, the precessing spin appears stationary in space 
with a fixed set of  x, y, and z coordinates. A short RF pulse is applied along the x’ axis. The magnetic 
field of  this radiation is given by the symbol B1. The radiofrequency (RF) pulse causes the bulk magne-
tization vector, M0, to rotate clockwise about the x’ axis. The longitudinal component Mz decreases over 
time while the transverse component Mxy increases. Reproduced from Goebel, 2007.
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precessing/relaxing back to equilibrium. The signal received by the coil is called free 
induction decay (FID).
The relaxation process is crucial for the MR experiment. Because of  local interac-
tions between individual spins, such as translation and rotation, phase coherence will be 
lost, and Mxy will decrease. Two types of  relaxation occur simultaneously: longitudinal 
(spin-lattice) relaxation and transverse (spin-spin) relaxation. In longitudinal relaxation, 
the z component of  M returns to its original position by transferring vibrational or 
translational energy to the molecular framework, the lattice. The time required for the 
system to recover 63% of  its equilibrium value after a 90o pulse is T1 or the spin-lattice 
relaxation time (Figure 4a). In transverse relaxation, energy is transferred to a neighbour-
ing nucleus in the same molecular environment and precessing in the transverse plane 
Figure 4. Representation of  T
1
 and T2 relaxation processes. a. Longitudinal relaxation. The mag-
netization M0 is tipped by a 90° pulse. After the pulse the system relaxes and magnetization will start its 
return to the equilibrium state. This effect causes recovery of  the longitudinal (z) component of  mag-
netization towards M0, at an exponential rate with time-constant T1. b. Transverse relaxation. Trans-
verse relaxation induce an increase in dephasing of  individual spins, so a progressive decrease of  the 
macroscopic magnetization is observed. This process causes shortening of  the transverse component 
of  magnetization, at an exponential rate with time-constant T2.
a b
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at the same ω0 frequency. T2 is the time it takes for the magnetization to reach 37% of  
its initial value. T2 occurs due to energy transferred from one excited nucleus to another 
nucleus nearby. This energy transfer can occur as long as nucleuses are in close proximity 
and retain the same ω0. Intermolecular and intramolecular interactions such as vibrations 
or rotations cause ω0 to fluctuate, which leads to a gradual loss of  phase coherence and 
reduce the magnitude of  transverse magnetization and consequently the signal (Figure 
4b). 
In addition, a sample always experiences a certain degree of  magnetic field inho-
mogeneity leading to a heterogeneous distribution of  resonance frequencies. This in-
homogeneity comes from three sources: 1) Main field inhomogeneity as a consequence of  
nonuniformity to B0 due to imperfections in magnet manufacturing; 2) Sample-induced 
inhomogeneity due to differences in the magnetic susceptibility of  adjacent tissues (e.g., air, 
bone) that distort the local magnetic field at the interface between different tissues; 3) 
Imaging gradients used for spatial localization that induce a transient inhomogeneity during 
the measurement. Consequently, the MR signal actually decreases more rapidly than it 
will be expected only by the contribution of  T2, with a decay constant T2*.
For the production of  an image, a sequence of  RF pulses is usually combined with 
specific magnetic gradient pulses superimposed upon the large external field B0. The 
formation of  an image involves the following procedures:
Localization of  the region of  interest - Linear magnetic field gradients applied along the 
x, y, and z axes allow for spatial encoding (Figure 5). As referred previously the 
Larmor frequency is proportional to the magnetic field strength. By varying the 
magnetic field linearly one can vary the frequency of  the signal.
Excitation of  spins in the region of  interest – Excitation of  the spins is performed 
through the application of  RF pulses. However, the application of  gradients to 
signal localization will amplify the dephasing of  spins. To avoid loosing the signal a 
gradient-echo or a spin-echo pulse are used (Figure 6). 
Spatial encoding of  the spins signal – Spatial encoding is performed by frequency en-
coding and phase encoding, both of  which contain spatial information needed for 
image reconstruction.
Signal detection and reconstruction.
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When acquiring MR data, two of  the most important parameters to manipulate are 
the timing values corresponding to the repetition time (TR), and the echo time (TE). TR 
is the time between successive RF excitation pulses applied and determines the amount 
of  T1-weighting contribution to the image contrast. Longer TR allows more time for the 
RF excitation energy to be dissipated trough spin-lattice relaxation, producing images 
with less T1 weighting. TE is the time between the excitation pulse and the peak of  the 
echo signal (Figure 6). During this time interval, the transverse magnetization decays due 
to T2 and T2* relaxation effects.
Figure 6 contains a simplified scheme of  one of  the most common pulse sequence 
used in MRI, the spin-echo sequence. This sequence contains at least two RF pulses, 
an excitation pulse (90o) and one or more 180o refocusing pulses that generate the spin 
echo(es). 
In a spin-echo sequence, the spins are initially excited by a 90o pulse, after which 
they dephase in the x’-y’ plane. This dephasing is not homogeneous, i.e., some loose 
phase faster than others. If, after a time delay τ, the system is exposed to a 180° pulse, 
Figure 5. Image formation. Assume that eight glasses with different amounts of  water are placed in 
the MRI scanner. If  a gradient is applied in the x direction, the spins will precess at frequencies that 
depend upon their position along the gradient. Spatial information is now frequency-encoded. The 
strength of  the signal at each frequency is directly proportional to the number of  protons from the 
respective glass of  water. The time domain signal is the sum of  these frequencies and a Fourier Trans-
form can be used to determine the strength of  the signal at each frequency. Since frequencies encode 
different spatial positions, an “image” of  eight pixels can be formed. The grey values of  these pixels 
reflect the relative amount of  water in the different glasses. Reproduced from Goebel, 2007. 
64 | Chapter 2
a refocusing is initialized. Now the faster spins lie behind the slower ones, but at a time 
delay 2τ they catch up, which leads to an echo at time TE = 2τ. A common analogy to 
the formation of  an echo is a race (Figure 7) where faster runners separate from slower 
runners after the starting signal (90o pulse). However, at a certain time during the race, 
the runners are transposed (180° pulse). Now the faster runners are behind the slower 
ones, but they are able to catch up. All runners will reach the finishing line together (i.e., 
create an echo at the echo time 2τ = TE).
Because of  the relatively long T1 relaxation time of  tissues, a delay of  a couple of  
seconds may be necessary before repeating the excitation to let the magnetization re-
cover. During this time a number of  parallel slices can be excited. The number of  slices 
obtainable can be calculated by dividing the TR by the time required for each slice. For 
example, if  TR = 2000 ms and TE = 80 ms, the theoretically number of  slices is 25 (in 
practice this number is reduced, since each slice requires slightly more than TE). 
Figure 6. Spin-echo pulse sequence. The spin 
system is excited by a 90o pulse. After a time delay 
(τ) one or several 180o pulse follow. This leads to 
the formation of  an echo. The time between the 
90o pulse and the peak of  the echo is called echo 
time (TE). The repetition time (TR) is the time be-
tween two complete pulse sequences. 
Figure 7. The race analogy for the echo forma-
tion in a spin-echo pulse sequence. At the time 
of  the 90° pulse, all runners are lined up at the 
starting line. After the 90° pulse, the faster runners 
separate from the slower runners (dephasing). At a 
certain time during the race, the runners are trans-
posed (at the time τ when the 180° pulse is trans-
mitted). Now the faster runners are behind the 
slower ones, but they catch up. All reach the finish-
ing line together (i.e., create an echo at the echo 
time 2τ = TE). Reproduced from Rinck, 2003.
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struCturAl imAGinG
Structural imaging relies on the fact that different types of  tissue have different physi-
cal properties providing signals that can be translated in detailed maps of  the brain. In 
a MR image different contrasts can be achieved by using different pulse sequences and 
manipulating the imaging parameters (e.g. TR, TE, pulse angle).  What makes MRI use-
ful for producing images of  the brain is that different tissues exhibit different values for 
both T1 and T2 relative to each other. For any given point in time during the relaxation 
phase, the T1 of  white matter signal is stronger than that of  grey matter, and the grey 
matter signal is stronger that of  the cerebrospinal fluid (CSF) (Figure 8a). These differ-
ences in signal intensity are exactly opposite for a T2 measurement (Figure 8b).  
In general images have contrast, which depends on either proton density (PD), T1 or T2, 
Figure 9. Proton density is related to the number of  hydrogen atoms in a particular vol-
ume. Signal intensities on T1, T2, and proton density-weighted images relate to specific 
tissue characteristics and allow discrimination between different types of  tissue. 
For quantitative structural brain analysis normally only T1-weighted and T2-weighted 
images are used. T1-weighted imaging (Figure 9a) offers the greatest segmentation clarity 
Figure 8. T
1 
and T2 time constants for brain tissue. a. For any given longitudinal magnetization 
relaxation time (T1) the white matter signal is stronger than that of  grey matter, and the grey matter 
signal is stronger that of  the CSF. Images acquired at a short TR will be T1-weighted (light-grey bar), 
while images acquired at long TRs will be more T2-weighted (dark-grey bar). b. For any given transver-
sal magnetization relaxation time (T2), the CSF signal is stronger than grey matter signal and the grey 
matter signal is stronger than that of  white matter. Images acquired at a short TE will be T1-weighted 
(light-grey bar), while images acquired at long TEs will be more T2-weighted (dark-grey bar).
a b
66 | Chapter 2
between grey matter, white matter and CSF, and is therefore most frequently used for 
quantitative MRI studies of  brain morphology. On the other hand, T2-weighted imaging 
(Figure 9b) may be preferably used for quantification of  intracranial volume, given that 
these images have increased signal intensity of  CSF that allows easier quantification of  
CSF and brain parenchyma together.  
Furthermore, T2-weighted and fluid attenuated inversion recovery (FLAIR) images 
are routinely used to detect areas of  high signal intensity in NF1, Figure 9d. FLAIR 
images are T2-weighted images with the CSF signal suppressed used to provide a better 
contrast between the lesion and brain parenchyma. The bright lesions observed in sev-
eral patients with NF1 are nonspecific and tissue composition cannot be deduced based 
on their visual observation because prolongation of  T2 relaxation occurs with pathologic 
lesions from different nature. 
FunCtionAl mAGnetiC resonAnCe imAGinG
The purpose of  functional magnetic resonance (fMRI) is to measure brain activity. 
The brain is a highly active organ and neuronal activity consumes energy. To maintain 
neural cells functioning there is a constant supply of  glucose and oxygen to the brain, 
delivered through an extensive network of  blood vessels. The fact that blood flow and 
energy metabolism are tightly linked to neuronal activity is crucial to many functional 
imaging methods.
Figure 9. Brain images with different contrasts. a. T1-weighted image. b. T2-weighted image. c. 
Proton density weighted image. d. FLAIR image of  a patient with NF1. Areas of  hyperintensity in the 
image correspond to T2w-hyperintensities. A black arrow points to one of  these hyperintensities com-
monly designated unidentified bright objects (UBOs).
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The neurovascular coupling ensures that when neuronal activity increases in a giv-
en region there is increased oxygen delivery by increasing blood flow to that region in a 
process denominated hemodynamic response. Oxygen is transported by haemoglobin 
and the state of  haemoglobin impacts differently the MR signal. Oxyhaemoglobin (oxy-
genated haemoglobin) has diamagnetic properties (weak, negative susceptibility to mag-
netic fields, all the electrons are paired so there is no permanent net magnetic moment) 
and therefore does not distort the surrounding magnetic field, in turn, deoxyhaemoglobin 
(deoxygenated haemoglobin) is paramagnetic (positive susceptibility to magnetic fields as-
sociated with the presence of  unpaired electrons) and leads to magnetic field distortions 
and signal loss. The local field inhomogeneities caused by deoxyhaemoglobin increase the 
speed of  dephasing and the T2* in tissue around the vessels. This effect is the basis of  
the blood-oxygen-level-dependent (BOLD) contrast used in fMRI (Ogawa et al., 1990). 
BOLD is the most common functional imaging method applied in neuroscience.
The fMRI BOLD response is dependent on the hemodynamic response (Figure 10c), 
which can be divided into three phases: 
1) Initial dip immediately after the onset of  stimulation caused by a fast transient in-
crease in oxygen consumption, that it is not immediately accompanied by a change in 
blood flow. It is caused by a small rise in the amount of  deoxyhaemoglobin (Figure 
10a); 
2) Positive BOLD response as a consequence of  increased cerebral blood flow, as well 
as increased cerebral blood volume. The increase in blood flow overcompensates for 
the amount of  oxygen being extracted, so that an oversupply of  oxygenated blood is 
delivered, Figure 10b. This means that the blood oxygenation actually increases fol-
lowing neural activation and levels of  the oxygenated to deoxygenated haemoglobin 
ratio increase resulting in a more homogeneous local magnetic field. The BOLD 
effect, thus, measures increased neuronal activity indirectly via a change in local mag-
netic field homogeneity, which is caused by an oversupply of  oxygenated blood. An 
overshoot might be present especially for long stimulation events as a consequence 
of  a local oversupply of  oxygenated haemoglobin; 
3) Post-stimulus undershoot occurs upon cessation of  the stimulus before the return of  
BOLD signal to baseline. This undershoot might be explained by an accumulation 
of  deoxyhaemoglobin in vessels while cerebral blood flow and oxygen extraction rate 
have already returned to baseline. This could be caused by a vasodilatation of  the 
venules and veins, because of  their balloon-like elasticity, which results in an increase 
in deoxygenated venous blood volume. 
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Figure 10. The hemodynamic BOLD response. a. Immediately after the onset of  stimulation there 
is a fast transient increase in oxygen consumption that it is not immediately accompanied by a change in 
blood flow. This results in an increase of  deoxygenated haemoglobin (Hb) to oxygenated haemoglobin 
(HbO2) ratio in the capillary bed and venules. Since Hb is paramagnetic, it distorts the magnetic field, 
which leads to rapid dephasing of  excited spins resulting in a decrease in the MRI signal. This effect 
accounts for the initial dip observed in the hemodynamic BOLD response at c. b. If  the cortical region 
is in activated state there is an increased oxygen extraction rate. However, the blood flow increases 
delivering oxygen beyond local need, which decreases the amount of  Hb and increases HbO2. Since 
HbO2 does not substantially distort the homogeneity of  the local magnetic field, excited spins dephase 
slower resulting in an enhanced MRI signal (BOLD effect). This effect accounts for the positive BOLD 
response observed in c. When the stimulus is turned off  there is an undershoot before returning to 
baseline, as a result of  accumulation of  deoxyhemoglobin in the venous blood. Adapted from Goebel, 
2007.
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In summary, enhanced neuronal activity resulting from activation of  neurons leads 
to a local increase in energy and oxygen consumption in functional areas. However, the 
BOLD contrast depends not only on blood oxygenation but also on cerebral blood 
volume and cerebral blood flow, constituting a complex response controlled by several 
parameters. A relevant question is what neuronal mechanisms underlie BOLD signal. 
Combined BOLD fMRI and electrophysiological recordings demonstrated that fMRI 
responses mostly reflect the synaptic input and local intracortical processing, including 
the activity of  excitatory and inhibitory interneurons (Logothetis et al., 2001; Goense 
and Logothetis, 2008). On the other hand, the interactions between neural activity and 
the vascular source of  the fMRI signal, mainly related with the increase in blood flow 
remain less understood. 
Although a clear understanding of  how neuronal activity influences the fMRI response 
is important to interpret functional imaging data, BOLD fMRI has several advantages, 
it is noninvasive, has relatively high spatiotemporal resolution, and holds the capacity 
to demonstrate the network of  brain areas engaged when subjects undertake particular 
tasks. One disadvantage is that it measures a surrogate signal whose spatial specificity 
and temporal response are subject to both physical and biological constraints. 
A major goal in fMRI is to determine the neural bases of  sensory, motor and cogni-
tive processes. Additionally, fMRI enables the characterization of  the response profile 
in various regions-of-interest (ROIs) by retrieving plots of  averaged signal time courses 
(Figure 11). To study the activity of  a certain brain area a task paradigm has to be de-
veloped, i.e. a strategy for presenting stimuli to subjects during an experiment. These 
paradigms are usually divided in two major categories: blocked designs or event-related 
designs. 
In a blocked design a series of  trials in one condition is presented during a discrete 
epoch of  time. The signal acquired during one blocked condition is then compared 
to other blocks involving different task conditions. In a typical study, task blocks will 
range in duration from 16 s to a minute and multiple task blocks will be presented to 
allow the contrast of  fMRI signals between task blocks. Event-related paradigms differ 
from blocked paradigms in that individual trial events (or even sub- components of  
trial events) are measured. Blocked designs are useful for obtaining high signal-to-noise 
information in neural processes that last a relatively long time. An example of  a block 
design is shown in Figure 11.
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Figure 11. fMRI activation as a result of  a visual experiment comparing activation to magno-
cellular vs parvocellular stimuli. An fMRI task paradigm is shown in the upper part of  the figure. 
The horizontal axis represents time (volumes). The vertical axis represents the amplitude of  the fMRI 
response. Each coloured segment corresponds to one condition. The green segments correspond to 
intervals where subjects were seeing a magnocellular stimulus; the red segments correspond to intervals 
where subjects were seeing a parvocellular stimulus; grey segments correspond to a control condition. 
White curves show BOLD responses for a selected group of  voxels in the brain that is more activated 
by magnocellular than parvocellular stimulation. A statistical map of  the comparison of  activation to 
magnocellular vs parvocellular stimuli is shown in the middle part of  the figure. Voxels responding 
more to magnocellular than parvocellular stimulus are coloured from red to yellow, while voxels re-
sponding more to parvocellular than magnocellular stimulus are coloured from green to blue. A region 
of  10 voxels was selected from the activation map (white cross indicates the centre of  the region). The 
averaged signal time course plot corresponding to the selected region is shown in the lower part of  
the figure. The horizontal axis represents time (scans). The vertical axis represents BOLD percentage 
signal change in relation to the baseline (rest condition). Green depicts the time course of  the BOLD 
response for the magnocellular condition and red for the parvocellular condition.
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The presentation and recording of  data during the complete task paradigm is called 
a run (4D volume composed of  information on space and time). A run is composed 
of  the repeated measurement of  a functional volume (3D volume of  the subject’s brain 
every TR). The volume TR specifies the temporal resolution of  the functional measure-
ments since all slices comprising one functional volume are obtained once during that 
time. Each functional volume contains a complete set of  slices, 2D representations of  
the brain that are one voxel thick. 
Prior to statistical analysis data is pre-processed to reduce artifact and noise-related 
signal components. Statistical analysis aims at identifying those brain regions exhibiting 
increased or decreased responses in specific experimental conditions as compared to 
other (e.g. control) conditions. In the end, statistical maps are created for visualization 
and interpretation of  the results, Figure 11.
mAGnetiC resonAnCe speCtrosCopy
Magnetic resonance spectroscopy (MRS) makes it possible to directly, in vivo, assess bio-
chemistry in localized brain regions, therefore adding a new dimension to non-invasive 
neuroimaging. MRS allows quantification of  neurochemical compounds within local-
ized regions of  the brain, allowing assessment of  neuronal and glial function, metabolic 
activity and neuronal degeneration. This technique has been widely applied in clinical 
research, especially as a biomarker of  altered brain metabolism. More recently, its ap-
plications to neuroscience gained a new breath through the measurement of  neurotrans-
mitters and its correlation with behaviour (Edden et al., 2009; Jung et al., 2009; Stagg et 
al., 2011).
The product of  MRS is a spectrum of  different peaks at different radio frequencies 
and intensities (Figure 12). Specific nuclei contained in a metabolite give rise to either a 
single peak or multiple peaks that are uniquely positioned along the frequency axis. The 
peak positions are dependent on the chemical shift. The chemical shift is a consequence 
of  the electronic cloud that surrounds the nucleus, which partially shields each nucleus 
in a given molecule from B0. The electrons around the nucleus generate their own mag-
netic field, with opposite direction to the lines of  force generated by the external mag-
netic field. This electronic magnetic field effect will cause nuclei with different electronic 
densities and chemical environments to yield different resonance frequencies from those 
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defined by the applied external field B0.
In general, each nucleus in a molecule experiences a unique shielding factor depend-
ing on the chemical environment of  the nucleus. This shielding factor results in a slightly 
different total effective field experienced by each nucleus in a molecule and therefore 
different frequencies and peak positions in the spectrum.
The signal amplitude of  a peak is directly related to the concentration of  that me-
tabolite, allowing quantitative determination.
Since molecules resonate at different frequencies when exposed to different mag-
netic fields, as stated in the Larmor Equation (Equation 1), a normalization of  the MRS 
units was necessary. In that sense, the x-axis is expressed in parts per million (ppm), rela-
tive to a reference frequency. In this way, the position of  the molecule in the x-axis will 
be the same regardless of  the field strength at which the spectrum was acquired.
Although MRS can be conducted with any nucleus with an overall spin, we will focus 
on 1H MRS. It has several advantages: the proton is the most sensitive stable nucleus, al-
Figure 12. 3T spectrum of  a voxel in the occipital cortex. The right part of  the figure shows the 
location of  the voxel and the left the spectrum. The spectrum is a plot of  frequency (horizontal axis) 
expressed in ppm as a function of  signal intensity (vertical axis). The signal intensities are proportional 
to the concentration of  the metabolites in the spectrum. The frequencies are distinct for protons in 
different chemical environments of  different molecules (NAA, N-acetylaspartate; Cr, creatine; Cho, 
choline; Ins, inositol; Glx, glutamate + glutamine). 
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most every compound in living tissue contains hydrogen protons and there is no need for 
additional hardware to acquire spectra. However, there are technical issues that needed 
to be overcome. Probably, the biggest problem is the large signal from water molecules 
that obscures the metabolites signals. Indeed, while the concentration of  water is around 
36 M (resulting in a proton concentration of  70 M, because each water molecule has 
two protons), the metabolites we want to measure have a maximum concentration of  10 
mM or less. Because of  that several methods of  water suppression have been developed 
(De Graaf, 2007). Another disadvantage of  1H MRS is the narrow chemical shift range 
of  1H signals (about 15 ppm). To overcome this problem several pulse sequences are 
designed to exploit T1 or T2 relaxation time differences (Frahm et al., 1989), resonance 
frequency, spin coupling and quantum coherence (Sotak, 1991). In chapter 4 we used a 
spectral editing technique to detect the neurotransmitter γ-aminobutyric acid (GABA) 
in the human brain.
Several metabolites are visible in a typical MR spectrum of  the brain, but three major 
peaks characterize the spectrum, N-acetylaspartate (NAA), creatine/phosphocreatine 
(Cr/PCr) and choline (Cho) compounds. The description of  the different metabolites 
and their biochemical relevance for the human brain can be found in several reports 
elsewhere (Ross and Bluml, 2001; Hajek and Dezortova, 2008). Briefly, NAA is located 
in neuronal mitochondria but its exact role as a metabolite is still under discussion (Mof-
fett et al., 2007). NAA is considered to be a neuronal marker because it is almost exclu-
sively located in neurons and its concentration is larger in grey matter than white matter. 
It constitutes the most prominent signal in 1H MRS spectra of  the human brain. Cr/PCr 
are metabolites needed to the cell energetic supply and therefore considered markers of  
energetic metabolism. Finally, Cho signal is considered a marker of  membranes, because 
it incorporates precursors or degradation products of  the membrane phospholipids. 
Recently, the application of  spectroscopy to quantify the neurotransmitters GABA 
and glutamate allowed a window into the study of  synaptic activity and plasticity impor-
tant for the understanding of  normal and pathological processes in the human brain.  
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Chapter 3
Research Methodology:
patient and control groups
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etHiCs stAtement
The studies presented in this thesis were conducted in accordance with the Declaration 
of  Helsinki and all procedures were reviewed and approved by the Ethics Commissions 
of  the Faculty of  Medicine of  the University of  Coimbra (Comissão de Ética da Fac-
uldade de Medicina de Coimbra) and of  the Paediatric Hospital of  Coimbra (Comissão 
de Ética do Centro Hospitalar de Coimbra). Written informed consent was obtained 
from participants older than 18 years of  age and from the parents/guardians in the case 
of  participants younger than 18 years of  age. Additionally, children and adolescents 
younger than 18 years of  age gave written or oral informed consent.
pArtiCipAnts’ reCruitment And seleCtion
The patients involved in this study were diagnosed in the Genetics Department of  the 
Paediatric Hospital of  Coimbra in Portugal and were recruited to meet the following 
criteria:
Inclusion criteria
Age > 7 years•	
NF1 diagnosis according to the criteria of  the National Institutes of  Health •	
Consensus (National Institutes of  Health Consensus Development Conference 
Statement: neurofibromatosis., 1988), as described in Panel 1, Chapter 1
Exclusion criteria
Presence of  optic gliomas and/or other brain tumours•	
Received cranial radiation therapy or chemotherapy •	
Undergone brain surgery•	
Epilepsy •	
Traumatic brain injury•	
History of  psychiatric illness•	
Being medicated for treating depression•	
Severely impaired vision •	
Full-scale intelligence quotient (IQ) <  70•	
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The control groups for children and adolescents were recruited from a school with 
wide socioeconomic coverage and by informal advertising, whereas additional healthy 
adults were recruited from an adult further education center. Unaffected siblings and 
parents and spouses of  patients with NF1 were also recruited (cases where these par-
ticipants belong to the control group are explicitly referred in the methods section of  
the correspondent chapter). We included participants older than 7 years and excluded 
participants with any neurological disorder or presenting any of  the criterion used to 
exclude patients with NF1. Moreover, the school records of  all children and adolescents 
belonging to control groups were in accordance with their chronological age, indicating 
adequate intellectual functioning. 
In the case of  children on stimulant medication (methylphenidate), parents were 
requested not to give the medication on the days of  testing, ensuring that these children 
were not under the influence of  methylphenidate.
reseArCH timeline 
Patients visited our laboratory at least four times in a period comprised between Septem-
ber 2008 and December 2011, Figure 1. 
In the first visit patients and control participants performed contrast sensitivity tasks, 
to assess achromatic and chromatic contrast sensitivity, and two neuropsychological tests, 
the Facial Recognition Test (FRT) (Benton, 1983a) (short version) and the Judgment of  
Line Orientation (JLO) (Benton et al., 1978) (Form H) (see description at section 7). The 
results of  the contrast sensitivity study are published elsewhere (Ribeiro et al., 2012) and 
are beyond the scope of  this thesis. The FRT and JLO neuropsychological tests were 
designed to probe visuoperceptual and visuospatial functions, respectively. Additionally, 
participants with 17 years old or older performed the first set of  the Raven Standard 
Progressive Matrices (Raven et al., 1993) as an indication of  non-verbal intelligence. 
Cognitive evaluation for participants younger than 17 years old was performed us-
ing the Portuguese adapted version of  the Wechsler Intelligence Scale for Children 
(WISC-III) (Wechsler, 2003). The administration and scoring of  the cognitive tests was 
performed by a neuropsychologist. Administration of  WISC-III was conducted in a 
separate visit (Visit 2) because of  the time required for the evaluation (2 to 3 hours per 
participant). 
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Although the results of  the studies performed during Visit 1 are beyond the scope 
of  this thesis, the same group of  patients as well as a substantial group of  controls 
participated in the magnetic resonance imaging (MRI) experiments conducted between 
September 2009 and November 2010 (Visit 3). Furthermore, the Raven Standard Pro-
gressive Matrices scores were used as part of  the adult participants’ characterization 
reported in Chapter 4. 
During the time period referred as Visit 3, 104 participants were scanned and those 
that did not presented any exclusion criterion were included in the study presented in 
Chapter 3. Additionally, a cohort of  children and adolescents from this study were se-
lected for the study presented in Chapter 6. 
The last visit to our laboratory occurred between April 2011 and December 2011 
(Visit 4). For this set of  experiments only children and adolescents were recruited. The 
Figure 1. Research timeline. Data presented in this thesis are a result of  a set of  experiments con-
ducted between September 2008 and December 2011. The duration of  each period of  experiments 
is showed with bars. The white bar corresponds to a set of  studies that are beyond the scope of  this 
thesis and belong to our larger research project on Neurofibromatosis type 1. However, a substantial 
cohort of  patients was included in all our experiments. Additionally, a substantial group of  controls 
participated in the experiments conducted during Visit 3. The scores obtained with the Raven Matri-
ces in Visit 1 were used as part of  participants’ characterization. Grey bars indicate visits from which 
experiments were analysed in this thesis. (JLO, Judgment of  Line Orientation; FRT, Facial Recognition 
Test; WISC-III, Wechsler Intelligence Scale for Children; MRI, Magnetic Resonance Imaging; MRS, 
Magnetic Resonance Spectroscopy).
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group of  patients was composed by the same participants and a new cohort of  control 
subjects was recruited. A total of  53 participants were scanned and the results of  the 
study are presented in Chapter 5. 
GenetiC CHArACterizAtion oF pArtiCipAnts witH nF1
To further characterize the NF1 population, patients’ DNA was extracted from periph-
eral blood using standard procedures. The DNA was sent to the Institute of  Medical 
Genetics at the University of  Cardiff, where whole gene sequencing and multiplex liga-
tion-dependent probe amplification analysis were carried out with the aim of  identifying 
the disease causing NF1 mutations (Upadhyaya et al., 2009). 
Briefly, the comprehensive NF1 gene mutation screen involved direct DNA sequenc-
ing of  amplified exons and cDNA fragments and multiplex ligation-dependent probe 
amplification (MLPA) analysis. The 57 constituent exons of  the NF1 gene were indi-
vidually amplified with an M13-tagged specific primer set. RNA was reverse transcribed 
and the NF1 gene coding region amplified in 24 overlapping fragments. Mutations iden-
tified at the cDNA level were confirmed by direct cycle sequencing of  genomic DNA. 
rAdioloGiCAl Assessment 
All control and patient subjects were screened for intracranial abnormalities. Radiologi-
cal examinations were performed by a neuroradiologist using anatomical data from T1-
weighted Magnetization-Prepared Rapid Gradient-Echo (MPRAGE) and T2-weighted 
Fluid-Attenuated Inversion Recovery (FLAIR) sequences acquired at the Portuguese 
Brain Imaging Network using a 3T Siemens TimTrio scanner. Unidentified Bright Ob-
jects (UBOs), T2-hyperintensities commonly found in patients with NF1, were not con-
sidered exclusion criteria when present in patients (unless otherwise specified). 
opHtHAlmoloGiC Assessment
Patients with NF1 were submitted to a complete ophthalmic examination, including 
best-corrected visual acuity, stereopsis evaluation (Randot Stereotest; Stereo Optical Co., 
Chicago, IL), slit-lamp examination of  anterior chamber structures, and fundus exami-
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nation performed by an experience ophthalmologist. This assessment ensured that pa-
tients were free of  anomalies that could affect vision.
visuospAtiAl And visuoperCeptuAl FunCtion in pAtients witH nF1
The judgement of  line orientation (JLO) test (Benton, 1983a) and the facial recognition 
test (FRT) (Benton, 1983b) are skewed for the function of  the ventral (for FRT) and 
dorsal (for JLO) pathways, and were therefore used for the assessment of  visuospatial 
and visuopercetual skills in patients.
The JLO is a neuropsychological test widely used to assess visuospatial processing 
(Lezak, 1995), Figure 2a. It requires subjects to identify the orientation of  pairs of  lines 
on a multiple-choice display, which consists of  11 lines, each separated by an angle of  
18°. The task consists of  five practice examples, which contain test lines of  the same 
length as those in the array. All subsequent lines are shorter than the array lines and com-
prise either the lower, middle or upper third of  the array lines, making it more difficult 
to correctly assign the line to its match. No time limits are placed on individual items or 
the test as a whole. 
The FRT test is used to assess face recognition abilities (Benton, 1983b). Subjects 
Figure 2. Examples of  an item from the Benton judgement of  line orientation test (a) and 
facial recognition test (b). 
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are presented with a series of  items each of  which composed of  a target face above six 
test faces, and they are asked to indicate which of  the six images match the target face, 
Figure 2b. Male and female faces are used, and the faces are closely cropped so that no 
clothing and little hair are visible. The faces are centered within a black background, and 
the entire image is ~6.5 cm x 6.5 cm. For the first six items, only one of  the six test faces 
displays the target individual, and the target image and the test image are identical. In 
the next seven items, three of  the test faces match the target face, and the poses for the 
test images are different from the target image. No time limits are placed on individual 
items or the test as a whole. 
The group of  patients studied during this thesis performed significantly worse than 
a matched control group in the Facial Recognition Test (FRT) and the Judgment of  Line 
Orientation (JLO) test (Ribeiro et al., 2012).
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Chapter 4
Abnormal brain activation in
Neurofibromatosis type 1:
a link between visual processing
and the default mode network
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AbstrACt
Neurofibromatosis type 1 (NF1) is one of  the most common single gene disorders 
affecting the human nervous system with a high incidence of  cognitive deficits, par-
ticularly visuospatial. Nevertheless, neurophysiological alterations at low-levels of  visual 
processing that could be relevant to explain the cognitive phenotype, are poorly under-
stood. Here we used functional magnetic resonance imaging (fMRI) to study early corti-
cal visual pathways in children and adults with NF1. We employed two distinct stimulus 
types differing in contrast and spatial and temporal frequencies to evoke relatively differ-
ent activation of  the magnocellular (M) and parvocellular (P) pathways. Hemodynamic 
responses were investigated in retinotopically-defined regions V1, V2 and V3 and then 
over the acquired cortical volume. Relative to matched control subjects, patients with 
NF1 showed deficient activation of  the low-level visual cortex to both stimulus types. 
Importantly, this finding was observed for children and adults with NF1, indicating that 
low-level visual processing deficits do not ameliorate with age. Moreover, only during 
M-biased stimulation patients with NF1 failed to deactivate or even activated anterior 
and posterior midline regions of  the default mode network. The observation that the 
magnocellular visual pathway is impaired in NF1 in early visual processing and is spe-
cifically associated with a deficient deactivation of  the default mode network may pro-
vide a neural explanation for high-order cognitive deficits present in NF1, particularly 
visuospatial and attentional. A link between magnocellular and default mode network 
processing may generalize to neuropsychiatric disorders where such deficits have been 
separately identified. 
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introduCtion
Neurofibromatosis type 1 (NF1) is commonly associated with cognitive impairment and 
learning disabilities. The neuropsychological deficits reported include visual perception, 
motor, visuomotor, language, memory and attention domains (Riccardi, 1992; Friedman 
et al., 1993; North, 2000; Levine et al., 2006). In particular, visuospatial deficits are con-
sidered to be one of  the hallmark characteristics of  the NF1 cognitive profile (Hyman 
et al., 2005; Rowbotham et al., 2009). 
In previous studies visuospatial deficits were mainly assessed using behavioural neu-
ropsychological tests (Eliason, 1986; Eldridge et al., 1989; Hofman et al., 1994; Bawden 
et al., 1996; Dilts et al., 1996; Schrimsher et al., 2003). The test most often documented 
to show visuospatial deficits is the Judgment of  line Orientation (JLO) test (Levine 
et al., 2006). In order to unravel the neural mechanisms underlying the JLO deficits 
in NF1, Clements-Stephens and colleagues (Clements-Stephens et al., 2008) performed 
a functional magnetic resonance imaging (fMRI) study using an adaptation of  this task. 
They reported that participants with NF1 had more neuronal activity in the left than the 
right hemisphere across anterior and posterior regions, while controls showed the opposite 
pattern. Furthermore, they found lower neural activation in Brodmann area 17 of  patients 
with NF1, an area that roughly corresponds to the primary visual cortex (V1). This con-
stituted an early observation of  a deficit in the visual cortex. The fact that performance on 
visuospatial tasks is impaired in individuals with NF1 suggests that information processing in 
early visual areas might be deficient. 
In the early visual system information is transmitted from the retina to the cortex via 
three parallel channels: the magnocellular (M), parvocellular (P) and koniocellular pathways, 
Figure 1a. Although these pathways may be difficult to differentiate in vivo, one can take ad-
vantage of  the physiological properties of  their constituent neurons and respective circuits 
(Leventhal, 1991) to generate stimuli with a preferential bias activation of  each pathway. 
Magnocellular population responses are relatively tuned to achromatic stimuli with low spa-
tial and high temporal frequencies and they provide the dominant input to the dorsal stream 
(Figure 1b), which plays an important role in spatial localization and motion processing. The 
parvocellular pathway is more sensitive to stimuli with low temporal and high spatial frequen-
cies and projects primarily to the ventral stream (Figure 1b), important in object processing. 
Additionally, at low contrast levels visual information is primarily conveyed via the magnocel-
lular system (Livingstone and Hubel, 1988). The function of  the koniocellular pathway is less 
defined, but it is known to play a role in colour vision (Hendry and Reid, 2000). 
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Recently, we showed abnormalities in low-level sensory processing using psycho-
physical measures of  contrast sensitivity. Our results indicated relative deficits in the M 
and P channels, with preserved koniocellular function in individuals with NF1 (Ribeiro 
et al., 2012). However, the neural substrates of  visual impairments in this condition are 
still poorly understood.
In the present study, we focused on the activation of  the early cortical visual system, 
V1, V2 and V3, and we used stimuli with different contrast and different temporal and 
spatial frequency properties to provide a relative bias concerning the activation of  the M 
or P pathways. Our aim was to establish the functional status of  the early visual cortex 
in patients with NF1. The human visual cortex is divided in several functional areas with 
distinct local neural properties (Zeki and Shipp, 1988). Area V1 plays a critical role in 
visual processing because most of  the visual information reaching the rest of  the visual 
cortex is first processed in this region. It differs from other cortical areas by having a 
higher density of  neurons, particularly in layer 4 (Rockel et al., 1980). This layer is packed 
with spiny stellate cells (Douglas and Martin, 1998) and has a thick band of  myelinated 
axons travelling from sublayers 4Cα to 4B, known as the stria of  Gennari. Because of  
this band, V1 is historically named striate cortex, and the term extrastriate denotes the 
rest of  visual cortex. V1 neurons are tuned for a number of  attributes, including orienta-
tion (Hubel and Wiesel, 1959), direction of  motion (Carandini et al., 1998), spatial and 
temporal frequency (De Valois and De Valois, 1988), binocular depth (Cumming and 
DeAngelis, 2001) and colour selectivity (Horwitz and Hass, 2012).
◄  Figure 1. Visual Pathways. a. Visual information is initially encoded in the retina where photore-
ceptors transduce the pattern of  light into an electrochemical signal. Specialized circuits extract basic 
sensory cues, such as spatial contrast and temporal frequency and encode these properties into the 
ganglion cells (GC), which fibers form the optic nerve. Each ganglion cell conveys different aspects of  
the visual input simultaneously to the brain. Three GC types are particularly well characterized: midget, 
parasol and small and large bistratified. Midget GCs are considered to be the origin of  the parvocellular 
pathway, they project to the parvocellular layers of  the lateral geniculate nucleus (LGN), which in turn 
project to layer 4Cβ of  V1 (red). Parasol GCs are considered to be the origin of  the magnocellular 
pathway, they convey information to the magnocellular layers of  the LGN, which projects to layer 4Cα 
of  V1 (yellow). Small and large bistratrified GCs make part of  the koniocellular pathway and convey 
signals to koniocellular layers 3 and 4 of  the LGN, which in turn projects to layer 1 and to the cytochro-
me oxidase blobs of  layer 2/3 (blue) in V1. Adapted from Zeki, 1993 and Nassi and Callaway, 2009. b. 
Dorsal and ventral streams originate in the primary visual cortex. The dorsal stream spreads from V1 
dorsally to the parietal lobe, while the ventral stream spreads to the temporal lobe.
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 V1 is bordered by two cortical regions that form area V2. Functionally, V2 has many 
properties in common with V1, such as selectivity for orientation, colour, stereoscopic 
disparity and motion (Boynton and Hegde, 2004). While a lesion in V2 spares visual 
acuity and contrast sensitivity it affects the ability to perform more complex spatial 
tasks (Merigan et al., 1993). Neurons in V2 are sensible to complex properties such as 
texture perception (El-Shamayleh and Movshon, 2011) and encoding of  illusory con-
tours (Dillenburger and Roe, 2010). There is a relative lack of  information concerning 
the functional role of  V3, and its receptive fields are generally larger than in V1 and V2. 
Studies in the macaque monkey revealed that the dorsal part of  V3 has more neurons 
selective for direction than for colour, while the pattern reverses in ventral V3 (Lyon and 
Connolly, 2012). M and P information is merged at V1 and V2 and then distributed to 
both dorsal and ventral streams (Levitt et al., 1996). Dorsal stream connections are more 
specifically dominated by M inputs whereas ventral connections have a mixed contribu-
tion of  M and P inputs. 
The organization of  the visual cortex is such that the visual field is represented 
several times in the occipital cortex with a topographic organization (Hubel and Wiesel, 
1977; Zeki, 1978; Hubel and Livingstone, 1987). This topographic/retinotopic organiza-
tion means that nearby regions in the retina project to nearby cortical regions. The reti-
notopic organization is particularly clear in the early visual areas V1, V2, and V3, Figure 
2. Retinotopic representations can be mapped using fMRI, provided that the subjects 
fixate, because the visual field shifts with eye position, and visual stimuli are presented 
at several locations (Engel et al., 1994; Sereno et al., 1995). Mapping between the retina 
and the cortex can be described as a log-polar transformation, in which standard axes 
in the retina are transformed into polar axes in the cortex, according to a logarithmic 
transformation (Grill-Spector and Malach, 2004). The phase (angle from the horizontal 
axis) component of  the retinotopic map reveals meridian representations (Figure 2a), 
while eccentricity describes the distance from the fovea. The representation of  the fovea 
is greatly expanded compared to the representations of  the periphery, Figure 2b.
In the present study we used retinopic mapping to define cortical visual areas V1, 
V2 and V3 for each subject, as they provide topological criteria that are the most certain 
for defining a cortical visual area (Felleman and Van Essen, 1991). Given inter-subject 
variability (Dougherty et al., 2003), the boundaries of  each visual area have to be mapped 
for each subject. The importance of  studying well-defined visual areas is that they con-
stitute an important part of  primate brain organization. Moreover, better understanding 
aBnormal BraIn aCtIvatIon In nF1 | 91
of  visual deficits in a neurodevelopmental disorder can be achieved by investigating 
how visual processing is performed in segregated areas. 
Based upon our prior study (Ribeiro et al., 2012), we hypothesized that patients with 
NF1 would show impairments in activation of  low-level visual areas, and therefore we 
conducted confirmatory analysis in retinotopically-defined areas, V1, V2 and V3. Addi-
tionally, we investigated the activation pattern of  high-level visual and non visual regions 
modulated by the different stimuli to examine possible functional consequences of  low-
level visual impairments. 
Figure 2. Representation of  the visual field in visual cortex. a. Visual field maps are measured in 
the left hemisphere of  a single subject using a rotating wedge stimulus. The visual areas V1, V2 and V3 
of  the left visual field are represented in a smoothed representation of  the white matter surface. The 
colour overlay at the bottom left of  the image indicates the angle (with respect to the centre of  gaze) 
that produces the most powerful response at each cortical location. Area V1 represents a hemifield of  
the contralateral visual space, so that the left hemisphere V1 represents the right half  of  the visual field 
and vice versa. Dorsal (d) V2/V3 represents the lower quarter of  the visual field and ventral (v) V2/V3 
the upper quarter. b. Illustration of  the visual field map in V1. The left visual field stimulates V1 in the 
right hemisphere; the image representation is inverted, and the centre of  the visual field, near the eye, 
is greatly expanded (cortical magnification). Adapted from Wandell et al., 2007.
a
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mAteriAls And metHods 
Participants
Ninety one individuals participated in this study: 25 children and adolescents with NF1, 
29 control children and adolescents, 17 adults with NF1 and 20 control adults. Due to 
the exclusion criteria defined concerning intracranial abnormalities, neuropsychological 
assessment, performance on the behavioural task and movement within MRI acquisi-
tions (see below), 24 participants were excluded from our analysis. Thus, for analysis, we 
included: 15 children and adolescents with NF1, 24 chronological age-matched control 
children and adolescents, 13 female adults with NF1 and 15 chronological age-matched 
control female adults. Demographic details are shown in Table 1.
Participants with NF1 were recruited and diagnosed in collaboration with the Clinical 
Genetics Department of  the Paediatric Hospital of  Coimbra according to the NIH de-
fined diagnostic criteria (National Institutes of  Health Consensus Development Confer-
ence Statement: neurofibromatosis., 1988). For the children/adolescent control group, 
participants were recruited among unaffected siblings and from a local school. The adult 
control group was recruited among the unaffected parents or from an adult educational 
school. These adult schools provide learning programs for adults with low educational 
levels and many adult participants with NF1 are also attendants.
In order to ensure that participants included in the study had no central nervous 
system pathology, a FLAIR MRI sequence was performed in addition to the standard 
structural scan. Neuroradiological assessment was carried out by an experienced neu-
roradiologist. Participants were excluded from this study if  they had a clinically signifi-
cant intracranial abnormality on MRI (n= 6 individuals with NF1, 2 controls) such as 
intracranial tumor, optic glioma or other imaging abnormalities. UBOs (Unidentified 
Bright Objects - T2 hyperintensities, commonly found in patients with NF1) were not 
considered exclusion criteria. 
None of  the participants had a psychiatric illness, epilepsy or were taking medication 
for treating depression. Participants were also excluded if  they had full-scale IQ below 
70, for the children/adolescent groups, or Raven score below 3 (n= 1 NF1), in the adult 
groups. Parents of  children on stimulant medication for attention deficit hyperactivity 
disorder (ADHD) were requested not to give their children the medication on the days 
of  testing (n= 2 NF1, 1 control). All the participants had normal or corrected-to-normal 
visual acuity. 
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Ophthalmological assessment was performed by an experienced ophthalmologist to 
rule out eye disorders in the NF1 group. This included best-corrected visual acuity, ste-
reopsis evaluation using Randot, slit lamp examination of  anterior chamber structures 
and fundus examination. No anomalies that could affect vision were found.
Neuropsychological assessment
Participants younger than 17 years old received the Portuguese adapted version of  the 
Wechsler Intelligence Scale for Children (WISC-III) (Wechsler, 2003), while 17 years old 
or older participants performed the first set of  the Raven Standard Progressive Matrices 
(Raven et al., 1993) as an indication of  non-verbal intelligence. Three control children/
adolescents and one adolescent with NF1 were unavailable to perform IQ tests. How-
ever, their school records were in accordance with their chronological age, indicating 
adequate intellectual functioning. Neuropsychological details are shown in Table 1. Chil-
dren with NF1 presented significantly lower full-scale IQ (FSIQ) score than control 
children (p=0.013). In the adult groups, the average Raven scores between NF1 and the 
control group were not statistically different.
 
Stimuli and task design
Retinotopic mapping. The boundaries of  low-level retinotopic visual areas were defined 
  
    
    
    
    
    
    
    
    
    
    
 
Table 1.  Demographic and neuropsychological characteristics of  patients and control groups
Significant differences between NF1 patients and controls are indicated by *p<0.05.
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employing a fast approach using the polar angle of  the standard retinotopic mapping 
procedure (Engel et al., 1994; Sereno et al., 1995), Figure 2a. Polar angle maps were ob-
tained using a black and white checkerboard wedge flickering at 8 Hz in counterphase 
(48 s full cycle, 4 cycles per scan and two scans per subject) centred around an orange-
coloured fixation point. Polar angle maps provide the information of  angle reversion 
needed to properly delineate both dorsal and ventral visual areas of  V1, V2 and V3. 
M- and P-biased stimulation. Stimuli were pattern-reversed checkerboards filling the entire 
screen (30.3º x 23.1º) designed using the Psychophysics Toolbox for Matlab (Brainard, 
1997). To bias the activation of  the M-pathway we used stimuli with low spatial frequen-
cy, 0.25 cycles per degree (cpd) fundamental frequency, and high temporal frequency (18 
Hz), with low contrast (18%) that preferentially activates (though not exclusively) the M 
pathway. This stimulus is similar to the one used by Liu et al (Liu et al., 2006a). P-biased 
stimulation was achieved using a higher spatial frequency (2 cpd), lower temporal fre-
quency (2 Hz) and 100% contrast. Stimuli were presented in a block-design composed 
of  6 blocks for each stimulus (16 seconds per block) randomly presented and interleaved 
with a rest condition (fixation only, 10 seconds), Figure 3. To maintain subjects engaged 
and to control for attention and fixation participants were asked to fixate a central dot 
and report a subtle colour change, from red to pink and the other way around, with a 
button press. Time intervals between colour changes were chosen randomly from 2, 4, 
6, 8 or 10 seconds. The task ran throughout the experiment. 
Only participants with a high level of  detection (>85%) and a low rate of  false 
alarms (<0.3, calculated as the ratio between the number of  false alarms and the num-
ber of  colour changes) were included in these study. 4 patients with NF1 and 4 control 
participants were excluded by not meeting these criteria. 
Stimuli were projected using an LCD projector (AVOTEC Silent Vision 6011, Flor-
ida, USA) onto a screen that participants viewed via a fixed mirror placed on the MRI 
head coil. Participants’ eyes were monitored with a camera placed on the mirror system 
(Avotec Real Eye 5721, Florida, USA).
Imaging procedures
Scanning was performed on a 3T Siemens TimTrio scanner at the Portuguese Brain Im-
aging Network, using a 12-channel birdcage head coil. For each participant we acquired: 
i) two T1-weighted (T1w) MPRAGE sequences, 1x1x1 mm voxel size, repetition time (TR) 
2.3 s, echo time (TE) 2.98 ms, flip angle (FA) 9º, field of  view (FOV) 256x256, 160 slices; 
aBnormal BraIn aCtIvatIon In nF1 | 95
ii) a T2-weighted (T2w) FLAIR sequence, 1x1x1 mm voxel size, TR 5 s, TE 2.98 ms, Inver-
sion Time (TI) 1.8 s, FOV 250x250, 160 slices; iii) one run of  fMRI scanning for the 
M/P-biased stimuli and two runs of  the polar angle stimuli using single shot echo planar 
imaging (EPI) acquired in the axial plane orthogonal to the anterior commissure cover-
ing the occipital, temporal and frontal cortices, with 2x2x2 mm voxel size, TR 2 s, TE 39 
ms with a 128x128 matrix, FA 90º, FOV 256x256, 26 slices.
FLAIR images were used to identify T2 hyperintensities, a common neuroradiologi-
cal finding in patients with NF1. A neuroradiologist, who was blind to the participants’ 
clinical history observed the MR structural scans and reported on the distribution and 
number of  UBOs. Twelve of  the fifteen (80 %) children and seven of  the thirteen (53.8 
%) adults with NF1 had one or more UBOs. The frequency of  UBOs is in accordance 
with published data (Payne et al., 2010). None of  the control participants had UBOs.
Figure 3. A schematic diagram of  the design for the M/P-biased stimulation. Stimuli were 
presented in a random order. Each stimulus was presented 6 times (16 seconds per stimulus) and inter-
leaved with a rest condition (fixation only, 10 seconds). To maintain subjects engaged and to control for 
attention and fixation participants were asked to fixate a central dot and report a subtle colour change, 
from red to pink and the other way around, with a button press. A patch of  the parvocellular stimulus 
is shown enlarged.  
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Image Analysis
Image processing and analysis were carried out using BrainVoyager QX 2.1 (Brain In-
novation, Maastricht, The Netherlands). Analyses to determine total intracranial volume 
were performed using Statistical Parametric Mapping 8 (SPM8, http://www.fil.ion.ucl.
ac.uk/spm).
Image processing and analysis in retinotopically-defined areas:
Anatomical Image processing. High-resolution T1w anatomical images were averaged, in-
tensity normalized and re-oriented into a space where the anterior and the posterior 
commissure lie in the same plane (AC-PC). Afterwards, cortex was segmented using au-
tomatic segmentation routines (Kriegeskorte and Goebel, 2001), mesh representations 
of  each hemisphere were created and inflated for polar angle maps projection.
Functional Image Processing. We applied slice scan time correction, linear trend removal, 
temporal high-pass filtering (2 cycles per run), modest spatial smoothing (FWHM 2mm, 
yielding a small but clear smoothing effect) and a correction for small interscan head 
movements. Participants were excluded from further analysis if  any within-run move-
ment exceeding 2 mm was detected (n= 2 NF1, 4 controls). 
Retinotopic mapping. Polar angle maps were obtained from the average of  two runs, created 
based on linear regression analysis and projected onto the AC-PC anatomical surfaces of  
each subject. The cross-correlation was calculated for each run, as a function of  the time 
lag (in TR units, 2 seconds per lag). Lag values at each voxel were encoded in pseudocol-
ors, voxels were included into the statistical map if  r >0.25, p <0.05. Retinotopic areas 
V1, V2 dorsal (d), V2 ventral (v), V3d and V3v were manually defined for each subject in 
each hemisphere in the inflated meshes, Figure 2a. Obtained regions-of-interest (ROIs) 
were used as “masks” to the analysis of  the blood-oxygen-level-dependent (BOLD) 
signal elicited by M- and P-biased stimulation. 
M- and P-biased stimulation. Statistical analyses were performed on individual and group 
data using the general linear model (GLM). Predictors for the response to M- and P- bi-
ased stimulation were obtained by convolution of  a condition box-car time course with 
a two-gamma function (Friston et al., 1998). Retinotopically-defined areas were used as 
ROIs to perform ROI analysis on each subject in the AC-PC space. Within each ROI, a 
GLM for the M/P-biased stimuli experiment, corrected for temporal serial correlations, 
was computed and the individual beta values evoked by each stimulus were retrieved and 
analysed using PAWS Statistics 18. 
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Volume-based processing and analysis of  cortical activation:
We were interested in effects that could be generalized to children, adults and overall 
population irrespective of  age and thus we compared the NF1 studied group (children, 
adolescents and adults) with a matched control group.
Since benign macrocephaly is common in NF1, previous fMRI studies were restrict-
ed to ROI analysis (Billingsley et al., 2003; Clements-Stephens et al., 2008; Shilyansky 
et al., 2010). To overcome this methodological difficulty and be able to perform whole-
brain analysis we ensured that the total intracranial volume was not statistically different 
between matched clinical groups. 
Total intracranial volume measurements. Total intracranial brain volume for each subject was 
calculated with the VBM8 toolbox in SPM8. Group comparisons for brain volume were 
evaluated with independent samples t-tests.
In the children groups, we observed no significant differences in total intracranial 
volume, which makes it valid to perform normalization procedures and group analysis 
since it is unlikely that systematic variances in the warping procedure result in false group 
differences. Adults, however, presented a significant difference in total intracranial vol-
ume. Therefore, for this analysis we excluded the 4 control participants with the smallest 
brain volumes. We analysed 13 patients with NF1 and 11 controls with no intracra-
nial volume significant group difference. Moreover, the overall control and NF1 groups 
composed by children and adults (without the 4 previously excluded adult participants) 
did not present a difference in total intracranial volume.
Cortex-based alignment. Whole-volume statistical comparisons regarding the activation to 
the M/P-biased stimuli were conducted in the cortical surface space after performing 
cortex-based alignment. In order to do that, brains previously transformed to AC-PC 
space were normalized into Talairach standard space (Talairach and Tornoux, 1988). Fol-
lowing normalization we performed the segmentation routine applied in BrainVoyager. 
The reconstructed folded cortical representations of  each subject and hemisphere were 
morphed into a spherical representation and aligned to all the other subjects’ spheres 
iteratively (Formisano et al., 2004; Goebel et al., 2006). This procedure was conducted 
to improve the spatial correspondence mapping between subjects’ brains (Fischl et al., 
1999). It has been demonstrated that cortical alignment substantially improves group re-
sults by reducing anatomical variability (Fischl et al., 1999; Jo et al., 2007). Cortex-based 
alignment was performed for the children, adult and overall groups separately.
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Group comparisons of  the neural activity elicited by the M- and P-biased stimuli in aligned cortices. 
Statistical analysis was performed using Random effects (RFX) analyses in order to 
generalize findings to the population level (Penny, 2003). In the first stage, a whole-
volume RFX GLM was performed to estimate condition effects (beta values) sepa-
rately for each subject and stimuli. At the second level, an independent samples t-test 
was used to compare patients and controls for each stimulus category. Statistical maps 
were corrected for multiple comparisons using cluster-size thresholding (Forman et al., 
1995; Goebel et al., 2006). Each map was thresholded at p <0.01 uncorrected and, for 
correction, submitted to cortex-based cluster threshold estimation based on a Monte 
Carlo simulation with 1000 iterations. This procedure yielded a statistical map with a 
cluster size of  45 mm2 for the adults group and 41 mm2 for the children and overall 
groups, corresponding to a corrected α value of  p <0.05.
We examined the BOLD timecourses in voxel clusters with statistical significant dif-
ferences between the clinical groups, NF1 and control. The functional response profiles 
for each group were reported after the subtraction of  the fixation condition from the 
timecourse. 
Demographic, Neuropsychological, Behavioural and BOLD activation in retino-
topically defined areas analyses
Statistical analyses were performed with PAWS Statistics 18 (SPSS Inc., Chicago, USA). 
First, we verified the normality assumption for the different parameters using the Shapiro 
Wilk’s test. For normally distributed data, we used independent samples t-tests, ANOVA 
and Pearson’s correlation analyses. When the data did not meet assumptions of  spheric-
ity, we used the epsilon value to choose the type of  correction applied: the Huynh-Feldt 
(for ε >0.75) or the Greenhouse–Geiser (for ε <0.75). For the non-normal data, we used 
the Mann-Whitney test for comparison between two independent samples. 
results 
Behaviour
There was no between group differences on the performance in the behavioural task, 
neither for children nor for adult clinical groups. Both NF1 patients and controls re-
sponded to the fixation task, which imposed a moderate attentional load, with a high 
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degree of  accuracy (above 95% correct trials) and low number of  false alarms. 
Activity in retinotopically defined areas 
The magnitude of  activation elicited by the M- and P-biased stimuli was retrieved from 
low-level visual areas V1, V2d, V2v, V3d and V3v of  each subject’s hemispheres. Analy-
sis was performed on 15 children with NF1, 24 control children, 13 adults with NF1 and 
15 control adults. First, we performed a repeated measures ANOVA using stimuli (M-
biased vs P-biased), visual area (V1, V2d, V2v, V3d, V3v) and hemisphere (left vs right) 
as within subjects variables and clinical group (NF1 vs controls) and age group (children 
vs adults) as between subjects factors. 
We found a highly significant effect of  clinical group [F(1,63)=12.892, p<0.001] and a 
significant effect of  age group [F(1,63)=5.988, p=0.017] with no interaction between clini-
cal group and age group [F(1,63)=0.133, NS], indicating a similar deficit in visual activation 
in both children and adults with NF1. Besides, we found a significant effect of  stimu-
lus type [F(1,63)=76.818, p<0.001], visual area [F(1,63)=38.039, p<0.001] and an interaction 
between stimulus type and visual area [F(4, 236)=84.595 p<0.001]. Differences between 
patients and controls were indicated by the overall clinical group effect and also by sig-
nificant interactions in visual area x clinical group [F(4, 228.3)=2.445, p=0.05] and stimulus 
type x visual area x clinical group [F(4,236)=3.483, p=0.01]. Differences between children 
and adults were revealed by the overall age group effect and also by significant visual area 
x age group [F(4, 228.3)=4.011, p=0.005] and a stimulus type x visual area x clinical group 
[F(4,236)=3.483, p=0.01] interactions. Three way interactions involving stimulus type, vi-
sual area and groups were explored in subsequent repeated measures ANOVA. 
Given that no effect of  hemisphere or interaction between hemisphere and group 
was found we averaged the signal of  both hemispheres and performed a repeated mea-
sures analysis for each stimulus type using visual areas (V1, V2d, V2v, V3d, V3v) as 
within subjects variables and clinical group (NF1 vs controls) and age group (children vs 
adults) as between subjects factors. 
Concerning the stimulus with low spatial and high temporal frequency and low 
contrast (biasing the M pathway), differences between patients with NF1 and controls 
were evident as an overall significant effect of  clinical group [F(1,63)=9.914, p=0.003] 
and a significant interaction between area and clinical group [F(3.5, 37)=6.194, p<0.001]. 
This interaction was attributable to significantly lower activations from patients with 
NF1 than controls in visual areas V2d (t(65)=3.5, p=0.001), V2v (t(65)=2.5, p=0.017) and 
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V3d (t(65)=3.5, p=0.001), but not in V1 and V3v, as shown in Figure 4. Differences 
between children and adults were indicated by a marginally significant effect of  age 
group [F(1,63)=3.850, p=0.054] and a significant visual area x age group interaction [F(3.5, 
37)=6.194, p<0.001]. This interaction was attributable to adults activating more than chil-
dren in visual areas V2d (t(65)=2.3, p=0.025) and V3d (t(65)=2.5, p=0.014), Figure 4. 
Regarding the stimulus with high contrast, higher spatial and lower temporal frequen-
cy (biasing the P pathway), we observed an overall clinical group effect [F(1,63)=5.785, 
p=0.019] but no visual area x clinical group interaction [F(3.8, 242.3)=1.026, NS], indicating 
that effects were comparable across visual areas (see Figure 4). Furthermore, for this 
stimulus type neither an age group effect [F(1,63)=3.285, NS], nor an interaction between 
visual area and age group [F(3.8, 242.3)=1.321, NS] were present, indicating that there is no 
Figure 4. BOLD activity in retinotopically defined areas for M- and P-biased stimuli. a.b. 
depict mean beta values in retinotopically defined areas V1, V2d, V3d, V2v, V3v for patients with 
NF1 (dark grey; n = 28, 15 children and 13 adults) and controls (light grey; n = 39, 24 children and 
15 adults) in the presence of  M-biased stimulus (a)  and P-biased stimulus (b). c.d. depict mean beta 
values in retinotopically defined areas for children (dark grey; n = 39, 15 with NF1 and 24 controls) 
and adults (light grey; n = 28, 13 with NF1 and 15 controls) in the presence of  M-biased stimulus (c) 
and P-biased stimulus (d). Significant differences between groups are indicated by *p<0.05, **p<0.01. 
Error bars represent SEM.
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difference in activation between children and adults when responding to the stimulus 
biased for the P pathway, as shown in Figure 4.
Correspondence between low-level visual deficits in NF1 and cognitive abilities
BOLD activation to each stimulus type in each visual area did not correlate with IQ 
for children and adolescents and Raven scores for adults. The lack of  correspondence 
suggests that abnormal activation of  low-level visual areas is not explained by low intel-
lectual abilities.  
Volume based analysis of  cortical activation: random effects analysis  
To further identify cortical regions showing group differences in brain activation evoked 
by each of  the stimuli used we compared the BOLD activation between clinical groups 
(NF1 n=28 and controls n=35, 4 control adults were not included in this analysis, see 
Materials and Methods section). Figures 5 and 6 show differences in BOLD activation 
elicited by the M- and P-biased stimulation, respectively. 
Figure 5 shows the differences in activation profiles between patients with NF1 and 
controls in the presence of  the low contrast, low spatial, high temporal frequency stimu-
lus (M-biased). Overall, individuals with NF1 showed significantly lower activations than 
controls in the middle and superior occipital gyri bilaterally, consistent with the locations 
for V2d and V3d, as observed in the ROI analysis; differences in V2v were probably not 
observed due to their lower statistical significance. Surprisingly, clusters of  higher acti-
vation for patients with NF1 relative to controls were observed in the cingulate gyrus, 
retrosplenial cortex, medial prefrontal cortex, parieto-occipital sulcus and lingual gyrus. 
Table 2 summarizes the brain regions with significant differences between groups.
In the presence of  the stimulus that biased, although not exclusively, the P pathway, 
patients with NF1 activated less than controls in regions within the occipital lobe, in-
cluding the inferior occipital gyrus, occipital pole, the calcarine and occipito-temporal 
sulci, Figure 6, Table 3.
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Figure 5. Significant differences in brain activations between patients with NF1 and controls, 
regarding the M-biased stimulus for children, adults and overall (children and adults) groups. 
Blue colours depict regions where activation was lower for individuals with NF1 than controls. Orange 
colours depict regions where activation was higher for individuals with NF1 than controls. Results are 
shown on views of  the left and right hemispheres of  cortex-based aligned three-dimensional recon-
structions generated from the average anatomical data sets of  the subjects in each group (children, 
adults, overall). Light grey represents gyri, dark grey represents sulci. T-maps thresholded at p <0.05 
corrected using cortex-based cluster threshold estimation (cluster size 41 mm2). N = 15 children with 
NF1, 24 control children, 13 adults with NF1 and 11 control adults.
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Figure 6. Significant differences in brain activations between patients with NF1 and controls, 
regarding the P-biased stimulus for children, adults and overall (children and adults) groups. 
Blue colours depict regions where activation was lower for individuals with NF1 than controls. Results 
are shown on views of  the left and right hemispheres of  cortex-based aligned three-dimensional re-
constructions generated from the average anatomical data sets of  the subjects in each group (children, 
adults, overall). Light grey represents gyri, dark grey represents sulci. T-maps thresholded at p <0.05 
corrected using cortex-based cluster threshold estimation (cluster size 41 mm2). N = 15 children with 
NF1, 24 control children, 13 adults with NF1 and 11 control adults.
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X, Y and Z indicate the center of  mass in Talairach coordinates. BA, Brodmann areas. LH, left hemi-
sphere. RH, right hemisphere. Regions were determined by t-test second level analysis corrected with 
cluster threshold estimation (p <0.05, cluster size 41 mm2) performed after the group-based RFX GLM 
analysis. Talairach coordinates are derived from the clusters shown in Figure 5. 
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Table 2. Localization and cluster size of  the regions with significant between-group differ-
ences in activation during M-biased stimulation for the overall (children and adults) group.
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X, Y and Z indicate the center of  mass in Talairach coordinates. BA, Brodmann areas. LH, left hemi-
sphere. RH, right hemisphere.  Regions were determined by t-test second level analysis corrected with 
cluster threshold estimation (p <0.05, cluster size 41 mm2) performed after the group-based RFX GLM 
analysis. Talairach coordinates are derived from the clusters shown in Figure 6. 
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Table 3. Localization and cluster size of  the regions with significant between-group differ-
ences in activation during P-biased stimulation for the overall (children and adults) group.
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We further examined the functional response profiles of  regions showing significant 
statistical differences between groups. Brain regions where patients with NF1 presented 
lower activation than controls (blue clusters in Figures 5 and 6) were due to hypoacti-
vation, i.e. less activation from the individuals with NF1 (timecourses not shown), as 
expected. However, the stimulus driving preferentially the M pathway resulted in a num-
ber of  regions showing significantly higher BOLD signal in individuals with NF1 than 
controls, as mentioned above. Interestingly, in the retrosplenial cortex, the anterior cin-
gulate cortex and the medial prefrontal cortex, the differences between groups emerged 
because individuals with NF1 presented positive BOLD activations while controls de-
activated, Figure 7. Additionally, in the lingual gyrus, controls showed negative BOLD 
signals while patients with NF1 did not show activations in this area.
Figure 7. Time course information of  the clusters with significantly higher activations for 
patients with NF1 than controls, regarding the M-biased stimulus for the overall (children and 
adults) group. Results are shown on lateral views of  the left and right hemispheres of  cortex-based 
aligned three-dimensional reconstructions generated from the average anatomical data sets of  the sub-
jects. T-maps are thresholded at p <0.05 corrected using cortex-based cluster threshold estimation 
(cluster size 41 mm2). Plots A to F correspond to the timecourse information for the clusters with the 
same letter in the cortex representations. Timecourse percent signal change is shown in orange lines 
for patients with NF1 and blue lines for controls. Error bars reflect mean SEs. N = 28 patients with 
NF1 and 35 control subjects.
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disCussion 
The present work provides the first fMRI study on basic visual processing deficits in 
children, adolescents and adult patients with NF1. We used stimuli that were designed, 
based on functional properties, to preferentially activate the magnocellular or parvocel-
lular pathways. Regions showing differences between controls and patients with NF1 
were either visual or belonging to the default mode network. 
Our findings indicate that individuals with NF1 have deficient activation of  the vi-
sual cortex, as compared to their respective control group, for both types of  low-level 
visual stimulation, in agreement with our previous report of  impaired contrast sensitiv-
ity in the M and P pathways of  patients with NF1 (Ribeiro et al., 2012). Accordingly, 
we observed a similar deficit in visual activation both in children and adults with NF1. 
Such similarity is also reflected in no significant effect in the interaction between clinical 
group and age group. This finding indicates that low-level visual processing deficits do 
not ameliorate with age.
In what concerns the stimulus with low contrast, low spatial and high temporal fre-
quency (driving into a larger extent the M pathway), patients with NF1 manifested more 
pronounced deficits in activating early visual retinotopic areas, V2d, V2v and V3d. The 
fact that early visual deficits are mainly explained by extrastriate V2/V3 contributions 
suggests that early complex (intermediate vision) functional properties are mostly im-
paired in NF1. Furthermore, dorsal V2 and V3 areas showed larger extent of  hypoac-
tivation than ventral V2 and V3 regions, in accordance with the notion of  functional 
asymmetries in early visual cortex (Liu et al., 2006b; Mendola et al., 2006; Eickhoff  et 
al., 2008), and with the notion that M input dominates in dorsal regions (Bullier, 2001; 
Bullier et al., 2001).
Regarding the stimulus with high contrast, higher spatial frequency and low temporal 
frequency (more tuned to the P pathway), patients with NF1 showed an activation deficit 
that was equally distributed across retinotopically-defined visual areas, and also deficient 
neural activation in visual areas in the inferior occipital and occipito-temporal regions. 
Altered visual processing in lower and higher levels of  the dorsal and ventral streams 
may explain the visuospatial deficits that characterize the cognitive phenotype in NF1. 
Accordingly, Clements-Stephens et al. (2008) reported, en passage, hypoactivation of  the 
occipital cortex in patients with NF1 while performing the judgement of  line orientation 
test. This test recruits preferentially dorsal stream structures that build-up on informa-
tion from low-level visual areas (Kesler et al., 2004; Tranel et al., 2009).
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Another finding from the present study is the difference in activation between age 
groups observed for the M-biased stimulation in dorsal areas V2 and V3, with adults 
showing higher magnitude of  activation than children. Recently, functional (Bucher et 
al., 2006; Klaver et al., 2008) and structural (Loenneker et al., 2010) studies focusing on 
the maturation of  the dorsal and ventral streams suggested a slower maturation of  the 
dorsal in relation to the ventral pathway. Our finding is an indication corroborating the 
late maturation of  the dorsal pathway even for low-level visual areas, where ventral and 
dorsal pathways emerge and bifurcate.
Turning now to the differences between patients with NF1 and controls in the func-
tional response profiles in brain regions outside visual areas, we were intrigued by the 
specific patterns observed for the M-biased stimulation. While P-biased stimulation did 
not cause differences outside visual regions, M tuned stimulus induced surprising posi-
tive BOLD activity in patients with NF1 while controls deactivated. This pattern was 
observed in posterior brain regions: parieto-occipital sulcus and retrosplenial cortex, 
as well as anterior brain regions: anterior cingulate and medial prefrontal cortex. Inter-
estingly, these findings imply an anomalous activation pattern in patients with NF1 in 
regions belonging to the brain default mode network (DMN). Regions belonging to the 
DMN commonly include the medial prefrontal cortex extending to the anterior cingu-
late, posterior cingulate/retrosplenial cortex and the parietal cortices in the region of  
the angular gyri. In Figure 8 there is a side by side representation of  the brain’s DMN 
and the activity profile observed in patients with NF1 while being stimulated with the 
M-biased stimulus.
Figure 8. Medial regions of  the brain’s default-mode-network. The left side of  the image is the 
brain’s default network identified in a meta-analysis that included 132 participants mapping brain re-
gions more active in passive as compared to active tasks using positron emission tomography (PET). 
Figure adapted from Buckner et al., 2008. On the right side of  the image the map of  significant differ-
ences in brain activations between patients with NF1 and controls, regarding the M-biased stimulus.
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  By definition, the DMN brain regions are active during task irrelevant thoughts 
(McKiernan et al., 2003), daydreaming (Mason et al., 2007) and self-referential thought 
(Gusnard et al., 2001) and deactivate during performance of  cognitively demanding or 
engaging tasks (Shulman et al., 1997; Raichle et al., 2001; McKiernan et al., 2003). This 
set of  brain regions comprises significant intrinsic correlations of  functional activity 
with each other (Greicius et al., 2003; Fox et al., 2005).
During M-stimulation the NF1 group failed to deactivate the DMN suggesting that 
during these particular stimulation periods the participants with NF1 had a higher ten-
dency to task-irrelevant thoughts than during the other task condition. The mechanisms 
behind this abnormal DMN activation could be related to the attentional deficits known 
to occur in children with NF1. In that sense, one may hypothesise that activity in the 
DMN is explained by greater incidence of  ADHD related symptoms in patients with 
NF1, and thus an inability to stay on the task and tendency to daydream. In any case in 
order to understand the neural mechanisms contributing to DMN activation it is impor-
tant to account its dependence on stimulus type, given it only occurred during M-biased 
stimulation. The “magnocellular advantage” theory proposed by Laycock et al. (Laycock 
et al., 2007; Laycock et al., 2008) suggests an important role for the M pathway in driving 
attentional mechanisms in higher-order cortical regions. How this relates to abnormal 
DMN activation is an intriguing aspect to be explored in future studies.
Although our data does not provide an ultimate explanation of  this effect, our find-
ing of  paradoxical activation in midline DMN regions (medial prefrontal cortex, anterior 
cingulate and retrosplenial cortex) might give insightful information that can help in 
better understanding attentional deficits in patients with NF1 (Huijbregts et al., 2010), 
and their implications for abnormal cognitive processing. Taking into account that low 
level visual impairments can impact high-level cognitive functions, our results provide 
evidence for a specific and intriguing link between the magnocellular pathway and the 
default mode network. In fact, it has been observed that in clinical populations with 
impaired magnocellular processing, as schizophrenia (Martinez et al., 2008; Coleman et 
al., 2009), autism (Pellicano et al., 2005; Sutherland and Crewther, 2010), and Fragile X 
syndrome (Kogan et al., 2004), the midline DMN regions fail to deactivate (Menon et al., 
2004; Kennedy et al., 2006; Pomarol-Clotet et al., 2008; Salgado-Pineda et al., 2011). 
In summary, this study provides the first functional brain imaging indication that 
the early visual system is impaired in NF1, providing pathophysiological evidence for a 
potential impact in the high-level visual cognitive profile of  patients with NF1. More-
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over, our results provide an intriguing link between impaired magnocellular and default 
mode network processing, a finding that has been separately observed in autism and 
schizophrenia. Additional studies will be needed to further define the impact of  these 
impairments in high-level cognitive functions of  patients with NF1, particularly the ab-
normal allocation of  neural resources observed in the midline regions of  the default 
mode network.
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Chapter 5
GABA is reduced in the
visual cortex of patients with
Neurofibromatosis type 1:
a new perspective on the 
disease mechanism
116 | Chapter 5
AbstrACt
Alterations in the balance between excitatory and inhibitory neurotransmission 
have been implicated in several neurodevelopmental disorders. Neurofibromatosis type 
1 (NF1) is one of  the most common monogenic disorders causing cognitive deficits 
for which studies on a mouse model (Nf1+/-) proposed increased GABA-mediated in-
hibitory neurotransmission as the neural mechanism underlying these deficits. To test 
whether a similar mechanism translates to the human disorder, we used magnetic reso-
nance spectroscopy (MRS) to measure GABA levels in the visual cortex of  children and 
adolescents with NF1 and matched controls. We found that patients with NF1 have 
significantly lower GABA levels than controls and that NF1 mutation type significantly 
predicted cortical GABA. Moreover, functional imaging of  the visual cortex indicated 
that blood-oxygen-level-dependent (BOLD) signal was correlated with GABA levels 
both in patients and controls. Our results provide in vivo evidence of  GABAergic dys-
function in NF1 by showing a reduction of  GABA levels in human patients. This con-
stitutes a relevant finding to understand the physiological profile of  the disorder with 
implications for the identification of  targets for therapeutic strategies. 
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introduCtion
The balance between excitatory and inhibitory neurotransmission is tightly regulated in 
the human brain and largely dependent on the levels of  glutamate, the major excitatory 
neurotransmitter, and γ-aminobutyric acid (GABA), the major inhibitory neurotransmit-
ter. Alterations in this push-pull mechanism might underlie the cognitive deficits found 
in several neurodevelopmental disorders (Ramamoorthi and Lin, 2011).
In Neurofibromatosis type 1 (NF1), studies employing the Nf1+/- mice model sug-
gested increased GABA-mediated inhibition as the cause underlying learning deficits 
(Costa et al., 2002). Furthermore, targeted deletion of  the Nf1 gene in specific brain cell 
types indicated that mice with reduced neurofibromin expression in GABAergic neu-
rons had spatial learning and long-term potentiation (LTP) deficits (Cui et al., 2008). In 
order to understand the mechanism by which neurofibromin could regulate GABAergic 
neurotransmission Cui and colleagues performed a series of  experiments in the Nf1+/- 
mice model, some of  which are reviewed below:
Electrophysiological recordings in hippocampal slices from the Nf1+/- mice: 
Recordings of  spontaneous inhibitory postsynaptic currents (sIPSCs) and miniature 
inhibitory postsynaptic currents (mIPSCs), which result from the spontaneous release 
of  neurotransmitters, were measured in hippocampal slices. Those revealed not to be 
altered in the Nf1+/- mice, indicating normal GABA-mediated inhibition under baseline 
conditions. Inducing high frequency stimulation to mimic inhibitory neuronal firing dur-
ing learning resulted in a larger increase in mIPSC frequency in Nf1+/- mice compared 
with the wild type (WT) mice, suggesting that neurofibromin regulates GABA release 
under periods of  high frequency stimulation. On the other hand, recordings of  minia-
ture excitatory postsynaptic currents (mEPSCs) under baseline and depolarizing condi-
tions showed no differences between WT and Nf1+/- mice.
Molecular mechanisms leading to altered GABAergic neurotransmission in the Nf1+/- mice: 
Neurofibromin is a negative regulator of  the Ras signalling cascade (Ballester et al., 
1990). Mutations in the Nf1 gene result in hyperactivation of  Ras downstream effectors, 
such as the kinase targets MEK and ERK. Those phosphorilate synapsin 1, a vesicle-
associated phosphoprotein localized at presynaptic terminals that regulate vesicle dy-
namics and neurotransmitter release (Hilfiker et al., 1999; Chi et al., 2001). 
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To characterize ERK activation and ERK-dependent phosphorylation of  synapsin 
1 in Nf1+/- mutants, mice were trained with a fear condition paradigm known to trigger 
biochemical changes related to cognition in the hippocampus (Kushner et al., 2005). 
Nf1+/- mice showed higher ERK and synapsin 1 phosphorylation than WT mice, sug-
gesting that neurofibromin regulates ERK signalling and synapsin 1 phosphorylation, 
Figure 1.
Figure 1. Schematic diagram of  transmitter release, transport and synthesis at a GABAer-
gic synaptic terminal. GABA is synthesized in inhibitory neurons from glutamate by the enzyme 
glutamic acid decarboxylase (GAD), and is transported into vesicles by a vesicular neurotransmitter 
transporter (VGAT). GABA can be released either vesicularly or non-vesicularly (by reverse transport). 
GABA receptors are located at pre- and postsynaptic sites. The effects of  GABA can be mediated by 
the activation of  metabotropic (GABAB) and ionotropic (GABAA and GABAC) receptors. Reuptake 
of  GABA by surrounding neurons and glia occurs through the activity of  GABA transporters (GAT). 
Subsequently, GABA is metabolized by a transamination reaction that is catalysed by GABA transami-
nase (GABA-T). The metabolism of  GABA occurs in both neurons (not shown) and glia. At presyn-
aptic locations neurofibromin (NF1) deficiency causes over activation of  the Ras pathway, leading to 
phosphorylation (P) of  the downstream kinase targets MEK and ERK. Activation of  ERK leads to 
increased phosphorylation os synapsin 1, a protein that regulates vesicular packing and could facilitate 
GABA release from inhibitory neurons. Adapted from Owens and Kriegstein, 2002.
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To assess visuospatial memory, mice were trained in the Morris water maze.  The 
Nf1+/- mice performed worse than the WT mice in this test, indicating that they have 
spatial learning deficits. The investigators were able to rescue this phenotype using low 
doses of  picrotoxin, a GABAA receptor antagonist. Picrotoxin administration to neuro-
fibromin knockout and WT mice before training in the water maze rescued the perfor-
mance of  the Nf1+/- mice, at doses that did not affect learning in the WT mice.
Recently, these results were extended to the medial prefrontal cortex and striatum of  
Nf1+/- mice, by showing increased frequency of  sIPSCs while sEPSCs were not affected 
(Shilyansky et al., 2010). This result indicates again that neurofibromin plays an impor-
tant role in the physiology of  inhibitory but not excitatory neurons and importantly, that 
the ratio of  excitatory to inhibitory transmission is low in the Nf1+/- mice.
These results inspired us to measure GABA levels and their potential functional im-
pact in patients with NF1. Before addressing the specific goals of  our study it is helpful 
to review the role of  GABA in the central nervous system and the processes contribut-
ing to regulation of  GABA levels.
GABA-containing cells are distributed throughout the cortical lamina and GABAer-
gic interneurons constitute 15-20% of  the cortical neurons, being the rest essentiality 
glutamatergic pyramidal cells (Hendry et al., 1987; DeFelipe, 1993; Markram et al., 2004). 
All mammalian neuronal circuits contain excitatory and inhibitory transmitter systems 
forming intense feed-forward and feedback connections. 
In the adult mammalian brain, GABA has been associated primarily with the me-
diation of  synaptic inhibition. However, inhibitory neurons do much more than just 
controlling the level of  neuronal activity. They are critical for organizing the complex 
spatiotemporal patterns of  network oscillations (Buzsaki et al., 2007; Mann and Paulsen, 
2007), selectively gating inputs or outputs (Klausberger and Somogyi, 2008; Lee et al., 
2012), suppression of  background activity (Bahner et al., 2011), and timing of  action 
potentials (Tukker et al., 2007). Regulation of  inhibitory strength is a dynamic process 
that adapts to the changing patterns and degrees of  network activity (Buzsaki et al., 
2007). A particularly important regulatory system is the modulation of  GABA content 
in inhibitory interneurons (Choi et al., 2012).
GABA is primarily synthesized from glutamate in a reaction catalysed by the en-
zyme glutamic acid decarboxylase (GAD). GABA is loaded into synaptic vesicles by a 
vesicular neurotransmitter transporter (VGAT). The effects of  GABA are mediated by 
ionotropic (GABAA and GABAC) and metabotropic (GABAB) receptors which can be 
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localized either pre- or postsynaptically (Owens and Kriegstein, 2002; Choi et al., 2012), 
Figure 1. 
Two general types of  GABA-mediated postsynaptic potential have been described. 
Fast responses are mediated by ionotropic receptors and slow responses by metabotro-
pic GABAB receptors. Both types of  receptors are capable of  regulating GABA release 
(Scanziani, 2000; Walker and Semyanov, 2008). 
GABA signals are terminated by reuptake into nerve terminals and glial cells through 
plasma-membrane GABA transporters (GATs), thereafter GABA is metabolized in a 
reaction catalysed by GABA transaminase (GABA-T), where it contributes to energy 
metabolism in the tricarboxylic acid cycle (Choi et al., 2012), Figure 1.
The concentration of  GABA in the living human brain is reported to be about 1 
mM (Rothman et al., 1993; Terpstra et al., 2002; Jensen et al., 2005b). However, there is 
a significant regional variance in GABA contents (Banay-Schwartz et al., 1993), in accor-
dance with the specific actions of  GABAergic neurons. For example, GABA may reach 
10 mmol/g in substantia nigra (Okada et al., 1971). 
Although overall concentration is determined, the knowledge on local GABA con-
centrations in different compartments is far from satisfactory. The absolute concentra-
tions of  GABA in the presynaptic cytosol, in vesicles, and in the extrasynaptic space are 
not known. On the other hand, concentration in the synaptic cleft has been estimated 
in different types of  neurons, with peak concentrations reaching values as high as 0.3 
to 3mM (Mozrzymas et al., 1999; Perrais and Ropert, 1999; Barberis et al., 2004). The 
cytosolic GABA concentration is most difficult to estimate, since most of  the neuronal 
GABA pool is used for energy metabolism rather than for synaptic inhibition.
GABA levels are dynamically modulated in response to increasing or decreasing net-
work activity and in the context of  brain disorders. For example, repetitive hyperactivity 
in the hippocampus of  chronically epileptic rats causes upregulation of  GADs (Esc-
lapez and Houser, 1999), while expression of  VGAT is altered following ischemia or 
excitotoxic stimulation (Gomes et al., 2011). 
In vivo assessment of  GABA levels in patients with NF1
Despite the evidence of  altered GABAergic inhibition in mice models, this hypothesis 
has never been tested in patients with NF1 and GABA levels have never been mea-
sured.
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We applied magnetic resonance spectroscopy (MRS) to measure GABA levels in 
patients with NF1. This is the only in vivo tool capable of  non-invasively measure brain 
metabolites. However, neurotransmitters can be difficult to detect in vivo because of  
complicated spectral patterns and overlap with other resonances, Figure 2a. To resolve 
the GABA signal we used an editing technique, which exploits the spin-spin or J-cou-
pling of  the GABA-C4 resonance at 3.0 ppm to the GABA-C3 resonance at 1.9 ppm, 
Figure 2b, as well as, the fact that the majority of  the signals present in the brain spectra 
at 3.0 ppm are not coupled to signals at 1.9 ppm. J-difference editing requires two sets 
of  experiments. In a given number of  acquisitions a frequency selective pulse is applied 
at 1.9 ppm. This pulse will have an effect on the GABA signals at 3.0 ppm, but will not 
interfere with other signals at this location since they are not coupled with spins at 1.9 
ppm. During another set of  equivalent number of  acquisitions the same pulse is applied 
to the opposite side of  the spectrum (7.5 ppm), in order to reduce baseline artifacts. 
The difference between these two experiments will give a spectrum that only contains 
the signals that are affected by the pulse. This editing approach is widely used, and the 
method most commonly applied is the MEGA-PRESS method (Mescher et al., 1998). 
The reliability of  GABA detection with an editing technique has been validated with ex 
vivo measurements (Bielicki et al., 2004).
A drawback of  MRS is that it is only capable of  detecting total concentration of  a 
metabolite within a localized region; it cannot distinguish between separate functional 
pools of  GABA. Nonetheless, given the relationships demonstrated in previous studies 
between behaviour and MRS measures of  local GABA (Goddard et al., 2004; Northoff  
et al., 2007; Edden et al., 2009; Sumner et al., 2010; Gomez et al., 2011; Stagg et al., 
2011), it seems likely that the MRS measure of  GABA is at least, correlated with the 
neurotransmitter pools of  GABA.
MRS measurements in patients with NF1 and controls were performed in early vi-
sual cortex, an area where the role of  inhibition has been widely studied and where we 
previously found evidences of  functional alterations (Ribeiro et al., 2012; Violante et al., 
2012). Moreover, it has recently been shown that GABA measures in the human visual 
cortex can reflect perceptual and behavioural processes in a parametric manner (Edden 
et al., 2009; Yoon et al., 2010). 
When studying the human disorder, the variability of  mutations that give rise to the 
disease (Thomson et al., 2002) should be taken into account. Therefore, it is important 
to investigate whether genotypic differences lead to changes in GABA levels. We ad-
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dressed this by testing the hypothesis that different types of  mutations would impact 
neurofibromin function differently and consequently manifest in cortical GABA levels.
To assess the functional correlates of  the MRS signal, participants underwent func-
tional magnetic resonance imaging (fMRI) while performing a visual task. Importantly, 
the blood-oxygenation-level-dependent (BOLD) signal is sensitive to the balance be-
tween excitation and inhibition (Logothetis, 2008) and therefore sensitive to variations 
Figure 2. Magnetic resonance spectra (MRS) of  GABA. a. 1H-MRS spectrum of  the human brain 
acquired at 3T, showing peaks corresponding to N-acetyl aspartate (NAA), creatine-containing com-
pounds (Cr), choline-containing compounds (Cho), glutamate (Glu), glutamine (Gln) and GABA. b. 
Chemical formula of  GABA and the GABA spectrum at 3T, showing the assignments to the GABA 
CH2 spins. Adapted from Puts and Edden, 2012.
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in GABA levels (Goddard et al., 2004). Consequently, it is physiologically relevant to 
determine whether the previously observed negative correlation between BOLD and 
GABA (Northoff  et al., 2007; Edden et al., 2009; Muthukumaraswamy et al., 2011) is 
preserved in patients with NF1. 
mAteriAls And metHods
Participants
We studied 20 patients with NF1 (mean age 13.0 ± 3.1 SD, age range 7.76 – 19.49, 15 fe-
males) and 26 healthy control subjects (mean age 13.1 ± 2.9 SD, age range 7.42 – 19.67, 
16 females), matched for age and gender. Patients were diagnosed by NIH-criteria (Na-
tional Institutes of  Health Consensus Development Conference Statement: neurofibro-
matosis., 1988). Exclusion criteria for all participants were as follows: psychiatric disor-
der, neurological illness affecting brain function other than NF1, epilepsy, or a clinically 
significant intracranial abnormality detected on MRI. UBOs (Unidentified Bright Ob-
jects - T2-hyperintensities commonly found in patients with NF1) located in the occipital 
cortex were considered exclusion criteria. Additionally, we excluded patients with intel-
ligence quotient <70. The control group was recruited from a local school and informal 
advertising. Participants’ academic records were in accordance with their chronologi-
cal age, indicating adequate intellectual functioning. Children prescribed with stimulant 
medication (methylphenidate) were not medicated on the day of  testing (4 NF1). 
All participants had normal or corrected-to-normal visual acuity. To rule out eye dis-
orders in the NF1 group, patients underwent an ophthalmological assessment including 
best-corrected visual acuity, stereopsis evaluation using Randot, slit lamp examination 
of  anterior chamber structures and fundus examination. No anomalies that could affect 
vision were found. We assessed handedness using the Edinburgh Inventory (Oldfield, 
1971); in the NF1 group 15 subjects were right-handed and 5 had mixed-handedness. In 
the control group 20 subjects were right-handed and 6 had mixed-handedness.
There were no between-group differences in age (t-test), gender or handedness (chi-
square test).  
Two participants with NF1 failed to perform the fMRI task as instructed, thus analy-
sis involving fMRI data was carried out on 18 patients with NF1 and 26 control subjects. 
Participants underwent all imaging acquisitions on the same session.
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Genetic characterization 
NF1 mutational profile was obtained by whole NF1 gene sequencing. The mutation 
analysis of  19 of  the 20 patients has been reported previously (Ribeiro et al., 2012). For 
the patient missing genetic testing, DNA was extracted from peripheral blood and stan-
dard procedures were used to perform whole-gene sequencing and multiplex ligation-
dependent probe amplification analysis (Upadhyaya et al., 2009).  
fMRI paradigm
Visual stimuli were similar to those employed by Muthukumaraswamy et al. (2009) and 
consisted of  a circular moving grating (80% contrast, spatial frequency 2 cycles/degree, 
4° diameter, velocity 1 degree/second), equiluminant to the background. Stimuli were 
presented in the lower left visual field, subtended 4° horizontally and vertically, with 
the centre of  the stimulus located 3.3° from a central fixation point, Figure 3. Stimu-
lus duration was chosen randomly in an interval between 1.5–2 s followed by 10 s of  
fixation point only; 30 events were presented. Participants were instructed to maintain 
fixation on the central point for the entire experiment and to press a button, as fast as 
Figure 3. A schematic diagram of  the design for the fMRI visual stimulation. Stimuli consisted 
of  a circular moving grating (80% contrast, spatial frequency 2 cycles/degree, 4° diameter, velocity 1 
degree/second), equiluminant to the background. Stimuli were presented in the lower left visual field, 
subtended 4° horizontally and vertically, with the centre of  the stimulus located 3.3° from a central 
fixation point. Stimulus duration was chosen randomly in an interval between 1.5–2 s followed by 10 s 
of  fixation point only; 30 events were presented. Participants were instructed to maintain fixation on 
the central green point for the entire experiment and to press a button, as fast as possible, when the 
grating disappeared.
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possible, when the grating disappeared. Fixation was ensured by monitoring partici-
pants’ eyes with a camera placed on the mirror system (Avotec Real Eye 5721, Florida, 
USA). All participants performed the task with a high-level of  accuracy, >95 % correct 
responses. 
MRI and MRS acquisitions 
Scanning was performed on a 3T Siemens scanner, using a 12-channel birdcage head 
coil. For each participant we acquired: i) a T1-weighted (T1w) MPRAGE sequence, 1 
mm3 isotropic voxel, repetition time (TR) 2.3 s, echo time (TE) 2.98 ms, flip angle (FA) 
9°, field of  view (FOV) 256x256, 160 slices; ii) a T2-weighted FLAIR sequence used to 
identify UBOs, 1 mm3 isotropic voxel, TR 5 s, TE 2.98 ms, Inversion Time 1.8 s, FOV 
250x250, 160 slices; iii) a single-shot echo-planar imaging (EPI) for the fMRI acquisition, 
3 mm3 isotropic voxel, TR 2 s, TE 39 ms, FA 90°, FOV 256x256, 23 slices; iv) a GABA-
edited MR spectra using the MEGA-PRESS method (Mescher et al., 1998; Edden and 
Barker, 2007), 3 cm3 isotropic voxel, TE 68 ms, TR 1.5 s, 196 averages, 1024 data points. 
During odd number acquisitions a frequency-selective inversion pulse was applied to the 
GABA-C3 resonance at 1.9 ppm (“On resonance”). During even number acquisitions 
the pulse was applied at 7.5 ppm (“Off  resonance”). The voxel was positioned within 
the occipital cortex with its lower face aligned with the cerebellar tentorium. The sagittal 
sinus was avoided ensuring that the volume remained inside the occipital lobe, Figure 4a. 
During structural and spectroscopic acquisitions, participants were watching cartoons. 
This helped children to stay motionless during acquisitions. During the spectroscopic 
acquisition participants’ eyes were monitored to ensure that none of  the participants 
was at sleep. 
MRI data analysis
 T1w images were used for MRS voxel placement and image segmentation. Segmentation 
was performed using in-house software written in Matlab7 (The MathWorks Inc., Mas-
sachusetts, USA) and the VBM8 toolbox in SPM8 (http://www.fil.ion.ucl.ac.uk/spm) 
and applied to determine the relative proportions of  grey matter (GM), white matter 
(WM) and cerebrospinal fluid (CSF) in the voxel. FLAIR images were used to identify T2 
hyperintensities, a common neuroradiological finding in patients with NF1. None of  the 
control participants had UBOs and none of  the UBOs found in patients were located 
in the occipital cortex.
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fMRI data analysis
 Image processing and analysis were conducted using BrainVoyager QX2.3 (Brain Inno-
vation, Maastricht, The Netherlands). We applied slice scan-time correction, linear trend 
removal, temporal high-pass filtering (2 cycles per run), spatial smoothing (FWHM 
5mm) and motion correction. General linear model predictors were built by convolving 
a 2/10 s boxcar time course with a two-gamma function. Statistical thresholding was 
performed using false discovery rate, q(FDR)<0.05.
MRS data analysis 
A difference spectrum was generated for each participant (“On resonance”-“Off  reso-
nance”). Using in-house software written in Matlab, we applied 4 Hz exponential line 
broadening to all spectra. Peak integration was used to quantify GABA (~3 ppm) and 
the combined glutamate plus glutamine (Glx) peaks (~3.75 ppm) in the difference spec-
tra and total creatine (tCr) peak (3 ppm) in the summed spectra. Integrals of  GABA, 
Glx and tCr peaks were automatically calculated using a linear fit of  the baseline and 
Gaussian fits to the peaks. 
Statistics 
Statistical analyses were performed with PAWS Statistics 18 (SPSS Inc., Chicago, USA). 
First, we verified the normality assumption for the different parameters using the Sha-
piro Wilk’s test. All data were normally distributed. For analysis, we used independent 
samples t-tests and Pearson’s correlation analyses. 
To assess the effect of  genotype on GABA levels, we first transformed GABA/
tCr measurements of  all participants to z-scores and performed a multiple regression 
analysis using a forced entry model, in which all predictors are forced into the model 
simultaneously. To construct the model we took into account the fact that age (Marenco 
et al., 2010), gender (O’Gorman et al., 2011) and GM content (Jensen et al., 2005a) may 
affect GABA concentration. Additional predictors were constructed from categorical 
variables relative to the type of  NF1 mutation (nonsense, missense, splice-site and muta-
tion not found in the NF1 gene). 
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results 
MRS GABA levels
MRS measurements were performed in the visual cortex (Figure 4) of  20 children and 
adolescents with NF1 and 26 matched control subjects. GABA and glutamate + glu-
tamine (Glx) peaks were well edited for all participants. Ratios of  GABA/tCr and Glx/
tCr were calculated for each subject. The tCr integrals were not statistically different 
between groups (t(44) = -0.784, p = 0.437). GABA/tCr provides reliable GABA concen-
tration estimates and reduces inter-subject variance attributable to differences in signal-
to-noise ratio and CSF fraction within the voxel (Bogner et al., 2009). 
Patients with NF1 displayed significantly reduced GABA/tCr levels compared with 
controls, (t(44) = -3.61, p = 0.001), while Glx/tCr levels were not significantly different 
(t(44) = -0.835, ns), Figure 1c,d. 
Figure 4. GABA measurements. a. Localization of  the MRS voxel (white square) in the visual cortex 
of  a representative participant. b. Edited MRS spectrum from a representative participant showing 
clearly resolved peaks for GABA and glutamine+glutamate (Glx). c,d. Cortical GABA/tCr levels and 
Glx/tCr levels for patients with NF1 (black, n=20) and controls (grey, n=26), respectively. Graphs 
depict individual values, mean and standard deviation. **p<0.01.   
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The percentages of  GM, WM and CSF in the spectroscopy voxel were assessed for 
each participant and were not significantly different between patients and controls (p = 
0.196, p = 0.074, p = 0.604, respectively). This ensured that any difference in metabolite 
levels did not arise as a consequence of  differences in tissue content between groups. 
Moreover, GABA/tCr was not correlated with GM (r = -0.066, p = 0.782 patients, r = 
0.203, p = 0.321 controls), WM (r = -0.037, p = 0.877 patients, r = -0.302, p = 0.134 con-
trols), or CSF (r = 0.023, p = 0.924 patients, r = 0.056, p = 0.785 controls). Additionally, 
differences in GABA levels cannot be explained by a different impact of  age or gender 
in patients and control groups because neither age nor gender were associated with 
GABA/tCr (age: r = 0.267, p = 0.255 patients, r= -0.095, p = 0.643 controls; gender: r 
= 0.266, p = 0.257 patients, r= 0.142, p = 0.490 controls).
Effect of  genotype on GABA levels
Table 1. Summary of  the NF1 mutations identified in the patients with NF1
* Genetic characterization reported for the first time
# Mutation found in two related patients





  
 
 
 
  
  
 
 
  
 
 
 

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The NF1 mutational profile of  the patients is shown in Table 1. The mutational analysis 
of  19 of  the 20 patients had been reported before (Ribeiro et al., 2012). For the new 
patient we found a novel missense mutation, which represents a change within the gene 
that has not been identified in > 1000 normal chromosomes studied for the entire NF1 
gene mutations. Disease-causing mutations were identified in 65% of  the patients, in 
accordance with previous studies (Griffiths et al., 2007). Cases where the mutation was 
not identified might have a mutation missed by whole-gene sequencing but affecting 
gene expression, given that the criteria for diagnosis were fulfilled. A multiple regression 
model was applied to establish whether the type of  mutation (nonsense, missense, splice 
site or mutation not found in the NF1 gene) might explain the GABA levels in the oc-
cipital cortex. We used as predictors the type of  mutation, age, gender and percentage 
of  GM in the voxel. Given that only one frameshift mutation was present in our cohort, 
this type of  mutation was not included as a predictor. The model obtained was signifi-
cant for the predictor variables (F(7,37) = 2.414, p = 0.039, R
2 = 0.31).
Figure 5. GABA/tCr z-scores for each participant grouped by genotype. GABA/tCr measure-
ments from each participant were transformed to z-scores and plotted grouped according to the type 
of  mutation found in our cohort of  patients with NF1. 
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We found that splice-site or missense mutations are significant contributors to pre-
dict reduced GABA levels in the occipital cortex (Beta = -0.423, t = -3.005, p = 0.005 
for splice-site mutations and Beta = -0.324, t = -2.104, p = 0.042 in the case of  missense 
mutations). However, nonsense mutations or cases where the mutation is not found are 
insufficient to predict GABA levels below those of  controls, Figure 5. Additionally, age, 
gender and GM content did not add predictive power to the model.
Correlation between GABA and BOLD
We measured fMRI BOLD signal while participants performed a low-level visual task, 
Figure 3a. GABA/tCr levels were significantly correlated with peak BOLD amplitude 
in patients (n= 18, r = -0.502, p = 0.034) and controls (n =26, r = -0.458, p = 0.019), 
Figure 3b. In contrast, no correlations were observed for the Glx/tCr levels in patients 
or control subjects, in agreement with previous findings (Edden et al., 2009; Stagg et 
al., 2011). Nevertheless, the regression slopes for the GABA-BOLD correlation were 
significantly different between groups (t(40) = 15.5, p<0.001), being steeper in patients 
with NF1. Given the reduced levels of  GABA found in patients and the correlation be-
tween GABA and BOLD, one might expect higher BOLD in NF1. However, this is not 
necessarily the case and peak hemodynamic responses were not significantly different 
between groups, Figure 3c. In fact for the different average GABA/tCr in each group 
the BOLD signal presents the same mean activation.
Figure 6. Functional magnetic resonance imaging results. a. BOLD activation in the visual cortex 
of  a representative participant (p<0.05, corrected for multiple comparisons using false discovery rate). 
A black crosshair indicates the peak voxel. b. GABA in the occipital cortex correlates with BOLD 
levels in patients (black, n=18) and controls (grey, n=26). c. BOLD response timecourses to the visual 
stimulation at the peak voxel for patients (orange) and controls (blue), error bars depict SEM. 
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disCussion
In this study, we report for the first time measurements of  GABA levels in patients with 
NF1, which proved to be crucial to translate the hypothesis of  altered inhibition in this 
condition. Our results point to lower GABA levels, while no alterations were observed in 
Glx/tCr levels, indicating an alteration in the balance between excitation and inhibition 
in the patients’ visual cortex. An imbalance in the excitatory/inhibitory push-pull mech-
anism is in agreement with our previous findings of  impaired visual contrast sensitivity 
in patients with NF1 (Ribeiro et al., 2012). Impaired contrast sensitivity was also found 
in pharmacological studies employing drugs that alter GABAergic transmission (Pearson 
and Timney, 1998). Furthermore, decreased GABA levels are in line with the evidence 
that lower GABA concentration is related to poorer visual orientation discrimination 
performance (Edden et al., 2009), a hallmark deficit of  the cognitive impairments found 
in patients with NF1 (Schrimsher et al., 2003). Recently, it was shown that increased 
spiking of  parvalbumin-positive (PV+) interneurons in the mouse primary visual cor-
tex (V1) sharpens neuronal feature selectivity and improves perceptual discrimination 
(Lee et al., 2012). Additionally, application of  bicuculine, a GABAA receptor antagonist, 
reversible reduces orientation selectivity in animals (Sillito, 1975; Tsumoto et al., 1979; 
Sillito et al., 1980; Wolf  et al., 1986). These results link GABAergic neurotransmission to 
a physiological impact of  local manipulations of  GABA concentration. 
Previous studies conducted in animal models applied electrophysiological recordings 
in brain slices and provided evidences of  increased IPSPs’, an indication of  augmented 
inhibitory neurotransmission. In an elegant study, Cui et al. (2008) used Cre-loxP mice 
to limit neurofibromin heterozigosity to specific cell types. They found that increased 
inhibition was related to a rise in miniature IPSPs’ frequency as a result of  NF1 hetero-
zigosity in inhibitory neurons, suggesting a role for neurofibromin in GABAergic neu-
rotransmission. Accordingly, increased frequency of  miniature IPSPs was attributable to 
higher levels of  GABA release due to increased phosphorilation of  synapsin 1, a protein 
with a critical role in the regulation of  neurotransmitter storage and release (Hilfiker et 
al., 1999). Our results in human patients point to reduced GABA levels, which may at 
first sight look contradictory to the animal model. Whereas no alterations were observed 
in Glx/tCr levels, in accordance with the findings from the animal model showing that 
neurofibromin alterations do not affect excitatory transmission. 
Reduced GABA levels in patients are not necessarily inconsistent with increased in-
hibitory activity observed in the (Nf1+/-) mouse model. It is important to highlight that 
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there is a distinction between total GABA concentration measured by MRS and GABA 
neurotransmission measured in the animal model, even though there is a close relationship 
between overall GABA concentration measured by MRS and the concentration at the 
vesicular pool (Golan et al., 1996). In fact, MRS measurements of  healthy individuals 
under the influence of  alcohol (Gomez et al., 2011) and benzodiazepines (Goddard et 
al., 2004) revealed decreased GABA levels in the visual cortex, while studies in animals 
reported increased IPSPs (Perrais and Ropert, 1999; Roberto et al., 2003). 
 Mechanistically, it is possible that in the human brain the activation of  synapsin 1 is 
also increased, leading to a larger pool of  releasable synaptic vesicles. The low GABA 
levels measured here might reflect a compensatory mechanism. Increased GABAergic 
neurotransmission can modulate GABA metabolism by down-regulating GABA synthe-
sizing enzymes (GADs), limiting the GABA available for packaging and release (Sheikh 
and Martin, 1998). As mentioned earlier GABA levels are dynamically modulated in re-
sponse to increasing or decreasing network activity and in the context of  brain disorders 
(Esclapez and Houser, 1999; Gomes et al., 2011). Further studies are needed to evaluate 
these possibilities. In particular, studies in both patients and animal models employ-
ing 13C-MRS and molecular imaging using positron emission tomography (PET) would 
deepen our understanding of  the disease mechanism. 
Interestingly, other neurodevelopmental disorders have been related with GABAer-
gic dysfunction, namely autism, Down syndrome, schizophrenia and Fragile X (Ra-
mamoorthi and Lin, 2011). Similarly to the alterations proposed by the NF1 mouse 
model, a mouse model of  Down syndrome (Ts65Dn) showed increased inhibition (Kle-
schevnikov et al., 2004), while decreased GABA levels have been reported in patients in 
vivo (Smigielska-Kuzia et al., 2010) as well as in biochemical measurements in foetuses 
(Whittle et al., 2007). To develop potential treatments, it is critical to understand how 
enhanced inhibitory neurotransmission in mice models might be reflected in decreased 
GABA levels in humans. For that, it will be crucial to apply to the mice models the ana-
lytical tools available to measure GABA levels in humans.
In this study, we also investigated the genotypic impact on GABA levels. The study 
of  genotype-phenotype correlations in NF1 is hampered by the high mutation rate of  
the NF1 gene, resulting in more than 1000 different disease-causing mutations report-
ed (HGMD, http://www.hgmd.cf.ac.uk). Nonetheless, by grouping mutations by type 
and performing linear regression analysis, we found that individuals with missense and 
splice-site mutations have significantly less GABA/tCr levels than control subjects.
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Our findings are consistent with the idea that abnormal neurofibromin proteins re-
sulting from missense or splice-site mutations can act as dominant negatives disrupting 
the function of  the healthy allele, given that patients with NF1 are heterozygous for 
the mutation (Jett and Friedman, 2009), and resulting in a more severe phenotype than 
nonsense mutations (Khajavi et al., 2006). These results should, however, be interpreted 
cautiously in terms of  mutation type, due to the relatively reduced number of  patients.
At last, we confirmed that BOLD and GABA levels are negatively correlated, in 
agreement with previous studies (Edden et al., 2009; Stagg et al., 2011). We performed a 
regression analysis for each group and although it indicated that we can predict equally 
well in both groups the effect of  GABA in BOLD (similar correlation coefficients, 
showing similarly explained variance), the difference in slopes observed indicates that 
changes in BOLD activity are larger for the same unitary change in GABA levels in 
NF1, under matched activation conditions. This suggests a more sensitive inhibitory vs. 
excitatory push-pull mechanism in patients. Peak hemodynamic responses were not sig-
nificantly different between groups, implying that other factors besides the physiological 
coupling between BOLD and inhibition also contribute to the BOLD signal variance 
(Logothetis, 2008).
Regarding methodological considerations, several studies have addressed the issue of  
sensitivity and validity of  GABA measurements using MEGA-PRESS (Puts and Edden, 
2012). Still, it is relevant to remind that the GABA peak may be contaminated by mac-
romolecules (Rothman et al., 1993; Kegeles et al., 2007). However, it seems unlikely that 
differences between patients with NF1 and controls were explained by macromolecules, 
particularly taking into account the correlation found between GABA measurements 
and BOLD signal. Besides, there are mounting evidences of  the biological relevance of  
GABA measurements using MRS, and its correlation with behavioural processes (Edden 
et al., 2009; Sumner et al., 2010; Stagg et al., 2011).  
In summary, we reported GABA changes in patients with NF1. Our results show 
that the excitation/inhibition balance is altered in the visual cortex of  patients, as a con-
sequence of  reduced GABA levels. Although our conclusions are derived from measure-
ments of  GABA in visual cortex, it is likely that analogous abnormalities generalize to 
other cortical areas, in agreement with the widespread GABAergic alterations observed 
in mice (Shilyansky et al., 2010). In addition, there is substantial evidence that the mor-
phological subtypes of  cortical neurons and their basic laminar and tangential connec-
tivity are conserved across cortical areas (Douglas and Martin, 2004). 
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GABA concentration was related to the type of  mutation, providing a link between 
neurofibromin function and regulation of  GABA metabolism in humans. Importantly, 
our experimental and methodological approach provides an example that could be ap-
plied to monitor GABA changes as a consequence of  therapeutic approaches in NF1 
and other neurodevelopmental disorders where alterations in GABAergic neurotrans-
mission were proposed to underlie cognitive deficits, namely autism, Fragile X syndrome 
and Down syndrome (Ramamoorthi and Lin, 2011).
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Chapter 6
Gyrification, cortical and
subcortical morphometry in
Neurofibromatosis type 1:
an uneven profile of 
developmental abnormalities
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AbstrACt
Neurofibromatosis type 1 (NF1) is a monogenic disorder associated with cognitive im-
pairments. In order to understand how mutations in the NF1 gene impact brain struc-
ture it is essential to characterize in detail the brain structural abnormalities in patients 
with NF1. Previous studies have reported contradictory findings and have focused only 
on volumetric measurements. In here we investigated the volumes of  subcortical struc-
tures and the composite dimensions of  the cortex, through the analysis of  cortical vol-
ume, cortical thickness, cortical surface area and gyrification. 
We studied 14 children with NF1 and 14 typically developing children matched for 
age, gender, IQ and handedness. Regional subcortical volumes and cortical gyral mea-
surements were obtained using FreeSurfer. Between-group differences were evaluated 
while controlling for the increase in total intracranial volume observed in NF1. Subcorti-
cal analysis revealed disproportionately larger thalami, right caudate and middle corpus 
callosum in patients with NF1. Cortical analyses on volume, thickness and surface area 
were however not indicative of  significant alterations in patients. Interestingly, patients 
with NF1 had significant lower gyrification indices than typically developing children 
primarily in frontal and temporal lobes, but also affecting the insula, cingulate cortex, 
parietal and occipital regions. 
The neuroanatomic abnormalities observed were localized to specific brain regions 
indicating that particular areas might constitute selective targets for NF1 gene mutation. 
Furthermore, the lower gyrification indices were accompanied by a disproportionate 
increase in brain size without the corresponding increase in folding in patients with 
NF1. Taken together these findings suggest that specific neurodevelopmental processes, 
such as gyrification, are more vulnerable to NF1 dysfunction than others. The identified 
changes in brain organization are consistent with the patterns of  cognitive dysfunction 
in the NF1 phenotype.  
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introduCtion
Brain development is dependent on a series of  complex events including cellular pro-
liferation, growth, differentiation and migration, programmed cell death and synaptic 
elimination. These events largely determine brain morphology (Rakic and Kornack, 
2007). Since brain structure is under significant genetic influence (Thompson et al., 
2001) it is important to use genetic models to understand its ontogeny. 
Neurofibromatosis type 1 (NF1) is a good model in this respect, because it is a mo-
nogenic disorder caused by mutations in the NF1 gene. In the brain, neurofibromin, the 
protein product of  the NF1 gene, is expressed in both neurons and glial cells (Daston 
and Ratner, 1992; Zhu et al., 2005) and is required for neural development (Hegedus et 
al., 2007; Lush et al., 2008). Loss of  neurofibromin results in increased cellular growth 
(Yunoue et al., 2003), while it is also involved in learning and memory (Fernandez-Me-
darde and Santos, 2011). Thus, this disease provides a unique window into gene-brain-
behavior relationships. The role of  neurofibromin in cellular growth and its ubiquitous 
expression in the brain suggest that brain structure might be affected in patients. In fact, 
there is a high incidence of  macrocephaly, optic gliomas and T2-weighted hyperintensi-
ties (Payne et al., 2010). Nevertheless, the gross brain anatomy appears normal and it has 
been difficult to determine if  brain structure is altered independent of  focal lesions.
Recent advances in neuroimaging allow an increasingly detailed delineation of  devel-
opmental anomalies. Previous studies focusing on NF1 brain structure have examined 
the relative contributions of  grey matter (GM) and white matter (WM) to increased 
brain size, with contradictory results (Payne et al., 2010). The majority of  studies points 
to macrocephaly being caused by increases in WM (Said et al., 1996; Steen et al., 2001) 
or a combination of  WM and GM (Cutting et al., 2002a; Greenwood et al., 2005). Only 
one study pointed to increases in GM (Moore et al., 2000). However, few reports at-
tempted to delineate specific regions with abnormal morphometry. Cutting et al. (2002a) 
focused on frontal and parietal lobe subdivisions and found they presented increased 
WM volume. Greenwood and colleagues (Greenwood et al., 2005) divided the brain in 
16 parcellations and besides a total increase in GM and WM volumes in patients with 
NF1, they reported increased GM in occipital and parietal regions and increased WM in 
anterior regions. Other brain structure anomalies observed included increased brainstem 
growth rate, suggestive of  abnormal cell proliferation (DiMario et al., 1999), smaller 
surface area and GM volume of  the left planum temporal of  NF1 boys compared with 
controls (Billingsley et al., 2002) and abnormal thalamic metabolic patterns observed 
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with positron emission tomography (Kaplan et al., 1997) and magnetic resonance spec-
troscopy (Wang et al., 2000). Furthermore, in a previous study from our laboratory, 
support vector machines were able to reveal the existence of  brain structural differences 
in GM and WM tissue that could accurately discriminate individuals with NF1 from 
controls (Duarte et al., 2012). 
However, no previous study performed morphometric measurements of  subcortical 
and cortical structures across the whole brain. Moreover, we extended our investigation 
beyond the volumetric dimension as alterations in neurofibromin expression might be 
differently reflected across the brain and manifest in distinct structures and morphologi-
cal traits.
In this study, our aim was to provide a multidimensional morphometric analysis to 
clarify how brain structure is affected by NF1. For that we measured subcortical and 
cortical volumes, cortical thickness, cortical surface area and gyrification across the en-
tire brain. The importance of  assessing multiple morphometric traits is explained by the 
fact that they underlie distinctive evolutionary (Rakic, 1995), genetic (Panizzon et al., 
2009) and developmental (Armstrong et al., 1995; Raznahan et al., 2011) processes. A 
crucial point in our study was a careful matching of  the control group, as several factors 
are known to influence the results, including age (Raznahan et al., 2011), gender (Luders 
et al., 2006), intelligence (Shaw et al., 2006; Luders et al., 2008) and handedness (Narr et 
al., 2007). Previous studies focusing on structural alterations in NF1 were often biased 
by gender (Cutting et al., 2002a) or included patients with brain tumors (Moore et al., 
2000; Greenwood et al., 2005). Moreover, the majority of  studies lacked matching for 
the intelligence quotient (IQ). Therefore, in the present study we selected both patients 
and controls to ensure matching for age, sex, handedness and IQ. 
We hypothesized that children with NF1 would present a pattern of  morphological 
alterations that it is not limited to one brain region given the range of  neuropsychologi-
cal deficits observed in patients and the wide expression of  neurofibromin in the brain. 
Nevertheless, we also expected that brain abnormalities would be most prominent in 
frontal and parietal neocortical regions in agreement with the consistent impairments 
observed across studies in executive and visuospatial domains (Levine et al., 2006).
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metHods
Subjects
The participants in this study belong to a larger cohort from our previous studies (Duarte 
et al., 2012; Violante et al., 2012) and were selected so that the groups were matched for 
age, gender, IQ and handedness. We studied 14 patients with NF1 (mean age: 11.34 ± 
2.51 SD; age range: 7.83 – 16.08 years; 6 males, 8 females) and 14 matched typically 
developing (TD) subjects (mean age: 11.89 ± 2.06 SD; age range: 7.83 – 15.33 years; 5 
males, 9 females). All participants were right-handed.
 



 



  
  
 



 



 




Table 1. Demographic and Neuropsychological characterization 
NF1 = Neurofibromatosis type 1; TD = typically developing; M = male; F = female; FSIQ = full-
scale intelligence quotient; VIQ = verbal intelligence quotient; PIQ = performance intelligence quo-
tient. Data are mean (SD).
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Patients were recruited and diagnosed in collaboration with the Clinical Genetics Depart-
ment of  the Paediatric Hospital of  Coimbra according to the NIH defined diagnostic 
criteria (National Institutes of  Health Consensus Development Conference Statement: 
neurofibromatosis., 1988). The TD group was recruited from a local school. Exclusion 
criteria for all participants were as follows: psychiatric disorder, neurological illness af-
fecting brain function other than NF1, epilepsy, tumors or other clinically significant 
intracranial abnormality detected on MRI. UBOs (Unidentified Bright Objects - T2-
hyperintensities commonly found in patients with NF1) were not considered exclusion 
criteria when present in patients. Additionally, we only included patients with intelligence 
quotient ≥90 in order to be able to match to typically developing children. Children pre-
scribed with stimulant medication (methylphenidate) were not medicated on the day of  
MRI acquisition and neuropsychological assessment (3 NF1). 
Neuropsychological assessment was performed using the Portuguese adapted ver-
sion of  the Wechsler Intelligence Scale for Children (WISC-III) (Wechsler, 2003). De-
mographic and neuropsychological characterization of  both groups is shown in Table 
1. 
MRI acquisition
Scanning was performed on a 3T Siemens TimTrio scanner, using a 12-channel birdcage 
head coil. In this study we analyzed acquired data with the following parameters: i) two 
T1-weighted (T1w) MPRAGE sequences, 1x1x1 mm voxel size, repetition time (TR) 2.3 
s, echo time (TE) 2.98 ms, flip angle (FA) 9°, field of  view (FOV) 256x256, 160 slices; ii) 
a T2-weighted (T2w) FLAIR sequence, 1x1x1 mm voxel size, TR 5 s, TE 2.98 ms, Inver-
sion Time (TI) 1.8 s, FOV 250x250, 160 slices. FLAIR images were used to identify T2 
hyperintensities. A neuroradiologist, blind to the participants’ clinical history observed 
the MR structural scans and reported on the distribution and number of  UBOs. 
MRI data analyses 
Cortical reconstruction and volumetric segmentation were performed with the Free-
Surfer image analysis suite (FreeSurfer v5.1.0, http://surfer.nmr.mgh.harvard.edu), as 
described in prior publications (Dale et al., 1999; Fischl and Dale, 2000; Fischl et al., 
2002). Briefly the processing included, motion correction, averaging of  the two T1w im-
ages, registration to Talairach space, segmentation of  the subcortical WM and deep GM 
gyrIFICatIon, CortICal and suBCortICal morphometry In nF1  | 145
volumetric structures (Fischl et al., 2002; Fischl et al., 2004), intensity normalization, tes-
sellation of  the GM/WM boundary, automated topology correction (Fischl et al., 2001; 
Segonne et al., 2007), and surface deformation following intensity gradients to optimally 
place the GM/WM and GM/CSF borders (Dale et al., 1999). Image outputs were visu-
ally inspected and inaccuracies corrected when required. Registration was performed to 
a spherical atlas (Fischl et al., 1999), Figure 1. 
Cortical thickness was calculated as the closest distance from the GM/WM bound-
ary to the GM/CSF boundary at each vertex on the tessellated surface (Fischl and Dale, 
2000). Surface area assigned to each vertex on the GM/WM matter surface was calculat-
ed as the average area of  all triangles that surround the vertex. Local gyrification indices 
(lGI) were computed using local measurements of  gyrification over the whole cortical 
surface using the method developed by Schaer et al. (2008). The lGI reflects the amount 
of  cortex buried within the sulcal folds.
Cortical volume, surface area, cortical thickness and the local gyrification indices 
were estimated for 34 gyral regions per hemisphere as defined by the atlas developed 
by Desikan et al. (2006), Figure 2, recently modified to include the insula as a region 
of  interest. GM volume was estimated for subcortical structures. WM and GM brain 
volumes, WM and GM cerebellar volumes, WM and GM lobar volumes and total intrac-
ranial volumes (TIV) were also estimated for each participant. 
Statistical analyses
Statistical analyses were performed with PAWS Statistics 18 (SPSS Inc., Chicago, USA). 
First, we verified the normality assumption for the different parameters using the Sha-
piro Wilk’s test. All data were normally distributed. Group differences in demographic 
and neuropsychological data were evaluated with independent samples t-tests. Gender 
differences were evaluated using Chi-square tests.
Group differences in overall volumetric measurements were assessed using indepen-
dent samples t-tests. For lobar regions and cerebellar WM and GM we used repeated 
measures ANCOVA with group (NF1 vs typically developing) as the between-subjects 
factor and hemispheres (left vs right) and brain regions (lobes/cerebellar WM/cerebellar 
GM) as the within-subjects factors and total intracranial volume (TIV) as covariate. 
Analyses of  subcortical volumetric differences were assessed using multivariate 
ANOVA. To determine whether the results were mediated by overall intracranial vol-
ume we performed an ANCOVA with TIV as covariate. We did not apply a repeated 
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measurement analysis with hemisphere as between-subjects factor because some regions 
investigated could not be split by hemisphere.
Cortical differences between groups were investigated using repeated measures AN-
COVA with group (NF1 vs typically developing) as the between-subjects factor and 
hemispheres (left vs right) and brain regions (34 gyral regions) as the within-subjects 
factors and TIV as covariate. Follow-up tests were performed using multivariate AN-
COVAs with TIV as covariate. 
Figure 1. Schematic representation of  FreeSurfer cortical reconstruction (top), segmentation 
(middle) and parcellation procedure (bottom). Adapted from Salat et al., 2009.
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Relationships between brain measurements and age were studied using Pearson’s correla-
tions.
To control for type I errors we used the Bejamini & Hochberg (Benjamini and Hoch-
berg, 1995) false discovery rate (FDR) method. We set q = 0.05 or 0.1 (i.e., 5% or 10% 
false positives). Multiple ROI-based analyses survived FDR control at q = 0.1 and sev-
eral survived FDR control at q = 0.05. Although FDR at q = 0.1 can be considered a lib-
eral correction for multiple comparisons, it should be taken into account the exploratory 
nature of  the present study.
Figure 2. Gyral based regions defined by the atlas developed by Desikan et al. Pial (left) and 
inflated (right) cortical representations of  the regions of  interest in one hemisphere. The top row 
illustrates the lateral view of  the hemisphere while the bottom row shows the medial view of  the 
hemisphere. The white asterisk on the pial surface (left) indicates the cortex around the perimeter of  
the central sulcus that is buried within the gyri and thus not visible. The yellow asterisks on the inflated 
surface (right) indicate the cortex around the perimeter of  the central sulcus that has been inflated and 
is now visible. Reproduced from Desikan et al., 2006.
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results
Demographic and neuropsychological
Demographic and neuropsychological data are described in Table 1. Children with NF1 
and typically developing (TD) children did not differ significantly in age [t(26) = -0.632, p 
= 0.533], IQ [t(26) = -1.219, p = 0.234], verbal IQ [t(26) = -0.584, p = 0.564], or gender [χ
2 
= 0.150, p = 0.699]. Performance IQ was marginally significant [t(26) = -2.016, p = 0.054], 
with larger scores observed in TD children. 
One or more UBOs were present in 85.7% (12 out of  14) of  the children with NF1 
distributed as follows: 85.7% (n=12) of  the patients had UBOs in the globus pallidus, 
21.4% (n=3) in the thalami, 14.3% (n=2) in the corpus callosum, 7.1% (n=1) in the 
putamen, 14.3% (n=2) in the cerebellum and 28.6% (n=4) had UBOs in the WM. The 
frequency and distribution of  UBOs is in accordance with published data (Payne et al., 
2010). None of  the TD participants had UBOs. 
Overall volumetric measurements
Children with NF1 showed a 10% increase in total intracranial volume (TIV) as com-
pared with the TD group [NF1: 1658 ± 127 cm3; TD: 1505 ± 138 cm3; t(26)= 3.041, p = 
0.005]. This overall increase was more attributable to an increase in WM [NF1: 517 ± 61 
cm3; TD: 428 ± 46 cm3; t(26)= 4.340, p < 0.001] than GM, including cortical and subcor-
tical GM [NF1: 789 ± 78 cm3; TD: 728 ± 74 cm3;  t(26)= 2.104, p = 0.045]. Age was not 
significantly correlated with TIV for our subjects [r = 0.067, p = 0.736]. 
We next examined overall volumetric differences at the lobar level. Results for WM 
are displayed in Figure 3. Group differences in WM were reflected by a main effect of  
group [F(1,25)= 8.028, p = 0.009], two-way interactions between hemisphere and group 
[F(1,25)= 5.287, p = 0.030] and lobe and group [F(3,75)= 6.758, p < 0.001]. Follow-up mul-
tivariate ANCOVA controlling for TIV, revealed that left and right frontal lobes were 
significantly larger in patients [left frontal lobe: F(1,25)= 10.456, p = 0.003; right frontal 
lobe: F(1,25)= 5.786, p = 0.026], as well as left and right temporal lobes [left temporal lobe: 
F(1,25)= 10.930, p = 0.003; right temporal lobe: F(1,25)= 12.125, p = 0.002]. However only 
the left hemisphere parietal lobe was significantly larger [left parietal lobe: F(1,25)= 7.980, 
p = 0.009; right parietal lobe: F(1,25)= 3.295, p = 0.081] and no differences were observed 
for the occipital lobe [left occipital lobe: F(1,25)= 0.078, p = 0.782; right occipital lobe: 
F(1,25)= 0.713, p = 0.406].
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Results for GM are displayed in Figure 3. The lobar GM volumes included only cor-
tical volumes and resulted in no significant effect of  group and no interaction between 
group and lobe. Nonetheless, we found a significant two-way interaction between hemi-
sphere and group [F(1,25)= 8.468, p = 0.007]. 
At the cerebellar level, neither the cerebellar white matter [left hemisphere: F(1,25)= 
0.042, p = 0.840; right hemisphere: F(1,25)= 1.908, p = 0.179], nor the grey matter volumes 
[left hemisphere: F(1,25)= 0.331, p = 0.570; right hemisphere: F(1,25)= 0.612, p = 0.441] 
where statistically different between patients and TD children.
Figure 3. Lobar volumes in patients with NF1 (grey bars) and typically developing children 
(white bars). Lobar volumes are displayed by hemisphere after controlling for total intracranial vol-
ume for lobar white matter (top) and lobar grey matter (bottom). Graphs depict mean and SEM, 
*p<0.05. LH = left hemisphere; RH = right hemisphere.  
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Subcortical regional brain volumes
Children with NF1 showed increased volumes when compared to TD children in almost 
all subcortical brain regions evaluated, Table 2. Using a FDR (q = 0.05) correction for 
multiple comparisons the majority of  regions remained significant with the exception 
of  the left putamen and the right pallidum. We next conducted an ANCOVA with TIV 
as covariate to determine whether these regional brain volume differences remained 
significant beyond overall increase in brain size in children with NF1. After controlling 
for TIV the thalami, the right caudate and the mid regions of  the corpus callosum (mid 
posterior, central, mid anterior) remained significantly different between patients with 
NF1 and TD, Figure 4. Furthermore, these regions remained significant after correcting 
for multiple comparisons (FDR, q = 0.1). After the more stringent control for multiple 
comparisons (FDR, q = 0.05), only, the right thalamus and the mid anterior region of  the 
corpus callosum remained significantly different, Table 2. Adding age or IQ as a covari-
ates to the ANCOVA did not change the results.
Figure 4. Group differences in subcortical regional brain volumes; superior view (a) and sagit-
tal view showing the divisions for the corpus callosum (b). Larger volume in patients with NF1 
was observed in the left and right thalamus (green) and right caudate nucleus (blue) after controlling 
for total intracranial volume (TIV) and multiple comparisons using FDR, areas in grey correspond 
to regions where group differences were no longer significant after controlling for total intracranial 
volume. In the corpus callosum, patients with NF1 showed larger volumes of  the mid regions (mid 
posterior, mid anterior and central). CC = corpus callosum; CC1 = posterior, CC2 = mid-posterior; 
CC3 = central; CC4 = mid-anterior; CC5 = anterior.
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   ↑   
   ↑   

   ↑   
   ↑   
    ↑   
    ↑   ↑
    ↑   ↑
    ↑   ↑
    ↑   
    ↑   

Table 2. Results of  ANCOVA analyses in subcortical regions
Bold font represents significant results (p < 0.05). a Represents significant results after correction for 
multiple comparisons with FDR (q = 0.05 or 0.1) and b after with FDR (q = 0.1). Arrows indicate the 
direction of  the group difference, ↑ = NF1 > Typically developing subjects. CC = corpus callosum; L 
= left; R = right; TIV = total intracranial volume.
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Cortical volume, cortical thickness and cortical surface area
 Cortical volume group differences, investigated using repeated measures ANCOVA 
with TIV as covariate, resulted in no main effect of  group [F(1,25)= 0.690, p = 0.414], but 
statistically significant two-way interactions between region and group [F(33,825)= 1.651, p 
= 0.013] and hemisphere and group [F(1,25)= 8.058, p = 0.009]. 
Repeated measures ANCOVA of  cortical thickness measurements resulted in no sta-
tistically significant effect of  group [F(1,25)= 1.084, p = 0.308], but a significant effect of  
brain region [F(33,825)= 5.870, p < 0.001], a two-way interaction between region and group 
[F(33,825)= 1.522, p = 0.031] and a three-way interaction between hemisphere, region and 
group [F(33,825)= 1.455, p = 0.049]. 
The results for cortical surface area resemble those found for cortical volume and 
cortical thickness, with no significant effect of  group [F(1,25)= 0.378, p = 0.544]. Never-
theless, we observed a significant two-way interaction between hemisphere and group 
[F(1,25)= 6.061, p = 0.021]. 
Because there was no group effect in any of  the cortical variables explored above, we 
did not perform post-hoc tests.
Gyrification Index
The gyrification index showed a significant effect of  group [F(1,25)= 10.400, p = 0.003], 
an effect of  region [F(33,825)= 3.263, p < 0.001] and a two-way interaction between region 
and group [F(33,825)= 2.591, p < 0.001]. Follow-up multivariate ANCOVA showed that pa-
tients with NF1 have reduced gyrification mainly in frontal and temporal lobar regions, 
but also in insula, parietal, occipital and cingulate gyri, Table 3 and Figure 5. After cor-
rection for multiple comparisons several gyral-regions remained statistically significant: 
left and right superior frontal, left and right superior temporal, right middle temporal 
and right transverse temporal (FDR, q = 0.05). The majority of  gyral-regions remained 
significant at FDR, q = 0.1 (Table 3). Adding age or IQ as covariates to the repeated 
measures ANCOVA and follow-up ANCOVAs did not change the results.
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
    

   ↓
   ↓

   
   ↓

   
   

   ↓
   

   
   

   ↓
   ↓

   ↓
   

   ↓
   ↓

   ↓
   ↓

   ↓
   

   ↓
   

   ↓
   ↓

   ↓
   ↓
    
Table 3. Results of  ANCOVA analyses for local gyrification index in gyral regions 
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    ↓

   
   ↓

   
   

   
   

   
   ↓

   
   ↓


   
   ↓

   
   

   
   

   
   ↓

   ↓
   ↓

   
   

   
   

   
   

   
   ↓

   
   ↓
    ↓
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Bold font represents significant results (p < 0.05). a Represents significant results after correction for 
multiple comparisons with FDR (q = 0.05 or 0.1) and b after with FDR (q = 0.1). Arrows indicate the 
direction of  the group difference, ↓ = NF1 < Typically developing subjects. L = left; R = right



 
↓


   ↓
   

   
   

   
   

   ↓
   ↓

Figure 5. Graphical illustration of  significant reductions in gyrification in patients with NF1. 
This figure shows an overlay of  F-test statistics (with p values indicated by the color bar) where patients 
with NF1 have lower local gyrification index than typically developing children. Between-group com-
parisons were performed controlling for intracranial volume. Blue colour depict gyri with significant 
group differences at p < 0.05, not corrected; Yellow p < 0.01 and Orange p < 0.005, both surviving 
correction for multiple comparisons with FDR q = 0.1; Red gyri p < 0.001, survives correction for 
multiple comparisons  with FDR q < 0.05. 
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Brain size and folding relationships
In humans, the volume of  the brain and the area of  its cortical surface are strongly cor-
related (Toro et al., 2008). This relation is such that larger brains are normally accompa-
nied by a higher increase in surface area than it would be expected by mere scaling of  
the brain. Furthermore, increase in folding is necessary for compactness of  connections 
(Ruppin et al., 1993; Murre and Sturdy, 1995). Indeed, when brain volume and surface 
area are plotted in a logarithmic scale the slope of  the regression line obtained indicates 
a disproportionate expansion of  the cerebral cortex in relation to brain volume related 
to an increase in gyrification. 
Given the group differences observed in lGI, we investigated whether the increase in 
brain size in NF1 is related to an increase in gyrification. 
Figure 6a shows the relationship between cortical surface area and intracranial vol-
ume for patients with NF1 and TD children plotted in a log-log graph. TIV is correlated 
with surface area in both groups [NF1: r = 0.806, p < 0.001; TD: r = 0.925, p < 0.001]. 
The slope of  the regression line is 0.941 for NF1 and 1.069 for TD children, higher than 
the value expected for an isometric scaling (2/3) as observed in the human brain (Toro 
et al., 2008). Interestingly, the slopes are significantly different between groups [t(24) = 
4.044, p < 0.001], being steeper for TDs.
To investigate whether the degree of  cortical folding is related with measurements 
of  TIV, surface area and cortical thickness we performed Pearson’s correlations between 
these variables. LGI was only positively correlated with TIV for TD subjects [NF1: r 
= 0.458, p = 0.099; TD: r = 0.744, p = 0.002], Figure 6b. The cortical surface area was 
correlated with lGI for both groups [NF1: r = 0.788, p = 0.001; TD: r = 0.875, p < 
0.001], Figure 6c; while lGI and cortical thickness were not correlated for any of  the 
groups (not shown), consistent with prior studies (Thompson et al., 2005; Lin et al., 
2007; Bearden et al., 2009). 
Figure 6. Brain size and folding relationships in NF1 (grey) and typically developing children 
(TD), (black). a. Cortical surface area versus intracranial volume (log-log graph). b. lGI versus intrac-
ranial volume. c. lGI versus surface area. 
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disCussion
In this study, we used computational methods to examine the impact of  NF1, a single 
gene disorder, on multidimensional morphological brain traits. This is the first study to 
examine measurements of  cortical thickness, cortical surface area and gyrification in 
this common neurodevelopmental genetic condition. We confirmed that children with 
NF1 have larger intracranial volumes than typically developing children (~10%) and our 
findings indicate that this enlargement is mainly a result of  increased WM volume. At 
lobar level, our results indicate that patients with NF1 have larger WM volumes in the 
frontal lobe, consistent with prior studies (Cutting et al., 2002a; Greenwood et al., 2005; 
Duarte et al., 2012), temporal lobe, in agreement with voxel-based morphometry find-
ings using a partly overlapping cohort of  subjects (Duarte et al., 2012), and also right 
parietal lobe, as previously observed (Cutting et al., 2002b). We did not find alterations 
in the occipital lobe. Our lobar data is in agreement with the notion that WM alterations 
are predominant in anterior brain regions. We also observed a parallel increase in GM 
volume in patients with NF1, a result attributable to larger subcortical rather than corti-
cal volumes. 
Measurements of  subcortical regional volumes indicated enlargements in patients 
with a dependence on overall brain volume for the majority of  regions. After controlling 
for the effect of  intracranial volume, the thalami, the right caudate nucleus and the mid 
portions of  the corpus callosum remained significantly larger in patients with NF1 than 
TD children. 
This study was the first, to our knowledge, to report a volumetric alteration of  the 
thalami in children with NF1. Moreover, we have previously identified this structure as 
belonging to a spatial pattern that significantly contributes to discriminate between brains 
from patients with NF1 and brains from controls (Duarte et al., 2012). Other studies 
reported thalamic hypometabolism (Kaplan et al., 1997), T1 reduction (Steen et al., 2001) 
and abnormal choline and N-acetylaspartate content content (Wang et al., 2000), pos-
sibly reflecting altered myelination and neuronal loss or neuronal dysfunction.
The thalamus is a highly interactive structure, with widespread connections to mul-
tiple cortical regions, that provides selection and transformation of  different sensory 
inputs to the cortex. The various nuclei of  the thalamus are involved in the integra-
tion of  sensory and motor information, memory and executive functions (Schmahmann 
and Pandya, 2008), competences in which NF1 patients show disabilities (Hyman et al., 
2005; Levine et al., 2006; Roy et al.). 
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The right caudate nucleus was also found to be larger in patients and it was previ-
ously identified as a relevant structure to discriminate between NF1 and control subjects 
(Duarte et al., 2012). The caudate is a nucleus of  the basal ganglia and therefore plays a 
role in sensorimotor coordination, while there is also cumulating evidences indicating an 
involvement in goal-directed behaviour (Grahn et al., 2008). It is widely connected with 
the frontal lobe and particularly with dorsolateral prefrontal cortex (Kemp and Powell, 
1970; Yeterian and Van Hoesen, 1978), which is involved in working memory and ex-
ecutive function. A recent functional magnetic resonance imaging (fMRI) study showed 
abnormal right caudate activation in NF1 in a spatial working memory task (Shilyansky 
et al., 2010). Moreover, Schrimsher et al. (Schrimsher et al., 2002) observed that children 
with a greater degree of  right to left caudate volume asymmetry show subclinical inat-
tentive behaviours that define ADHD. Interestingly, there is a high incidence of  ADHD 
in NF1 (Hyman et al., 2005). 
Finally, the enlargement observed in the midline portion of  the corpus callosum 
corroborates previous reports from our group, in a partly overlapping cohort, using an 
independent method (Duarte et al., 2012) and others (Kayl et al., 2000; Dubovsky et al., 
2001; Steen et al., 2001; Cutting et al., 2002b; Pride et al., 2010). Besides morphometric 
abnormalities, there is evidence of  altered microstructure of  the corpus callous in NF1 
(Zamboni et al., 2007; Wignall et al., 2010). Behaviourally, higher volumes of  corpus 
callosum were previously related to low IQ, impaired visuospatial and motor skills and 
learning problems in children with NF1 (Moore et al., 2000; Pride et al., 2010). Interest-
ingly, we observed that the volume of  the corpus callosum remains abnormal even for 
normal IQs. 
Unlike the specific observations concerning subcortical structures, examination of  
cortical measurements indicated that alterations in cortical volume, cortical surface area 
and cortical thickness are not significant. Gyrification index was the only changed mea-
sure in cortex. 
One of  the most evident features of  human evolution is the increase in brain size 
(Passingham, 1973). In response to evolutionary demands, a high level of  gyrification 
occurred in parallel with an increase in cortical GM in order to maximize cortical sur-
face while maintaining a smaller intracranial size (Zilles et al., 1988). The increase in 
folding in bigger brains seems to be necessary for the formation of  efficient cortico-
cortical connections in larger volumes (Ruppin et al., 1993; Murre and Sturdy, 1995). 
This evolutionary trait appears disrupted in NF1, with an increase in brain size without 
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a corresponding adaptive increase in folding. Accordingly, the correlation observed in 
TD children between lGI and intracranial volume is absent in NF1. Moreover, although 
both TD and NF1 children presented an allometric scalling between surface area and 
volume, showing more surface area than predicted by a homothetic relationship (Toro 
et al., 2008), the difference in slopes indicates that NF1 have less surface area than what 
would be expected for their brain volume. 
The phylogenetic development of  gyral and sulcal folds likely optimizes compaction 
of  neuronal fibers while keeping neuronal signalling at efficient transit time (Ruppin 
et al., 1993; Murre and Sturdy, 1995). Given that abnormal cortical folding may reflect 
deficits in structural and, consequently, functional cortical connectivity, we will speculate 
on potential links between cortical folding abnormalities and the patterns of  cognitive 
dysfunction that characterize the NF1 phenotype.  
Concerning the cognitive phenotype related to cortical functions, executive func-
tions have been reported to be impaired in children with NF1 (Roy et al., 2010; Payne et 
al., 2011), even when controlling for IQ (Roy et al., 2010). In here, we observed lower 
lGI in several frontal lobe regions that could underlie executive impairments, namely 
the superior frontal gyri (du Boisgueheneuc et al., 2006), right frontal pole (Tsujimoto 
et al., 2011) and orbitofrontal regions (Elliott et al., 2000; Zald and Andreotti, 2010). 
Moreover, the anterior cingulate cortex was also found to have lower lGI values in NF1 
and it plays a role in attention and error detection (Bush et al., 2000). Interestingly, we 
have previously found an abnormal activity pattern in this region using an overlapping 
cohort of  subjects (Violante et al., 2012), possibly related with a deficit in default-mode 
network function.
Patients with NF1 have deficits in expressive and receptive language, vocabulary and 
phonologic awareness (Levine et al., 2006). Previously, a correlation has been reported 
between verbal skils in NF1 and the inferior frontal gyrus morphology, such that indi-
viduals with “typical” gyral patterns in the right hemisphere performed worse across lan-
guage measures than those showing “atypical” gyrus (Billingsley et al., 2003). In here, we 
observed a deficit in gyrification in regions involved with language functions, namely in 
regions belonging to the Broca’s complex (pars opercularis, pars orbitalis, pars triangu-
laris) (Hagoort, 2005; Xiang et al., 2010), superior temporal gyrus and middle temporal 
gyrus (Chao et al., 1999; Cabeza and Nyberg, 2000) and supramarginal gyrus (Gough 
et al., 2005; Hartwigsen et al., 2010). Moreover, right transverse temporal gyrus, known 
as the Heschl’s gyrus also presented lower lGI in patients. Abnormalities in the inferior 
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frontal gyrus and Heschl’s gyrus were associated with performance across language and 
neuropsychological measures in individuals with NF1 (Billingsley et al., 2003). 
Motor deficits for both simple and complex motor tasks have been reported in NF1 
(Feldmann et al., 2003; Levine et al., 2006; Rowbotham et al., 2009) consistent with the 
observed bilateral deficits in lGI in both precentral and paracentral gyri, underlying mo-
tor functions (Purves and Williams, 2001). 
In spite of  our identification of  altered patterns of  gyrification in regions underly-
ing cognitive deficits typically observed in children with NF1, this was not the case for 
the posterior parietal lobe. This is rather surprising given that visuospatial deficits are 
considered a hallmark of  the NF1 cognitive phenotype. This might be explained by 
the suggestion that other brain regions such as fronto-executive regions contribute to 
the pattern of  impairment observed in specific visuospatial tests (i.e judgement of  line 
orientation test).
 In agreement with the notion of  impaired low-level visual processing in NF1 (Cle-
ments-Stephens et al., 2008; Violante et al., 2012), we observed lower lGI in the right 
cuneus and pericalcarine regions. 
It is estimated that around 30% of  phenotypic variance in gyrification is attributed to 
genetic variation (Rogers et al., 2010). Therefore, the observed reductions in lGI point 
towards early abnormalities in control over neuronal migration or proliferation. Deeper 
fissures develop earlier and are more strongly influenced by genetic processes and thus 
might be less susceptible to environmental perturbations. Insular sulci and the central 
sulcus are among the first macroscopical structures identified on the human fetal brain 
(Afif  et al., 2007) (Rajagopalan et al., 2011), and both the insula and the gyri surrounding 
the central sulcus presented less gyrification in NF1 than TD individuals. 
The mechanisms that drive cortical folding remain poorly understood and there are 
different possible explanations for the observed abnormalities of  cortical gyrification 
in NF1. The two most widely accepted hypothesis to explain gyrification are: 1) folding 
is caused by differential growth of  the cortex and 2) folding is caused by mechanical 
tension generated in axons. The first model proposes that differential growth rates of  
cortical layers directly affect the degree of  cortical convolutions (Caviness, 1975). An 
alternate theory to this hypothesis suggests that changes in subcortical connections can 
lead to altered cortical folding patterns without changing the area of  the cortical surface 
(Kostovic and Rakic, 1990). The second model, based on tension-based cortical mor-
phogenesis, proposes that the mechanical tension along axons is the driving force for 
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cortical folding (Van Essen, 1997). In line with this theory, we observed a significant 
increase in WM in the anterior NF1 brain accompanied by an enlargement of  the corpus 
callosum. Moreover, diffusion tensor imaging studies showed altered microstructure in 
several white matter regions (Zamboni et al., 2007). Both models are not necessarily 
contradictory and could jointly explain the gyral abnormalities in NF1. 
The present study has several limitations that need to be acknowledged when inter-
preting our findings. First, we studied a large age range and we were limited to a relatively 
small number of  participants. In that sense, longitudinal studies are clearly warranted 
to disentangle the complex genetic and nongenetic influences that contribute to the 
neuroanatomic and cognitive abnormalities in NF1. Secondly, 12 of  the 14 (85.7%) pa-
tients in this study have UBOs. These hyperintensities are the most common identified 
abnormality observed on MRI in patients with NF1 (Lopes Ferraz Filho et al., 2008) and 
might be associated with other clinical features (Szudek and Friedman, 2002). However, 
the location of  the UBOs does not seem to indicate a regional causal link between struc-
ture volume and the presence of  UBOs, given that hyperintensities were more frequent 
in the globus pallidus and this structure did not differ in terms of  volume in relation to 
TD children.
In summary, we found that the overall increase in intracranial volume in patients with 
NF1, is explained by an enlarged WM volume in anterior brain regions and subcorti-
cal GM volumes, with a disproportionate increase in the volumes of  the thalami, right 
caudate nucleus and corpus callosum. At the cortical level we observed abnormalities 
of  gyrification, which could reflect developmental abnormalities in both cortical archi-
tecture and cortico-cortical connectivity. This newly identified pattern of  gyral malfor-
mation, required quantitative tools such as lGI to be detected. Given the emphasis on a 
careful matching between patients and TD children we believe that the brain alterations 
observed in here are shaped primarily by genetically programmed anomalous neurode-
velopment. The fact that neuroanatomic abnormalities in patients with NF1 are local-
ized to particular brain regions adds to the growing body of  evidence that specific genes 
independently control the morphometry of  specific cytoarchitectonic areas. 
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disCussion 
The present thesis entails a tripartite methodology, employed to study the neurobiological 
basis underlying the cognitive deficits observed in patients with neurofibromatosis type 
1 (NF1). Those involve visuospatial, executive function, motor, language and memory 
domains (Levine et al., 2006). Although these deficits have been extensively examined 
at the behavioural level, there is much to disentangle about the biological mechanisms 
contributing to the observed phenotype. Only by exploring these mechanisms one 
can truly understand pathogenesis and find adequate treatments that target disease 
mechanisms. 
To gain access into the living human brain, we used magnetic resonance imaging 
and spectroscopy to acquire functional information on neural activity, and structural 
and neurochemical profiles of  patients with NF1. In this final chapter I integrate these 
findings with reference to the results from other studies and provide suggestions for 
future studies. In addition, I propose a general mechanism to integrate functional, 
structural and neurochemical findings in NF1 based on our results and contributions 
from others. 
Functional and neurochemical profiles in NF1: a focus on the visual cortex
The first two research questions investigated in this thesis focused on the visual cortex 
(Chapters 4 and 5). Our group has recently shown a pattern of  psychophysiological 
impairment in visual sensory processing in NF1 (Ribeiro et al., 2012). In Chapter 4, we 
explore this pattern further by using functional Magnetic Resonance Imaging (fMRI) 
to assess neural activation at the level of  primary sensory visual cortex. fMRI has the 
advantage of  probing neural activity and is able to provide spatial information within 
hierarchically defined early brain regions. We measured neural activation to stimuli that 
preferentially drive the activity of  the two main pathways conducting information from 
the retina to the cortex: magnocellular (M) and parvocellular (P). Patients with NF1 
showed deficient activation of  the low-level visual cortex to both stimulus types, in 
agreement with our previous report of  impaired contrast sensitivity in patients with NF1 
(Ribeiro et al., 2012) and with deficient activation of  the early visual cortex observed 
during performance of  the judgment of  line orientation task (Clements-Stephens et 
al., 2008). Importantly, impaired magno- and parvocellular activation was observed for 
children and adults with NF1, indicating that low-level visual processing deficits do not 
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ameliorate with age. 
Altered visual processing at lower and higher levels of  the dorsal and ventral streams 
may explain the visuospatial deficits that characterize the cognitive phenotype in patients 
with NF1. Moreover, impaired sensory processing can contribute to higher order 
cognitive deficits such as working memory and executive processing. In fact, besides 
the early visual cortex impairment, the NF1 group also presented a failure to deactivate 
regions belonging to the default mode network (DMN) during M-stimulation, particularly 
anterior medial prefrontal cortex/anterior cingulate cortex and the posterior cingulate 
and retrosplenial cortices. The mechanisms behind this abnormal DMN activation 
could be related to the attentional deficits known to occur in children with NF1. In that 
sense, one may hypothesise that activity in the DMN is explained by greater incidence 
of  attention deficit hyperactive disorder (ADHD) related symptoms in patients with 
NF1, and thus an inability to stay on the task and tendency to daydream. In any case, 
in order to understand the neural mechanisms contributing to DMN activation it is 
important to account its dependence on stimulus type, given it only occurred during 
M-biased stimulation. The “magnocellular advantage” theory proposed by Laycock et 
al (Laycock et al., 2007; Laycock et al., 2008) suggests an important role for the M 
pathway in driving attentional mechanisms in higher-order cortical regions. According 
to Laycock, the M system plays a key role in guiding P processing by providing a general 
low-resolution ‘‘frame’’ for the visual environment, which is then ‘‘filled in’’ by details 
from the slower P system. How this relates to abnormal DMN activation is an intriguing 
aspect to be explored in future studies. Interestingly, it was recently shown that the 
pattern of  connectivity of  the DMN is altered in children with NF1, particularly the 
connections between the posterior cingulate cortex and the anterior medial prefrontal 
cortex (Chabernaud et al., 2012), regions with abnormal activity in our study. A normal 
connectivity pattern could be restored using lovastatin although it remains to be proven 
whether this rescues attentional deficits. 
Our findings associated for the first time a visual sensory deficit to the NF1 
cognitive profile. In other clinical populations there is already increasing appreciation 
of  the contribution of  early sensory dysfunction to higher order cognitive functions, 
particularly in autism (Sutherland and Crewther, 2010), Fragile X syndrome (Kogan et 
al., 2004) and schizophrenia (Martinez et al., 2008; Dias et al., 2011). This phenomenon 
is accompanied by an increasing comprehension of  the complexity of  early visual cortex 
involvement in many levels of  visual computation (Alonso, 2002; Lee, 2003).
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A deeper understanding of  the processes that are capable of  driving abnormal neural 
activation of  the early visual cortex can be achieved by inspecting the neurotransmitters 
that shape visual responses. Information processing in the visual cortex relies on 
interactions between excitatory and inhibitory circuits, where excitatory outputs are 
shaped by the action of  GABAergic interneurons (Dykes et al., 1984; Nelson et al., 1994; 
Swadlow, 2003; Atallah et al., 2012). For that reason, measurements of  GABA levels can 
provide relevant information on the function of  neuronal responses and subsequent 
behavioural processes. Therefore, the second research question explored in this thesis 
relied on measuring GABA in the early visual cortex to determine whether inhibition 
might be altered in NF1. 
In Chapter 5 we showed that GABA levels were reduced in patients with NF1 and that 
they could be predicted by the type of  NF1 mutation. Reduced GABA levels are in line 
with the evidence that lower GABA concentration is related to poorer visual orientation 
discrimination performance (Edden et al., 2009), a hallmark deficit of  the cognitive 
impairments found in patients with NF1 (Schrimsher et al., 2003). Correspondingly, the 
role of  GABA in defining selectivity for stimulus orientation and direction of  motion in 
the primary visual cortex has been well established in animals (Rose and Blakemore, 1974; 
Sillito, 1979; Tsumoto et al., 1979; Katzner et al., 2011). These results link GABAergic 
neurotransmission to local manipulations of  GABA concentration. In that sense, it will 
be important to study orientation discrimination in NF1 and determine whether GABA 
levels are correlated with behavioural measurements.
Another point worth mentioning is the possible link between altered GABA 
concentration and psychophysical measurements of  impaired contrast sensitivity in 
NF1. Contrast gain control operates in the retina (Shapley and Victor, 1981; Brown 
and Masland, 2001; Chander and Chichilnisky, 2001; Baccus and Meister, 2002) and is 
strengthened in the thalamus and visual cortex (Kaplan et al., 1987; Sclar et al., 1990; 
Cheng et al., 1995). However, the role of  GABAergic inhibition in this process is subject 
to great controversy (Carandini and Heeger, 1994; Carandini et al., 1997; Freeman et 
al., 2002; Katzner et al., 2011). Furthermore, while measurements of  GABA levels 
in the human visual cortex were correlated with surround suppression the same was 
not observed for contrast discrimination performance (Yoon et al., 2010). In future 
studies it will be interesting to assess surround suppression and overlay suppression 
in NF1. These two psychophysical approaches should constitute a good model to 
probe the extension of  GABA abnormalities in NF1 and to further explain contrast 
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sensitivity deficits, given that they are thought to arise from two distinct suppressive 
neurophysiological mechanisms within the visual system. While surround suppression 
is thought to originate within the primary visual cortex (Walker et al., 2000; Akasaki et 
al., 2002; Osaki et al., 2011) and involves GABA mediated inhibition (Fu et al., 2010; 
Yoon et al., 2010), overlay suppression is thought to originate within the lateral geniculate 
nucleus (Freeman et al., 2002; Bonin et al., 2005; Li et al., 2006; Priebe and Ferster, 2006) and 
is not dependent upon GABA mediated inhibition within the visual cortex (Katzner et 
al., 2011). 
Although our conclusions are derived from measurements of  GABA in visual cortex, 
it is likely that analogous abnormalities generalize to other cortical areas, in agreement 
with the widespread GABAergic alterations observed in mice (Shilyansky et al., 2010). In 
fact, we performed GABA measurements in the dorsal anterior cingulate cortex of  the 
same group of  patients and observed reduced levels of  GABA in this region. Given the 
substantial evidence that the morphological subtypes of  cortical neurons and their basic 
laminar and tangential connectivity are conserved across cortical areas (Douglas and 
Martin, 2004) it is quite probable that the concentration of  GABA is generally reduced 
in patients with NF1. If  that is the case, this could contribute to explain the complex 
ocular motor pattern observed in children with NF1 (Lasker et al., 2003), where GABA 
is known to play a key role in saccadic behaviour (Schiller and Tehovnik, 2005; Hikosaka, 
2007; Keller et al., 2008; Pouget et al., 2009).
Finally, our results should be conciliated with increased GABAergic neurotransmission 
measured in the Nf1+/- mice model. In that sense, the low GABA levels observed in 
patients might reflect a compensatory mechanism, since there is a dynamic modulation 
of  GABA levels in response to increasing or decreasing network activity and in the 
context of  brain disorders (Esclapez and Houser, 1999; Gomes et al., 2011). However, 
it remains an open possibility that the animal model does not recapitulate the 
neurochemical phenotype of  the human disorder. Further studies are needed to evaluate 
these hypotheses. In particular, studies in both patients and animal models employing 
13C-Magnetic Resonance Spectroscopy (MRS) and molecular imaging using positron 
emission tomography (PET) to map GABA receptors, would deepen our understanding 
of  the disease mechanism. 
Brain regions involved in NF1
Our studies would not be complete without investigating the neuroanatomy of  NF1. In 
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order to understand how mutations in the NF1 gene impact brain structure it is essential 
to characterize in detail the brain structural abnormalities in patients. Therefore, in Chapter 
6 we assessed for the first time simultaneously, the variety of  traits and brain regions 
that could be altered by the disorder in carefully matched patient and control groups. 
Our findings indicate that overall brain volume is increased in NF1 as a consequence of  
larger white matter and subcortical grey matter volumes. Moreover, patients with NF1 
presented disproportionately larger thalami, right caudate and middle corpus callosum 
than typically developing children. In agreement with our findings, previous studies 
have identified the thalamus and the corpus callosum as structures involved in the 
neuroanatomy of  NF1. In fact, the most consistent structural finding across studies is 
an enlargement of  the corpus callosum in patients with NF1 (Kayl et al., 2000; Moore 
et al., 2000; Dubovsky et al., 2001; Steen et al., 2001; Cutting et al., 2002; Wignall et al., 
2010). The corpus callosum is the major commissural structure in the human brain and 
it connects the left and right cerebral hemispheres. The principal function of  the corpus 
callosum is to facilitate interhemispheric communication and transfer motor, sensory, 
and cognitive information between the hemispheres. Thalamic involvement in NF1 also 
pops out from the neuroanatomical findings reported. Diffusion-tensor imaging studies 
consistently reported alterations in the white matter microstructure of  the thalamus 
(Zamboni et al., 2007; van Engelen et al., 2008; Ferraz-Filho et al., 2012). Moreover, 
PET studies employing radiotracers of  glucose observed altered metabolism of  the 
thalamus in patients with NF1 (Kaplan et al., 1997; Buchert et al., 2008). Interestingly, 
reports employing both the glucose radiotracer 18F-fluoro-deoxy-glucose (FDG), and the 
GABAA receptor antagonist 
11C-flumazenil to quantify the density of  GABAA receptors 
in epileptic patients, indicate that the hypometabolism documented by FDG-PET is 
co-localized with regional reduction of  GABAA receptors (Ryvlin et al., 1998; Arnold 
et al., 2000). Future studies should investigate whether this evidence holds true for the 
NF1 thalamus. On the other hand, abnormal choline and N-acetylaspartate content in 
the thalamus of  NF1 patients was observed using 1H-MRS (Wang et al., 2000), possibly 
reflecting altered myelination and neuronal loss or neuronal dysfunction. The thalamus 
is a highly interactive structure, with widespread connections to multiple cortical regions, 
that provides selection and transformation of  different sensory inputs to the cortex. 
The various nuclei of  the thalamus are involved in the integration of  sensory and 
motor information, memory and executive functions (Schmahmann and Pandya, 2008), 
competences in which NF1 patients show disabilities (Hyman et al., 2005; Levine et al., 
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2006; Roy et al.).
Unlike the specific observations concerning subcortical structures, examination of  
cortical measurements indicated that alterations in cortical volume, cortical surface area 
and cortical thickness were not significantly different from controls. Gyrification index 
was the only changed measure in cortex. Patients with NF1 showed lower gyrification 
indices than typically developing children primarily in frontal and temporal lobes, but 
also affecting the insula, cingulate cortex, parietal and occipital regions. 
One of  the most evident features of  human evolution is the increase in brain size 
(Passingham, 1973). In response to evolutionary demands, a high level of  gyrification 
occurred in parallel with an increase in cortical grey matter in order to maximize cortical 
surface while maintaining a smaller intracranial size (Zilles et al., 1988). The increase in 
folding in bigger brains seems to be necessary for the formation of  efficient cortico-
cortical connections in larger volumes (Ruppin et al., 1993; Murre and Sturdy, 1995). 
This evolutionary trait appears disrupted in NF1, with an increase in brain size without 
a corresponding adaptive increase in folding. The phylogenetic development of  gyral 
and sulcal folds likely optimizes compaction of  neuronal fibers while keeping neuronal 
signaling at efficient transit time (Ruppin et al., 1993; Murre and Sturdy, 1995). In that 
sense, abnormal cortical folding may reflect deficits in structural and, consequently, 
functional cortical connectivity. Lower gyrification indices were particularly evident 
in the frontal cortex, a region that has been successively associated to functional 
impairments (Billingsley et al., 2003, 2004; Shilyansky et al., 2010; Chabernaud et al., 
2012; Violante et al., 2012).
Despite the pervasive expression of  neurofibromin in the brain, the neuroanatomic 
abnormalities observed were dominantly localized to specific brain regions indicating 
that particular areas and specific neurodevelopmental processes, such as gyrification, 
might constitute selective targets for the NF1 gene mutation. 
 
Integration of  functional, structural and neurochemical findings
Collectively, our data obtained in the same group of  patients and convergent evidence 
from other functional and structural neuroimaging studies suggest the involvement 
of  the visual cortex, the thalamus, the striatum (particularly the caudate), the corpus 
callosum, and the frontal cortex including the anterior cingulate cortex in NF1 disease 
mechanisms. It is therefore plausible that alterations in the circuitry interconnecting the 
cortex, basal ganglia, and thalamus are affected. The canonical connections forming these 
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cortico-striato-thalamo-cortical loops are shown in a simplified diagram here, Figure 1. 
Projections in this circuit use both the excitatory neurotransmitter glutamate and the 
inhibitory neurotransmitter GABA, as shown. The diagram is focused on the alterations 
observed in the visual cortex and thalamus, displayed as increased or reduced variables 
in comparison with controls. The role of  the striatum in NF1 is less explored. However, 
it is certainly influenced by thalamico-cortical alterations. Furthermore, studies focusing 
on the functional consequences of  increased volume and altered microstructure of  the 
corpus callosum function in NF1 are warranted. 
Interestingly, there is an absence of  collective sustained findings involving the parietal 
cortex. This is rather surprising given that visuospatial deficits are considered a hallmark 
of  the NF1 cognitive phenotype. This might be explained if  the pattern of  impairment 
observed in specific visuospatial tests (i.e judgement of  line orientation test) is caused 
instead by impaired function of other brain regions such as fronto-executive regions. 
Evidence for this hypothesis can be found in visuospatial studies in NF1 (Billingsley et 
al., 2004; Clements-Stephens et al., 2008).
Figure 1. Simplified diagram of  the ortico-striato-thalamo-cortical connections indicating 
alterations observed in NF1.
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Finally, it remains to be referred the lack of  correlations between our neuroimaging 
findings and IQ. Although, it is tempting to relate to relate neuropsychological 
performance directly with brain activity and structure, this is not entirely realistic. The 
majority of  cognitive functions involve distributed processes in the brain and IQ certainly 
belongs to this category. 
ConClusions 
As a single gene disorder, NF1 has a larger potential for elucidating gene–brain–behaviour 
connections than multigenic disorders, such as ADHD, autism, and schizophrenia. 
To further understand these connections we investigated the neurobiological basis 
underlying the cognitive deficits in patients with NF1. Although the studies presented in 
this thesis were not designed to yield knowledge directly applicable in clinical practice, 
our conclusions   provide several aspects with relevance in clinical neuroscience:
Patients with NF1 have impaired visual sensory processing- . Impairments in downstream 
perception can contribute to higher order cognitive deficits that build up the 
information gathered from sensory areas.
GABA is reduced in the visual cortex of  patients with NF1- , a pattern that possibly 
extents to other cortical regions. A distributed imbalance between excitatory 
and inhibitory systems is the most probable cause for the multiple cognitive 
deficits observed in NF1. 
Subcortical structures are enlarged in NF1, while the cortical mantle has lower gyrification- , 
a pattern that indicates abnormal neuroanatomical development. The increase 
in folding in bigger brains enables efficient cortico-cortical connections. This 
evolutionary trait appears disrupted in NF1, with an increase in brain size 
without a corresponding adaptive increase in folding. 
The work presented in this thesis identified novel neurobiological mechanisms and 
markers of  NF1, which open new frontiers to comprehend the pathophysiology of  the 
cognitive deficits and find adequate treatments for patients. 
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